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ABSTRACT 
The human breast cancer cell line, MDA 468 overexpresses the epidermal 
growth factor receptor, the EGFR to 1-2 x 106 receptors per cell. Receptor 
phosphorylation influences the EGF-mediated signaling events initiated at the cell 
surface. In this study we used a protein tyrosine kinase inhibitor (PTK) to study the 
effects of inhibition of EGFR kinase activity on EGF-dependent effects on 
phosphatidylinositol (PI) tumover, cell viability, and cell proliferation. 
In the initial phase of the study, 'N8 tested some of the frequently used PTK 
inhibitors for their ability to inhibit the EGF-stimulated EGFR autophosphorylation. 
MDA 468 cells exhibited a differential sensitivity to inhibition of receptor 
autophosphorylation with these PTK inhibitors. Of the inhibitors tested, only the 
dihydroxybenzene moiety containing inhibitor lavendustin A (LA) effectively inhibited 
(- 95°/o at 1 IJM) the EGF-stimulated EGFR autophosphorylation in intact cells and in 
crude membrane preparations in a time and dose dependent manner. Exposure of 
cells to 1 IJM LA beyond 1 o h caused morphological changes such as nuclear 
condensation and membrane blabbing. Morphological changes and occurrence of a 
subdiploid peak at higher concentrations are consistent with the fact that LA produced 
cell death by apoptosis. 
Earlier experiments from this laboratory had shown that EGF stimulates an 
increase in the total PI tumover and that a major portion of the metabolites was being 
converted to a component whose elution time did not correspond to the that of the 
elution times of non-cyclic inositol phosphates. This is an outcome of EGF- stimulated 
EGFR autophosphorylation. This metabolite was acid-labile and comprised over 50% 
of the PI tumover components in control untreated cells. Treatment of cells with EGF 
increased the levels of this component, while 1 IJM LA treatment decreased it. Using 
the technique of electrospray ionization tandem mass spectrometry, we identified this 
metabolite to be myo-inositol1,2-(cyclic) monophosphate (ciP) through the specific 
fragmentation pattern as compared to the standard. Change in the total PI turnover by 
stimulation (with EGF) or inhibition (with LA) of EGFR phosphorylation could be entirely 
accounted for by alterations in the percentage of ciP generated by these cells. This 
type of PI tumover profile is atypical and unlike that generated by phospholipase C-y. 
ciP is the major constituent of EGF-stimulated PI tumover and it is the metabolite which 
is most closely linked to changes in phosphorylation of EGFR in MDA 468 cells. 
MDA 468 cells are growth inhibited by 1 a-a M EGF between 48-72 h of 
exposure. Previous work has shown that this growth inhibition is due to a pronounced 
G1 growth arrest. Using a PTK inhibitor we hoped to see how changes in this 
relationship would affect the proliferative response in MDA 468 cells. At 0.2 IJM, LA 
reduced cell proliferation (as estimated by cell number) and DNA synthesis ([3H]-
thymidine uptake). Growth inhibition was accompanied by perturbations in the cell 
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cycle. LA, EGF, and EGF+LA produced a pronounced G1 arrest. LA and EGF+LA-
induced arrest was reversed 24 h after their removal, but EGF-treated cells showed 
a more persistent arrest. MDA 468 cells possess the p53273·Hs mutant, which positively 
enhances cell proliferation, but it transforms into an altemate "pseudo-wild type" 
conformation during EGF-mediated G1 arrest as demonstrated by previous work in this 
laboratory. In fact, p53 in cells treated with EGF, LA, or both, showed an altered 
subcellular localization at 24 h. The p53 in the nucleus lost reactivity to PAb 240 (it 
reacts with mutant p53), but reacted positively to PAb 1620 (it reacts with wild-type 
p53). This altered conformational shift of p53273·Htsfrom mutant to wild-type was also 
accompanied by a strong nuclear localization of p21 WAF11c1P1 and an absence of 
nuclear localization of cyclin dependent kinase 2 (cdk2). Thus we hypothesize a role 
of p53273·His dependent participation of p21 WAF11c1P1 and cdk2 in G 1 arrest in response 
to EGF, LA alone or both in combination. The augmented growth inhibitory response 
in presence of both EGF and LA is intriguing and is probably indicative of a 
segregated relationship between receptor phosphorylation and proliferative response. 
In this study we provide evidence of EGF-dependent changes associated with 
phosphorylation in the levels of an unusual PI metabolite, whose levels cause changes 
in total PI tumover. Apparently, this receptor phosphorylation-mediated changes in ciP 
during short-term exposure do not correlate with changes in proliferative response. 
Time and concentration dependent inhibition of receptor kinase activity by LA is 
reflected in later times by growth inhibition. Furthermore, the data presented suggests 
a function of p53273·His in growth arrest. 
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CHAPTER I 
INTRODUCTION 
2 
Signal transduction is key to life as we know it. Unicellular organisms had 
mechanisms by which one cell could influence the behavior of another. With the 
evolution of multicellular organisms, elaborate inter and intracellular signaling 
mechanisms enable cells to communicate to coordinate their mutual behavior for the 
benefit of the whole organism. Cellular signal transduction processes are coordinated 
by growth factors, differentiation factors, and hormones which are the primary 
components of a signaling system in the multicellular organisms that also largely 
coordinate their growth (Ullrich and Schlessinger, 1990). One of the many important 
phenomenon in signal transduction is tyrosine phosphorylation. 
Phosphorylation is considered to be a major currency in signal transduction 
pathways (Hunter, 1995}. Protein tyrosine kinases (PTKs) are associated with receptor 
and non-receptor proteins which are activated by tyrosine phosphorylation. Tyrosine 
phosphorylation is central to many cellular processes, including regulation of intracellular 
calcium concentration [Ca2+]1 (Marhaba eta/., 1996}, synapse formation (Catarsi et al, 
1995), induction of ornithine decarboxylase activity in parotid glands (Kinoshita et al, 
1996}, acrosome reaction in sperm head, mammalian fertilization (Meizel and Turner, 
1996), and in many developmental processes such as establishment of ventral cell fates 
and production of cuticle in Drosophila (Perrimon and Perkins, 1997). 
Activation of receptor tyrosine kinase (RTK) signaling pathways is one of the 
common routes via vvhich extracellular signals regulate gene expression. The effects of 
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many growth factors are mediated by high-affinity RTKs. RTKs catalyze the transfer of 
the y-phosphate of ATP to specific tyrosine residues in certain protein substrates 
(Burke, 1992). In mammalian systems, the binding of ligand to the extracellular domain 
activates the tyrosine kinase in the cytoplasmic domain ultimately leading to the 
downstream activation of a number of common signaling proteins, including 
phospholipase C-y (PLC-y), phosphatidylinositol-3 kinase (PI3'K), GTPase-activating 
protein (GAP) etc. (Fantl eta/., 1993). RTKs regulate processes such as cell growth, 
differentiation, migration, viability, and homeostasis (Perrimon and Perkins, 1997). 
Early events of growth factor receptor interaction following receptor phosphorylation 
include a transient increase in free calcium, the temporary expression of several genes 
like the nuclear-located proto-oncogene products c-mycand c-fos and a stimulation of 
monovalent ion-transport across the plasma membrane (Church eta/., 1989). Several 
distinct subfamilies of RTKs, though diverse, share common features (Fantl et a/., 
1993). Site-directed mutagenesis within the insulin receptor or the epidermal growth 
factor receptor which eliminate their PTK activities nullify their biological activity. Thus 
specific tyrosine residues responsible for the tyrosine kinase activity are essential for 
the signaling action (Gazit eta/., 1989). 
In the present study we have examined the influence of EGFR phosphorylation 
on epidermal growth factor mediated signaling in MDA 468, a human breast cancer cell 
line. 
4 
1.1 MECHANISM OF GROWTH FACTOR RECEPTOR ACTION 
Growth factor receptors possess an extensively glycosylated, protease-resistant 
extracellular ligand-binding domain, a single hydrophobic transmembrane region and 
a cytoplasmic domain which contains the tyrosine kinase catalytic domain. Thus, the 
RTKs possess a topology by which the ligand binding domain and the protein kinase 
activity are separated by the plasma membrane. Therefore, receptor activation due to 
extracellular ligand binding must be translated across the membrane barrier for the 
activation of the intracellular domain functions. 
Ligand-induced activation of the receptor kinase domain is mediated by 
receptor oligomerization. Receptor oligomerization is universal among growth factor 
receptors in living cells, isolated membranes, and purified receptors. Oligomerization 
may be induced by monomeric ligands like EGF or bivalent ligands like PDGF and 
CSF-1. Monomeric ligands induce conformational changes and bivalent ligands 
mediate dimerization of neighbouring receptors. Oligomerized growth factor receptors 
have elevated protein tyrosine kinase activity and enhanced ligand binding affinity 
(reviewed in Ullrich and Schlessinger, 1990). 
Binding of growth factors to receptors triggers the formation of complexes 
between receptors and cellular components; these complexes are responsible for the 
generation of second messengers. Tyrosine phosphorylation in the receptor forms links 
to the other intracellular reactions. Growth factors such as EGF, PDGF and insulin 
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enhance the phosphorylation of their own receptors in their tyrosine residues. By this 
phosphorylation, certain cellular serine/threonine kinases (such as PKC, Raf-1, MAP 
kinase, Pl3' K) interact with the receptors in a ligand· dependent fashion through their 
SH (src homology) domains. The SH regions preferentially bind to the tyrosine 
phosphorylated sites (Koch et a/., 1991; Pawson, 1995). A mitogenic signal 
transduction from the cell membranes to the nucleus involves the participation of 
adaptor proteins SHC and Grb2, which mediate the activation of the Ras/mitogen-
activated protein (MAP) kinase pathway (Daub eta/., 1996). 
1.2 EPIDERMAL GROWTH FACTOR (EGF) AND THE EPIDERMAL GROWTH 
FACTOR RECEPTOR (EGFR) 
EGF is a 53 amino acid polypeptide. It is a powerful mitogen which acts in a 
variety of cells both in culture and in vivo (Cohen eta/., 1980; Carpenter and Cohen, 
1990). EGF stimulates the proliferation of fibroblasts and most types of epithelial cells 
(Wu eta/., 1995). EGF exerts its tissue specific actions through its membrane-bound 
receptor, EGFR. EGF also regulates functions such as inhibition of gastric acid 
secretion and causes premature eye opening in newbom mice when injected daily 
(Gregory, 1975). EGF, along with HGF (hepatocyte growth factor), act as powerful 
mitogens in liver regeneration in vivo (Stolz and Michalopoulos, 1994). 
EGFR is a 170 kD transmembrane phosphoglycoprotein (Xu et a/., 1984; 
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Maiorano eta/., 1998) consisting of 1186 amino acid residues and an N-linked 
oligosaccharide ( 40 kD) (Carpenter and Cohen, 1990). It can regulate the cell cycle in 
a large number of target cells including stratified squamous epithelia, salivary and 
mammary gland epithelial cells, glial cells, and endothelial cells (Maiorano et al, 1998). 
EGFR has an NH2-terminal extracellular domain (621 residues) (Weber et al., 1984) 
separated from a COOH-terminal intracellular domain (542 residues) by 26 
preponderantly hydrophobic amino acids which form a membrane-spanning region. The 
cytoplasmic side of the transmembrane domain consists of 9-15 extremely basic amino 
acids; this feature is common to many membrane-spanning segments. The extracellular 
region has 51 cysteine residues which are clustered in two regions, each of about 170 
amino acids. These regions mightform a two-folded structure with an EGF-binding cleft; 
this so-called "duplicated" structure could be involved in ligand-mediated receptor 
oligomerization (Hunter, 1984). EGFR exits in two active states on the cell surface as 
demonstrated by the Scatchard analysis of EGF binding. These are the high-affinity and 
low-affinity states of the receptor (with respect to their EGF binding affinity) respectively. 
Although the nature of such difference in the existence of the receptor populations is not 
clear, it has been suggested that the dimeric form (the active form) of the receptor 
represents the high-affinity state (Sorokin eta/., 1994). 
EGFR dimerization is thought to be a critical early event in the response to 
stimulation with EGF. It has been shown that coexpression of wild-type EGFR with a 
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mutated or a truncated receptor lacking most of the cytoplasmic domain results in the 
suppression of signaling by the normal receptor (Honnegar eta/., 1990; Kashles eta/., 
1991 ). The importance of EGFR dimerization was elegantly demonstrated by Sorokin 
eta/. (1994). They generated a mutated form of the EGFR by inserting a cysteine 
residue in the extracellular domains of two receptors via disulfide bond formation. The 
mutation resulted in the ligand-induced appearance of covalently linked EGFR dimers 
and, in parallel, increased the number of high·affinity receptors present on the surface 
of cells expressing the mutated EGFR. The dimeric form of the EGFR is essential for 
the activation of the kinase moiety of the receptor and dimer formation is associated 
with the appearance of high-affinity binding EGFRs on the cell surface (Sorokin eta/., 
1994). Thus the EGFR dimer represents the active form of the receptor. 
When the EGFR interacts with ligands such as EGF and transforming growth 
factor-a (TGF-a) (Modjtahedi eta/., 1993). phosphorylation of tyrosine residues 992, 
1 068, 1148, 1173 and 1183 respectively results. Binding sites for adenosine 
triphosphate (ATP) and phosphate acceptor substrate proteins are located within the 
kinase core domain. The ATP-binding domain is highly conserved and contains the 
essential lysine residues (Chen eta/., 1987); if these lysine residues are replaced by 
neutral amino acids, then the ligand-stimulated protein kinase activity of EGFR is 
abolished (Carpenter and Cohen, 1990; Pandiella eta/., 1989). Interestingly, the 
Drosophila homolog of the EGFR contains both the EGF binding and the tyrosine 
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kinase domains; this indicates that both these activities have been present in the same 
molecule for over 800 million years (Livneh eta/., 1985). The erbB oncogene protein 
of the avian erythroblastosis virus lacks the extracellular ligand-binding domain (Xu et 
at., 1984). EGFR can act as an oncoprotein not only when it lacks the restraining 
structural features but also when there is an excessive expression (amplification) of 
structurally normal receptors (Filmus eta/., 1985). 
The EGFR belongs to the ErbB type I family of RTKs. The other members of this 
family include Erb82, Erb83 and ErbB4. These receptors play an important role in 
regulating cell growth and differentiation. Several growth factors including EGF, TGF-a, 
amphiregulin, HBEGF (heparin binding EGF), epiregulin, and betacellulin bind and 
activate the EGFR (Modjtahedi eta/., 1996). Since the coexpression of EGF related 
peptides and their own receptors frequently occur in human carcinomas, it has been 
suggested that autocrine activation of the receptor might play a role in cancer cell 
growth (Jannot eta/., 1996). EGF and TGF-a are able to directly activate EGFR; 
interaction of EGFR with signaling proteins such as transforming growth factor-P (TGF-
(3), platelet derived ~rowth factor (PDGF) and protein kinase C (PKC) influence 
stimulation (PDGF, PKC) or inhibition of cell replication (Maiorano et al., 1998). 
1.2.1 EGFR and tyrosine phosphorylation 
Signaling from the activated EGFR, leading either to cell proliferation or 
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transformation, requires the enzymatic activity residing in the receptor itseH; the 
activated receptor triggers further signaling events. Briefly, after EGF binds to its 
receptor, the activated receptor dimerizes and autophosphorylates its tyrosine 
residues. Phosphorylated tyrosine residues on the receptor are recognized by signaling 
proteins with SH2 domains. These are the Src homology regions 2 and 3 which are 
highly conserved non-catalytic domains (they were first found in the Src protein) in 
certain endogenous substrates. These regions form tight associations with specific 
peptide sequences of phosphorylated tyrosine residues and appear to direct protein-
protein interactions, such as binding of substrate to the PTK. Mutations in the SH2 
regions have been shown to lead to the activation of the transforming potential (Burke, 
1992). SH2 domains recognize phosphorylated tyrosine and enable proteins containing 
them [such as PLC-y, Ras GTPase (guanosine triphosphatase)-activating protein, 
PI3'K, and Src-like tyrosine kinases that have been transiently phosphorylated on 
tyrosine residues)] to bind to the activated receptor as well as to other intracellular 
signaling proteins (Koch et al., 1991 ). EGFR tyrosine kinase associates with PLC-V 
through the high-affinity interaction between tyrosine 992 in the EGFR and the SH2 
domain of PLC-y (Koch et al., 1991; Rotin eta/., 1992). EGFR and other growth factor 
receptor kinases also bind to protein phosphatases with SH2 domains (Sun and Tonks, 
1994) thus causing rapid dephosphorylation of receptor kinases; in EGFR, tyrosine 
residue 1173 was mapped to be the major binding site for SHP-1, through a SH2 
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domain in this protein tyrosine phosphatase (Keihack et at., 1998). 
Research has shown that the action of oncogenic proteins and other molecules 
Yt'hich constitute the •signal transduction machinery of tha cen• can contribute to 
excessive proliferation of cells. The concept is based on the fact that interfering with 
signal transduction interferes with proliferation. It is therefore widely believed that 
specific inhibitors of signal transduction might constitute the next generation of 
anticancer chemotherapy regimes (Levitzki and Gazit, 1995; Corbly eta/., 1996). Since 
the mitogenic action of EGF is mediated through the ligand·induced 
autophosphorylation of the EGFA (Wakeling et al., 1996), overexpressioo of EGFR in 
a variety of human tumors makes these receptors promising targets for directed tumour 
therapy (Schmidt and Wels, 1996). 
1.3 INHIBITION OF EGFA PROTEIN TYROSINE KINASE 
Overexpression of the EGF receptor is a hallmark in several solid tumors. Thus 
its inhibition may be an important strategy for selectively targeting therapeutic agents. 
EGFR and its ligands such as EGF and TGF.a have been associated with poor 
prognosis and metastatic spreading. Pioneering studies have defined two important 
facts, namely, that the receptor for EGF is a transmembrane tyrosine kinase (Carpenter 
and Cohen, 1990) and that ligands such as TGF·a could activate the receptor in an 
autocrinefashion (Taketani, and Oka, 1983). Thus the EGFR is an attractivetargetfor 
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the delivery of therapeutic agents. Use of anti-EGFR monoclonal antibodies (MAb) or 
EGFR-specific tyrosine kinase inhibitors are some of the extensively studied 
therapeutic strategies, with the aim of achieving inhibition of EGFR activity and 
subsequent regression of several types of tumors with EGFR overexpression. It has 
been shown that PTK inhibitors or monoclonal antibodies produce the same biological 
changes, namely inhibition of EGF-stimulated EGFR phosphorylation and inhibition of 
growth. Their sites of action are different. The PTK inhibitor inhibits the cytoplasmic 
tyrosine kinase domain, whereas the antibody blocks EGF binding in the extracellular 
domain (Modjtahedi eta/., 1998). Such therapeutic tools have been tested in vitro in cell 
lines of tumors overexpressing EGFR, in animal studies and even in clinical trials alone 
or in conjunction with other modes of treatment. 
1.3.1 PTK Inhibitors and EGFR inhibition 
The EGFR protein tyrosine kinase was one of the first tyrosine kinases chosen 
as a target for the development of a new class of inhibitors, the protein tyrosine kinase 
(PTK) inhibitors (Traxler, 1997). Since then many potent PTK inhibitors for both receptor 
and non-receptor tyrosine kinases have been developed. Many currently available 
anticancer drugs including taxol, platins, and adriamycin are cytotoxic possessing highly 
toxic side effects. On the other hand, hormonal agents such as antiestrogens and 
antiandrogens are generally well tolerated and effective against hormone-dependent 
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tumors, but are ineffective often when such tumors become hormone-independent. 
Hence the medical need for new well-tolerated treatments for common solid tumors is 
extremely urgent. Although growth factor receptor mediated signal transduction via 
inhibition of protein tyrosine kinase is not a novel idea, its inhibition as a clinical 
approach to the regulation of cell proliferation is not yet proven. It can be speculated that 
PTK inhibitors might be able to inhibit or reverse the growth of tumor cells and slow 
down disease progression because in the absence of positive growth signals, some 
of the cancers may differentiate or die via various mechanisms of cell death such as 
apoptosis or necrosis (Traxler, 1997). Several active compounds such as erbstatin, 
herbimycin A and staurosporine, flavonoids and isoflavonoides have been isolated from 
biosources. Some of the synthetic compounds that have been synthesized are 
derivatives of natural PTK inhibitors. One such compound is methyl 2,5-
dihydroxycinnamate, a well-known PTK inhibitor, which is an erbstatin derivative 
(Umezawa eta/., 1990). Many synthetic compounds have been synthesized: these 
include dianilinopthalimides (Trinks eta/., 1994), anilinoquinazolines (Wakeling et al., 
1996), hydroxycinnamides, thiazolidinediones, phenylaminopyrimidines (DeWitte eta/., 
1993) and tyrphostins (Posner et al., 1993). All these classes of compounds have been 
reported to inhibit the growth of cells in culture and also in vivo by interference with PTK 
activity (DeWitte et a/., 1993). 
Lavendustin A (LA) is one of the most potent natural products to possess a PTK 
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inhibitory activity with a reported IC50 value of 12.0 nM in vitro (Onoda eta/., 1989). It 
is a microbial metabolite which was isolated from Streptomyces griseolavendus and 
is selective for the inhibition of tyrosine kinases relative to serine/threonine kinases. It 
is an exceptionally potent inhibitor of ATP binding to the EGFR kinase (Onoda eta/., 
1989). LA contains multiple aromatic rings and also has the 2,5-dihydroxyphenyl group 
of erbstatin (Burke, 1992) and has been shown to be a "mixed-type" inhibitor (Hsu eta/., 
1991 ). Some other natural PTK inhibitors include quercitin (flavone) and genistein 
(isoflavone) which have both been used extensively for the purpose of studying EGFR 
tyrosine kinase inhibition. 
1.3.2 EGFA inhibition-other strategies 
Besides the ongoing search for various EGFR protein tyrosine kinase inhibitors, 
both natural and synthetic (as is discussed in the previous section), various other 
strategies have been used to inhibit the EGF receptor tyrosine kinase activity. 
Strategies of EGFR inhibition are based on two functional aspects of the receptor, 
binding of EGF to the receptor, and secondly, the protein tyrosine kinase activity of the 
receptor (Gill eta/., 1984). 
Extensive studies with monoclonal antibodies (MAb) to the EGF receptor have 
been done as a means for inhibiting the EGFR. During the past 20 years or so, a 
number of MAbs have been synthesized and tested against human cell lines 
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overexpressing EGFR. 
Mouse MAb 425 and 528 blocked ligand interaction with EGFR, reduced 
anchorage-independent growth of NS2T2A 1 (a cell line derived from normal human 
breast epithelial cell culture transformed by SV4o-T antigen, and possessing increasing 
levels of EGFR, TGF-a, amphiregulin), and reduced the mean tumor mass after 
NS2T2A 1 cells were grafted in nude mice (Ma et al., 1998). MAb C225 in combination 
with an 18-mer antisense oligonucleotide HYB 190 (targets expression of the Ala 
regulatory subunit of c-AMP dependent protein kinase I) has been found to inhibit the 
growth of human renal can~er cell lines, 769-P, ACHN, A498 and SW839 in soft agar 
(Ciardiello et al., 1998). MAb 225 caused a G, arrest and programmed cell death 
(apoptosis) in DiFi colorectal adenocarcinoma cells by inhibiting receptor tyrosine 
kinase (Wu eta/., 1995). Mouse MAb225,528and579, prepared from EGF receptor 
protein from the A431 carcinoma cell line, have been shown to be competitive against 
EGF binding and they antagonize EGF-stimulated protein tyrosine kinase activity as 
assayed in intactA431 cells or by using an exogenous peptide substrate in solubilized 
membranes. Many such competitive antagonist MAbs can be used to control the 
concentration of receptors activated by EGF (Gillet a/., 1984; Mendelsohn, 1997). 
A most promising aspect of MAbs has been their use in phase I or phase II 
clinical trials in patients with head, neck, lung or brain cancers (Modjtahedi eta/., 1996). 
The purpose of such studies was to determine whether the treatment produced life-
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threatening toxicities by their binding to EGFR expressed by normal tissues. Two 
mouse MAbs, 225 and 528, which have been extensively characterized for their 
biological and preclinical properties, represent the first series of antiEGFR blocking 
reagents that have entered clinical evaluation in cancer patients (Ciardiello et al., 1998). 
Rat MAb ICR62 had been safely administered in patients with unresectable squamous 
cell carcinoma in phase I clinical trials. This antibody was found to be safe and also 
localized efficiently in the metastatic sites. In this study the safety of administration (and 
not its therapeutic potency) was assessed (Modjtahedi eta/., 1996). 
Other strategies that have been used to inhibit the EGFR activity include use of 
chimeric molecules comprising of a natural ligand (such as the chimeric molecule 
consisting of heparin and EGF, a ligand that will bind to the EGF receptor) with high 
affinity to the EGFR attached to a cytotoxic protein (ribosome-inactivating protein 
saporin, a plant mitotoxin) to deliver specific toxins to the cells (Chandler eta/., 1998). 
Another approach is tumor gene therapy. Human breast cancer MDA-MB-231 cells 
transfected with EGFR in the antisense orientation, showed decreased EGFR RNA 
expression which resulted in the suppression of the transformed phenotype, which, in 
turn correlated with the decrease in the expression of EGFR (Hong eta/., 1998). 
1.4 APOPTOSIS 
Apoptosis or "programmed cell death" (PCD) is an active process of cell 
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destruction in the normal development of an organism (Alison and Sarraf, 1992). This 
name was derived from a Greek word meaning a flower losing its petals or a tree 
dropping its leaves (Wyllie, 1993). Apoptosis occurs in developing embyro where 
genetically controlled cell death occurs at precise developmental stages in the process 
of organogenesis. In normal healthy adult tissues cell death (or loss) must keep pace 
with cell production in the great renewal systems (bone marrow, gastrointestinal tract, 
skin) in order to maintain tissue homeostasis between cell proliferation and loss. 
Certain cellular environments such as serum-starvation or growth factor deprivation, 
(Moyer et al., 1997) also trigger apoptosis. Apoptosis is regarded as "physiological" 
cell death since it is a genetically determined cellular program (Raff, 1992). In 
apoptosis, cells shrink, their chromatin is pushed to the periphery of the nucleus, and 
the cells lose their plasma membrane integrity. The remnants of apoptotic cells are 
eliminated through phagocytosis by the neighboring cells and macrophages (Alison 
and Sarraf, 1992). 
Apoptosis is a phenomenon which has been shown to be of immense 
importance in determining the efficacy of various anticancer agents because many kill 
tumor cells by apoptosis. Also much attention has been focussed on understanding 
factors which cause cells to acquire or lose their sensitivity to chemotherapeutic agents 
(Lowe et al., 1993). Many cellular targets including p53 have been identified which 
influence the sensitivity of cells to apoptosis. Evidence suggests that expression of 
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oncogenes such as adenovirus early region 1 A (E1 A) and c-myccan also increase the 
cellular susceptibility to PCD (lowe eta/., 1993). On the other hand, oncogenes like 
bcl-2 have been found to prevent apoptosis (Fairbarin et a/., 1993) by promoting 
survival of cells in the non-cycling state (Schmandt and Mills, 1993). Apoptosis thus 
involves interplay between repressor and inducer genes (Buja eta/., 1993). 
1.5 PHOSPHOINOSITIDE BREAKDOWN-A SECOND MESSENGER SYSTEM IN 
CELLULAR SIGNALING 
Coordination of cell growth and division is mediated by specific growth factor 
receptors and intracellular messengers. This is true when growth is considered under 
physiological (fetal growth, wound healing and tissue regeneration} and pathological 
(cancer) conditions. Receptors for Ca2• -mobilizing hormones, neurotransmitters and 
growth factors utilize a well-studied second-messenger system involving the hydrolysis 
of phosphatidylinositol (PI) (Rhee, 1991) to elicit at least part of their biological 
responses (Hurley, 1995). The very first version of the phosphoinositide system was 
elucidated by Hokin and Hokin (1964). They proponed that phosphoinositide (inositol-
containing phospholipids) was hydrolyzed in response to cell stimulation with an 
increase in phosphatidic acid, whose phosphate moiety was not directly derived from 
phosphatidylinositol, but from diacylglycerol (DAG), formed as a result of 
phosphoinositide breakdown {phosphorylation of DAG produces the phosphate moiety 
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in phosphatidic acid; this reaction is catalyzed by the enzyme diacylglycerol kinase). 
Through subsequent accumulation of research data a well-studied sequence of events 
have been shown to occur as a result of phosphoinositide breakdown. 
Phosphoinositides in cell membranes varies from 2-12 °/o in different tissues, the 
proportion of PI being highest among them. Most PI is located in the inner membranes, 
whereas phosphoinositides which contain the most phosphate groups [including 
phosphatidylinositol {PI), phosphatidylinositol 4·phosphate {PIP), and 
phosphatidylinositol4,5-bisphosphate {PIP2)] are preferentially located in the plasma 
membrane {Michell, 1975). Pl·specific phospho I ipase C (PLC)-mediated hydrolysis of 
phosphatidylinositols, namely phosphatidylinositol (PI), phosphatidylinositol 4-
phosphate (PIP) and phosphatidylinositol4,5·bisphosphate {PIP:z), produces inositol 
mono, di, andtrisphosphates (IP, IP2, IP3) respectively with diacylglycerol (DAG) as the 
common product (Rhee eta/., 1989). Figure 1.1A shows the interconversion of the 
phosphoinositides by the stepwise phosphorylation of PI by the respective kinases. 
Phosphoinositides which are substrates for PLC usually contain stearic {at the first 
position of glycerol) and arachidonic (at the second position of glycerol) acids (Tkachuk, 
1998). IP3 and DAG are the primary intracellular second messengers produced as a 
result of the PLC-mediated PI (PIP2) hydrolysis (Kim eta/., 2000) (Figure 1.1 B). DAG 
plays an integral role in the activation of protein kinase C (PKC), and I P3 diffuses from 
the plasma membrane through the cytoplasm to intracellular calcium stores to release 
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Figure 1.1 Phospholnosltldes and the generation of second messengers 
(reproduced from Alberts et al., 1994). 
Figure 1.1 A describes the formation of polyphosphoinositides (PIP and PIP2) by the 
stepwise phosphorylation of phosphatidylinositol (PI). 
Figure 1.1 B describes the generation of the second messengers IP3 and DAG. All three 
classes of PLC (J3, y, and 0) hydrolyse Pis. PLC-V is activated by receptor tyrosine 
kinases, including EGF receptor tyrosine kinase. 
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intracellular Ca2• (Phillippe, 1994). Ca2• combines with a calcium-binding protein 
calmodulin; the calcium-calmodulin complex is responsible for activating Ca2•-
dependent protein kinases (Boume and DeFranco, 1989). 
PLC plays an essential role in the PI signaling pathway utilized by many 
receptors. Mechanisms of PLC regulation that have been clearly identified include those 
that are G-protein mediated and those linked through a tyrosine kinase. The presence 
of multiple isoforms of PLC conforms to the notion of differential regulation of these 
enzymes (Cockcroft and Thomas, 1992). Three families of PLC have been identified. 
These are the p, v, and l5 families respectively. The classification of the families of PLC 
has been based on the deduced amino acid sequences. The P family has three 
subtypes, namely, P 1, (32, and (33 respectively. The v family has two subtypes, y1 and 
y2, whiletheOfamily has three subtypes, 01, 02, and 03 respectively.ln addition, the 
existence of at least two more families, namely, PLC-a and PLC-e has been predicted. 
PLC-P is regulated by G proteins whilst PLC-V is under the control of tyrosine kinases 
(Cockcroft and Thomas, 1992). 
Hydrolysis of phosphoinositide resuhs in the generation of non-cyclic and cyclic 
inositol phosphates. When PLC cleaves PI, it leads to the production of cyclic inositol 
1:2 monophosphate (ciP) (Kim et al., 1989). Current evidence suggests that the 
percentage of cyclic inositol phosphates to non-cyclic phosphates generated decrease 
in the order of PLC-a>PLC·B>PLC-O>PLC-y (Kim eta/., 1989; Rhee eta/., 1989). As 
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such, DAG, IP, IP2, and IP3 constitute 90-95o/o of all the PLC-y1-mediated PI products 
(Berridge and Irvine, 1989; Majerus et a/., 1990; Rhee and Choi, 1992), with cyclic 
phosphates of inositol considered to comprise only the remaining 5-1 0°/o (Berridge and 
Irvine, 1989; Kim eta/ .• 1989; Majerus eta/., 1990; Putney and Bird, 1993). It is unclear 
as to what factor determines the ratio of cyclic compounds to their non-cyclic 
counterparts (Majerus, 1992). In some species, such as the intracellular bacterial 
pathogen L. monocytogenes, for instance, a specific PLC produces only ciP and DAG 
from PI breakdown (Camilli et a/., 1991 ). Increased production of cyclic inositol 
phosphates have also been noted in various tumor cell lines. 
All cyclic inositol phosphates are metabolized through cyclic 1 :2-inositol 
phosphate hydrolase (ciPH}. Therefore, it is likely that this enzyme plays a key role in 
the regulation of cellular concentrations of ciP (Ross et a/., 1990). The enzymatic 
breakdown of ciP was first demonstrated by Dawson eta/. ( 1971 ). It was later identified 
that the enzyme responsible for this reaction is ciPH. Annexin Ill, a calcium-dependent, 
phospholipid-binding protein was identified as having an enzymatic property consistent 
with ciPH (Ross eta/., 1990; Tait eta/., 1993). This identity was widely accepted until 
recently, when a dissociation of ciPH activity from that of annexin Ill was demonstrated 
(Sekar eta/., 1996; Perron eta/., 1997). 
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1.5.1 The Inositol phosphates 
The production of the two second messengers, IP3and DAG, are the key steps 
in the signaling pathways initiated by the breakdown of PIP2 by PLC-y. The 
deactivation of this pathway is necessary to terminate the increase in free [Ca2•]1 as 
well as the recycling of inositol for the restoration of precursor inositol stores (Putney 
and Bird, 1993). Various PI turnover metabolites, from inositol monophosphate to 
hexaphosphate (IP, IP2.IP3, IP 4, IP5, IP 6}, are produced by the rapid phosphorylation and 
dephosphorylation cycles by the actions of various inositol phosphate kinases and 
phosphatases. 
Myoinositol is one of the nine stereoisomeric hexahydroxycyclohexanes, 
collectively termed inositols. This molecule is an essential component of membrane 
lipids down the evolutionary scale from eubacteria to eukaryotes.lnositol is essential; 
S. cerevisiae mutants unable to synthesize inositol show a defect in the acid-hydrolase 
secreting system. Even though most mammalian tissues other than brain and testis, 
make small amounts of inositol. the ubiquitous presence of inositol in the diet makes 
it quite difficult to render mammals inositol deficient (Michell, 1997). 
Inositol phosphates also have important functions. IP3 (inositol 1 ,4,5 
trisphosphate) has an identified role as a potent second messenger, which leads to the 
mobilization of [Ca2•]1 stores (Furuichi and Mikoshiba, 1995). Inhibition of IP3-induced 
Ca2• release by PIP2-specific antibodies has been shown to greatly lengthen the 
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duration of the cell cycle in microinjected two-cell stage Xenopus embryos. 
Synaptotagmin II, an integral membrane protein of synaptic vesicles binds to IP 4 
(inositol-1 ,3,4,5 P 4) suggesting it has an important role in the regulation of 
neurotransmitter release (Niinobe eta/., 1994). Calciotropic compounds like IP3 and 
IP 4 are also natural chelators of Ca2• and may thus be partly responsible themselves, 
for providing a basis for the diverse biological actions of the metal ion. The coupling of 
chelation with enzyme or receptor interactions offers a general mechanism for the 
divalent cation control of diverse biological processes. Inositol monophosphate 1-
phosphatase and inositol polyphosphate 1-phosphatase are the two enzymes 'Nhich 
may conform to this mechanism (Luttrell, 1994). IP5 and IP6 have been suggested to 
have roles as antioxidants (Graf et al., 1987). IPs has also been suggested as an 
intracellular iron transporter which binds iron during its transport through cytosol or 
cellular organelles (Hawkins eta/., 1993). IP a has been shown to promote Ca2• uptake 
and modulate neurotransmitter release in cultured cerebellar granule cells (Nicoletti et 
a/., 1989). Recently IP6 has been shown to have an antineoplastic effect. It decreases 
cell proliferation by causing G1 arrest of human colon carcinoma cells by upregulating 
the tumor suppressor genes p53 and p21 WAF11c1P1 (Saied and Shamsuddin, 1998). 
Cyclic inositol 1:2, 4, 5-trisphosphate (ciP3) has been shown to have an 
intracellular Ca2•-mobilizing role, although this must be reconciled with its reported 
relatively long half-life of = 1 0 min (Putney and Bird, 1993). In Limulus photoreceptor 
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cells, cl P3 was five times more potent than IP3 in increasing Ca2+ conductance (Wilson 
et al., 1985). Cyclic inositol phosphates accumulate in stimulated cells for longer 
periods than their non-cyclic counterparts. This is suggestive of their importance in 
evoking sustained or delayed responses, including stimulation of cell growth (Ross et 
a/., 1990). 
1.6 TYROSINE PHOSPHORYLATION AND PI TURNOVER 
The link between tyrosine phosphorylation and PI turnover is through PLC-y 
(Haugh eta/., 1999). EGF stimulation causes autophosphorylation of the EGFR in cells 
expressing the receptor; the activated receptor tyrosine phosphorylates its substrate, 
PLC-y, which, in turn, is responsible for enhanced PIP2 breakdown. Thus, the EGF-
mediated receptor activation is linked to PI turnover via PLC-y in EGF-stimulated cells. 
PLC·V is a substrate of the PDGF and EGF receptor kinases. It has been 
suggested that this phosphorylation is responsible for the increase in PLC-y activity in 
the cell types where these growth factors stimulate PI turnover (Meisenhelder eta/., 
1989). In a high percentage of mammary carcinomas, increased phosphotyrosine 
content of PLC-y1 has been observed resulting in amplification of signaling steps in 
receptor tyrosine kinase stimulated signal transduction pathways (Arteaga et al., 1991 ). 
Phosphorylation of PLC-V on tyrosine residues has been shown unequivocally in cells 
treated with growth factors EGF and PDGF. Both these growth factors induce PI 
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turnover in 3T3, A431 (Meisenhelder eta/., 1989}, MDA 468 cells and R1 hER cells 
(Church et a/., 1992). In MDA 468 cells autophosphorylation of the EGFR, its 
association with and activation of PLC-y (by tyrosine phosphorylation) leads to an 
increase in the total PI tumover (Church et at., 1992). 
1.7 THE CELL CYCLE 
"All things began in order, so shall they end, and so shall they begin again; 
according to the ordainer of order and mystical mathematics of the city of heaven." 
Sir Thomas Browne, 1658 
This statement is truly applicable for the cell cycle. Cells never re-duplicate their 
chromosomes before sister chromatids have been segregated at the previous mitosis, 
never start mitosis before DNA duplication is completed, nor attempt to segregate 
sister chromatids until all pairs have been aligned on the mitotic spindle at metaphase 
(Nasmyth, 1996). Thus cells have mechanisms by which the events related to cell 
division occur in the right sequence. The cell cycle is a mechanistic explanation for the 
proliferative nature in cells (Lopez-Saez eta/., 1998 ). Therefore the balance among the 
cell populations in an organism is controlled by regulating the rates of proliferation, 
differentiation, and cell death (Collins and Rivas, 1993). 
Looking back at the history of the elucidation of cell cycle events, it was 
recognized from early microscopic studies that cell division was preceded by mitosis 
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(M phase), during which cells condensed their chromosomes, aligned them on a 
microtubular spindle and segregated sister chromatids to opposite poles of the cell. Not 
much knowledge could be gained by simple observation, of the interval between 
succeeding mitoses (known as interphase) except that there was an increase in cell 
volume. Chromosome duplication was detected and shown to occur during a narrow 
window during interphase. Interphase was thus split into three intervals: G1, the gap 
between mitosis and the onset of DNA replication; S phase (synthetic phase), the 
period of DNA synthesis; G2 the gap between S and M phases. G, S, G2, and M 
gradually were thought of as major cell cycle states (Nasmyth, 1996). The gap phases, 
G 1, and G2, represent the pre- and post-replication periods respectively between the 
replication and segregation of DNA. Through the cell cycle there is growth of cellular 
mass, as well as the replication and segregation of DNA in S and M phases 
respectively. 
In general, in response to an effective stimulus, the cell starts proliferating by 
initiating a cycle. This is the G0 toG, transition. In the presence of signals to proliferate, 
cells first leave G0 , a state of quiescence, and commit themselves to start the cycle in 
G1• The proliferative potential of a tissue is often expressed by its G1 to G0 ratio (L6pez-
Saez et al., 1998 ). In G1 cells contain a 2N or diploid DNA content between division and 
S phase, and G2 is when the cells have a tetraploid DNA content, separating the S 
phase from mitosis. Many events which are essential for the progression of cells through 
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the cell cycle occur during these two gap phases. In normal cycling cells G, is the 
longest phase, resulting in the preponderance of 2N cells seen in the typical DNA 
histogram produced by flowcytometry of asynchronous, cycling cells. During G 1, the cell 
size, protein content, and RNA content increase markedly because cells must ultimately 
divide again maintaining a characteristic size.lf protein synthesis is prevented, cells do 
not reach S phase from G1.1n addition, histone H1 is progressively phosphorylated 
together with a variety of other proteins, such as the retinoblastoma protein (Rb ). During 
G2, the tetraploid cells have to prepare for mitosis, and again, protein and RNA 
synthesis is required for progression. In G2 the cell gets the time to check for any 
damage that might have occurred due to irradiation, thus allowing repair of any 
damaged DNA. 
S phase is important not only for DNA replication, but also because it is 
responsible for the maintenance of the genomic integrity during cellular proliferation for 
the continued viability of the organism. When the cells bypass normal restrictions to 
entering S phase, often imposed by conditions which cause DNA damage, the 
continued replication of such cells can contribute to cancer formation (Hartwell and 
Castan, 1994). Howard and Pelc (1951) showed that [32P] orthophosphate was 
incorporated into the roots of Vicia seedlings during a particular stage of interphase, 
which is now known to be in the S phase or the DNA synthesis phase. Synthesis of 
more specific DNA label, (3H)-thymidine (Taylor eta/., 1957), was then used to study 
29 
DNA synthesis. Only cells in the process of synthesizing DNA take up and retain the 
[3H]-thymidine. A number of specific enzymes increase markedly, including thymidine 
kinase, ribonucleotide reductase, and DNA polymerase. These enzymes are 
associated into a large multienzyme complex called replitase, 'Nhich may provide a high 
concentration of precursors for DNA synthesis at the replication site. Then the entire 
DNA content of the human chromosome is replicated. In addition to DNA synthesis, 
structural elements of the chromosomes, such as histones are also duplicated. S phase, 
like mitosis, is not a natural point of replication, because cells do not pause at this point 
unless inhibited by agents such as hydroxyurea or iron chelators, both of 'Nhich interfere 
with ribonucleotide reductase, a rate-limiting enzyme for DNA synthesis (Bybee and 
Thomas, 1991 ). 
1. 7.1 Regulation of the cell cycle 
Progression through several major checkpoints in the cell cycle is controlled by 
multiple protein kinases, generally a regulatory cyclin and a catalytic unit, making up a 
cyclin dependent kinase (Chen and Hitomi, 1999). The first molecular models of cell 
cycle regulation focused on how a single enzymatic oscillator comprised of a regulatory 
cyclin ( cyclin B) and a catalytic cyclin-dependent kinase ( cdk) controlled mitotic entry 
and exit. The cdks provide the enzymatic activity of this complex. An important element 
of this cyclin-regulated cell cycle is the rapid induction of expression of the cyclins and 
30 
their facile destruction as the cell progresses into the next phase of the cell cycle 
(Rodriguez-Puebla eta/., 1999). It was recognized later that cdks have roles in multiple 
cell cycle events, including DNA replication, mitosis, centrosome/spindle pole body 
duplication, and cell morphogenetic changes (Roberts, 1999). The activity of these 
kinases is regulated by the expression level of each component, its phosphorylation 
status, and the presence of specific inhibitory proteins (Hall and Peters, 1996). The 
cdks are constitutively expressed throughout the cell cycle. They are the promoters of 
the progression through the cell cycle, and they are sequentially activated and 
deactivated. 
Several mammalian cyclins have been identified, and their functions at specific 
points of the cell cycle have been established. The three 0-type cyclins (01, 02, and 
03) function during mid-to-late-G, phase. They are regarded as growth factor sensors, 
because various combinations of them, depending on the cell lineage, are induced in 
response to various mitogenic stimuli during G1 phase. This induction is concomitant 
with an increase in the catalytic activity of their specific cdk partners, cdk4 and cdk6 
respectively. Expression of cyclin E peaks sharply during the G1/S phase transition (its 
main partner is cdk2) and is followed by the expression of cyclin A, which maintains 
cdk2 activity of their specific cdk partners (Rodriguez-Puebla et a/., 1999). In 
mammalian cells, the D cyclins and their catalytic partners cdk4 and cdk6 function as 
the cells leave Go and progress through G1, while cyclin Elcdk2 is activated from G1 into 
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S phase. Cyclin Alcdk2 operates in the Sand G2 phases, whereas cyclin Blcdk1 (or the 
cell division cyclin in yeast, the cdc2) regulates the G2M transition (Hall and Peters, 
1996). The phases of the cell cycle and the periodicity of expression of the cyclins in 
the various phases of the cell cycle are shown in Figure 1.2A and Figure 1.28 
respectively. 
The control of cellular proliferation relies on both accelerating and braking 
mechanisms, and hence the checkpoint and tumor suppressor pathways are of great 
importance. Proteins encoded by checkpoint genes are crucial components of these 
pathways that evaluate the final balance between the mitogenic and non-mitogenic 
pathways (L6pez-Saez eta/., 1998). 
Positive control is brought about by proteins encoded by the cell division cycle 
(cdc) genes. The cyclin dependent kinases (cdks) are the key regulatory enzymes of the 
cell cycle. The precise activation and inactivation of CDKs at specific points in the cell 
cycle are required for cell division to proceed in an orderly fashion. 
Cyclin dependent kinase inhibitors such as p21 WAF,JCIP, and p27'<1P1 are actively 
involved in the negative regulation of cdk activities, playing a role in controlling cell cycle 
progression and thus acting as tumor suppressors (Hirama eta/., 1995; Cheng eta/., 
1999). Among the genes that are well-known regulators of the cell cycle. the tumor 
suppressor gene p53is well recognized as a checkpoint gene which not only regulates 
the G1 checkpoint (Kagawa eta/., 1997), but also the G2 phase as well (Schwartz eta/., 
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Figure 1.2 The cell cycle and expression of various cyclins during the phases 
of the cell cycle (reproduced from Santa Cruz Biotechnology Inc., catalogue, 
1999). 
Figure 1.2A describes the various phases of the cell cycle and the involvement of the 
various cdk·cyclin complexes during the cell cycle. 
Figure 1.28 describes the periodicity of expression of the various cyclins during the 
various phases of the cell cycle. 
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1997). p21wAFlJCIP1 is induced by p53 (L6pez-Saez eta/., 1998). p21WAF1te1P1 acts as 
a downstream effector of p53 in the inhibition of mitotic progression. p21 WAFl/CIP, can 
also be induced independent of p53 through various regulators, including growth factors 
PDGF, fibroblast growth factor (FGF), and EGF (Michieli eta/., 1994). Uke p21 WAF1te1P1, 
p27K1P1 is another cyclin dependent kinase inhibitor which binds to a number of cdk 
complexes (Hirama eta/., 1995). This protein is abundant in quiescent cells and growth 
factor stimulation causes its levels to fall (Cheng et al., 1999) and cell cycle to progress. 
1.8 GROWTH ARREST 
In a properly functioning cell, deprivation of essential growth factors in 
pathway(s) dependent on the factors, acting as primary mediators of intercellular 
communication (Schmandt and Mills, 1993), can lead to growth inhibition, leading to 
growth arrest at the G, checkpoint, which is known as the restriction point. Cells which 
are damaged by chemotherapy often arrest at another checkpoint, the G2M phase, in 
order to enable them to repair DNA. In malignant cells, chemotherapeutic damage 
signals the cells to pause for repair.ln such a case, the requirementfor growth factors 
to allow for the traversal of the cell cycle is converted to the requirement of a growth 
factor for cell survival. In such a situation, when receptor kinase activity is inhibited (such 
as the EGFR), cells can no longer survive and undergo apoptosis (Mendelsohn, 1997). 
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1.9 MDA 468 CELLS 
The MDA 468 (MDA-MB-468) cell line was established from pleural perfusion 
of a breast cancer patient (Pathak eta/., 1979). MDA 468 cells express large numbers 
of EGFRs, -1-2 X 1 06/cell, as a result of an EGFR gene amplification (Filmus eta/., 
1985; Film us eta/., 1987). This is in comparison to -1 as or less receptors/cell in other 
cells. Although there is a gene amplification, the EGFR in MDA 468 shows 
characteristics of wild-type receptors; the overexpressed receptor protein appears 
normal with respect to its binding affinity, synthesis, turnover and autophosphorytation 
(Kudlow, eta/., 1986; Filmus eta/., 1987). 
1.9.1 EGFR overexprassion and growth inhibition in MDA 468 cells 
Elevated levels of EGFRs are commonly associated with breast cancers 
(Gusterson, 1992), which suggests a critical role for EGF in transformation. It has been 
suggested that increased EGFR levels may confer a growth advantagFJ in situations of 
limiting EGF concentrations (Gill et a/., 1985). Further in vitro studies have 
demonstrated that EGF inhibits cellular proliferation at concentrations above 1 nM 
{Filmus eta/., 1985). A431 is a human epidermoid carcinoma cell line which also 
exhibits EGFR amplification (Gill and Lazar, 1981) and overexpress EGFRs upto 1-2 
X 1 a6/cell (Merlino eta/., 1984). Similarly, studies with A431 cells indicated that EGF 
induced growth inhibition could be observed at nanomolar concentrations, while it 
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stimulated cell proliferation at picomolar concentrations (Kawamoto eta/., 1983). 
Both MDA 468 and A431 cells overexpress the EGF receptor and are growth 
inhibited by nanomolar concentrations of EGF. Taking advantage of this fact studies 
have been performed with clonal variants of both cell lines to study the relationship 
between EGF receptor number and growth. Filmus eta/. ( 1987) have isolated six clonal 
variants of MDA 468 cells. The six had EGFR levels similar to normal human fibroblasts, 
had lost EGFR gene amplification and were resistant to EGF-induced growth inhibition 
observed in the parental cell line. Karyotype analysis showed that MDA468 cells had 
an abnormally banded region (ABR) in chromosome 7p, which was not present in the 
variants. Five of the six variants were able to generate tumors in nude mice with a lower 
growth rate from that of the parental cell line. Only one variant S4 was unable to 
generate tumors in nude mice and was unable to grow independently in soft agar in the 
absence of EGF (Filmus eta/., 1987). The parental cell line was able to generate 
significantly larger tumors than the nonamplified variants. The basis for this size 
difference at 9 weeks may have been due to a growth rate advantage, since the 
parental cells had a shorter doubling time. Other variants most likely did not have a 
growth advantage as much as the parental cells did, because of their lack of EGFR 
gene amplification. Therefore, amplification of the EGFR gene provides a progression-
related growth advantage (Filmus eta/., 1987). 
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t .1 0 p53, A TUMOR SUPPRESSOR 
p53 is a tumor suppressor gene, whose loss or inactivation is a very common 
lesion in human neoplasia (Bennett, 1999). Lack of p53 expression, although frequently 
a late event in tumorigenesis, is seen as a major step towards the development of the 
neoplastic phenotype. In certain cases, some breast cancer tissues inactivate p53 
function without mutation to render the functional wild-type p53 to be non-functional. 
Examination of breast cancer specimens from 27 breast cancer tissues showed how 
important wild-type p53 is as a tumor suppressor. 30°/o (8 cases) had very high levels 
of p53 in the nucleus, 33°/o (9 cases) had a complete lack of detectable staining, 37% 
( 10 cases) had a pattern of cytoplasmic staining with sparse nuclear staining. 
Nucleotide sequence analysis of p53 cDNAs derived from the samples with 
cytoplasmic staining revealed wild-type p53 alleles only in 6 out of 7 cases. In contrast, 
the samples containing nuclear p53 contained a variety of missense mutations and 
nonsense mutations. A normal lactating breast tissue also shovvec:t intense cytoplasmic 
staining for nuclear p53 with sparing nuclear staining. Thus, these data suggest that p53 
protein may inactivate its tumor-suppressor activity by sequestering the wild-type p53 
protein in the cytoplasm, away from its site of action in the cell nucleus (Moll eta/., 
1992). 
p53 induces both growth arrest and apoptosis, and therefore it was suggested 
that the same pathways might mediate both responses. While this may be partially true, 
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it is also true that p53 might mediate apoptosis by pathways distinct from that of growth 
arrest. The separation of ~dependent pathways for growth arrest and apoptosis may 
be based on selective induction of gene products specific to each pathway. For 
example, p53 has been shown to up-regulate pro-apoptotic genes such as Baxand to 
suppress anti-apoptotic genes such as bcl-2, by transcriptional activation or repression, 
thus altering the relative quantities of these genes and shifting the balance towards 
apoptosis. Also, promoter selectivity of p53 mutants can determine whether p53 
induces growth arrest or apoptosis. For example, p53 also directly induces transcription 
of IGF-bp3, a protein that can inhibit both the mitogenic and anti-apoptotic activity of 
IGF-1, via a p53 consensus motif in the promoter region (Bennett, 1999). 
p53 is a nuclear phosphoprotein, and its nuclear localization is essential for its 
growth-suppressing activity in late G1 (Shaulsky et a/., 1990). The subcellular 
localization of p53 has been shown to vary throughout the cell cycle in Balblc 3T3 cells. 
The newly synthesized protein accumulates in the cytoplasm during the G1 phase. 
Around the beginning of the S phase, p53 accumulates in the cell nucleus, where it stays 
for about 3 h. Following this step of DNA synthesis, p53 is no longer found in the nuclear 
compartment, but accumulates in the cytoplasm. This modulation in the subcellular 
localization of p53 suggests that the protein is spatially regulated during the cell cycle 
(Shaulsky eta/., 1990). 
Mutated forms of p53 have been implicated in the etiology of breast cancer 
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because mutant p53 is continuously required to maintain the transformed phenotype 
(Avila eta/., 1994). The p53 mutation converting codon 273 arginine to histidine is 
frequently present in human tumors (Hollstein eta/., 1991 ). This mutant, p53273·His has 
a wild-type epitope map, which is PAb 240 (this antibody recognises mutant p53) 
negative and PAb 1620 (this antibody recognizes wild-type p53) positive (Slingerland 
eta/., 1993). MDA 468 cells possess a single allele for p53 with a point mutation at 
codon 273 {p5~73-Hts) resulting in the substitution of arginine by histidine (Nigro eta/., 
1989; Bartek et al., 1990). Evidence suggests that subcellular localization of p53273· .... 
has relevance to the growth suppressor function of p53, a function of wild-type p53 
(Prasad and Church, 1997). 
The p53273·His mutant in cooperation with H-ras showed a weak transforming 
potential in rat embryo fibroblasts even when it was highly expressed from the strong 
human 13-actin promoter (Slingerland eta/., 1993). It was concluded that this mutant 
allele lacked the ability to interfere with wHd-type p53 protein in a dominant negative 
manner. When single copies of wild-type human p53 and p53273·His alleles were 
coexpressed in SAOS-2, an osteosarcoma cell line lacking endogenous p53 protein 
expression, the wild-type p53 phenotype function slowed growth, decreased saturation 
density, and reduced tumorigenicity (Chen et al., 1990). However, in the absence of 
wild-type p53, the mutant promoted cell growth to a higher saturation density than that 
of parental cells (Chen eta/., 1990) .In rat embyo fibroblast transformation assays, the 
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weakly transforming p53273·His became strongly transforming when the intact nuclear 
localization signal site was replaced by the mutated nuclear localization signal site 
(Slingerland eta/., 1993). 
This behavior of p53 has been explained in different ways. In the murine system, 
point mutations exert a common effect on the structure and function of p53. They result 
in the synthesis of p53 molecules with a different epitope structure. In cells expressing 
murine p53, a variable fraction of the p53 molecules are in the wild-type state. Bartek 
et al. (1990) called the p53 molecules with mutations in the primary sequence as 
"pseudo-wild type." On the other hand they have, on careful examination of cell lines with 
mutant p53, found a second population of molecules which they call "overtly mutant." 
These molecules are also present in human cell lines because both PAb 240 positive 
(overtly mutant) and PAb 1620 positive (pseudo-wild type) forms are derived from the 
same mRNA (Bartek et al., 1990). Halazonetis eta/. (1993) have shown that wild-type 
p53 can adopt a "mutant" conformation and that conformational changes of wild-type 
p53 is associated with sequence-specific DNA binding. In fact under certain conditions 
wild-type p53 can transiently adopt the "mutant" conformation such as during cell 
division (Halazonetis eta/., 1993). Thus p53 (mutant or wild-type) is associated with 
changes in its conformation under certain conditions and also in a majority of tumors 
which is manifest in its altered conformation. 
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1.11 AIM OF THE PRESENT WORK 
MDA468 cells overexpress the EGFR. Binding of EGF (or other natural ligands) 
causes autophosphorylation of the EGFR, which in tum triggers the binding of several 
signali11g proteins such as PLC·V, PI3'K, GAP etc. via their SH2 domains. Binding of 
ligands to the receptor triggers early and delayed biochemical events such as receptor 
dimerization, phosphorylation of the receptor, PI turnover, and other intracellular protein 
substrates, ultimately leading to mitogenesis (Modjtahedi eta/., 1998). Several lines of 
evidence suggest that amplification, rearrangements, or abnormal expression of the 
EGFR gene are associated with neoplasia. Various strategies (discussed in sections 
1.3, 1.3.1, and 1.3.2) have been developed to inhibit the activity of the EGF receptor 
tyrosine kinase. 
Blocking the EGFR kinase activity can have growth inhibitory effects in cells 
leading to growth arrest, or the kinase activity inhibited cells can no longer survive and 
they ultimately die. Growth arrested cells can still survive as quiescent cells in G0 when 
the EGFR pathway is blocked (Moyer eta/., 1997). Studies with various monoclonal 
antibodies against the EGFR have shown that activation of the receptor is required for 
both progression through the cell cycle and for the prevention of apoptosis (Wu eta/., 
1995). 
Receptor autophosphorylation is one means by which PTK function can be 
modulated. Taking advantage of this fact we aimed to study the EGF-mediated 
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signaling events associated with receptor tyrosine kinase activity. Initial experiments 
showed that EGF stimulated an increase in PI tumover (Church et aL, 1992). On careful 
examination of the EGF-generated PI turnover profile, it became clear that a 
considerable portion of the metabolites were being converted to a metabolite of 
unknown identity, which eluted in the early part of the separation profile (Church eta/. 
unpublished observations). Therefore, our initial aim was to identify this metabolite and 
quantitate it. This metabolite was found to constitute over 50% of the total inositol 
phosphates. EGF causes a stimulation of EGFR autophosphorylation and an increase 
in PI tumover; these are the immediate effects of EGF stimulation. It is assumed that 
activation of PLC-V by the dimerized EGFR initiates PI tumover. Since EGF caused an 
increase in the generation of this metabolite, we hypothesized that the mitogenic 
response of these cells as a long term effect might, in some way, be related to the 
generation of this metabolite in the shorter term. In order to gain insight into this 
relationship between PI tumover and proliferative responses, we planned to use a PTK 
inhibitor to block the receptor autophosphorylation. By using this strategy we hoped to 
block the signaling pathway initiated by EGFR phosphorylation. Our aim was to 
examine the effect of receptor phosphorylation by inhibiting this process such that we 
could examine a response such as PI tumover, which is a direct effect of receptor 
autophosphorylation. We also wanted to investigate if modulation of receptor 
autophosphorylation affects the cell's proliferative responses. Receptor phosphorylation 
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and growth have a positive correlation at picomolar EGF concentration. This correlation 
however, does not hold good at nanomolar concentrations. In fact, at nanomolar 
concentrations, the relationship becomes inverse in cell lines overexpressing the 
EGFR, such as MDA468 (Film us eta/., 1985), A431 (Gulli eta/., 1996), andcolorectal 
DiFi cells (Grosset a/., 1991). In this way we hoped to study the interdependence 
between EGF-mediated growth inhibition and EGFR kinase activity in MDA 468 cells 
and correlate EGF receptor tyrosine kinase activity to growth and progression of cells 
through the cell cycle. 
Proliferation is reflected in the cell's traversal through the cell cycle; our aim was 
to further study the role of the cell cycle checkpoint regulators by reflecting on any 
changes that might be occurring as a result of perturbations in the cell cycle. Previous 
work by Prasad and Church (1997) has demonstrated a role for p53273·Hts in EGF-
mediated growth inhibition. They proposed that EGF was clearly tilting the balance of 
p53 from mutant-like to more of a wild-type like conformation. They also suggested a 
confonnational flexibility for this p53 mutant, where a dynamic equilibrium between two 
conformations in the nucleus would determine the G1-S progression. In view of these 
findings, and evidence from the literature, which demonstrates an inhibition of receptor 
tyrosine kinase activity is responsible for cell cycle arrest, we wanted to further study a 
link between EGF-mediated signalling, proliferation and the possible role of p53 and 
other cell cycle proteins influencing the proliferation in MDA 468 cells. Keeping these 
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objectives in mind, we initially intended to use some of the widely used PTK inhibitors 
which would effectively block the EGFR kinase activity. We would subsequently choose 
the appropriate one for further investigation. 
CHAPTER II 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Chemicals 
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Epidermal growth factor (EGF) was obtained from Collaborative Biomedical Products, 
Bedford, MA. A/G Plus Agarose was obtained from Santa Cruz Biotechnology Inc., 
Santa Cruz, CA. Dimethyl sulfoxide (DMSO), protein A-sepharose beads, and 
propidium iodide were purchased from Sigma-Aldrich Canada Ltd., Oakville, ON. 
RNAse was obtained from Boehringer Mannheim Canada (Laval, Quebec). 
2.1.2 Tissue Culture Reagents 
Tissue culture reagents were all obtained from GIBCO BRL (Burlington, ON). 
These reagents included Leibovitz-15 (L-15) media, modified with L-glutamine, fetal 
bovine serum (FBS), methionine-free L-15, inositol-free Oulbecco's Modified Essential 
Medium (DMEM), trypsin/EDTA, penicillin (10,000 IU/ml, and streptomycin 10,000 
~g/ml. 
Tissue culture ware included 75 cm2 flasks from Falcon (distributed by Becton 
Dickinson, Mississauga, ON), 6-well plates, 60 mm, 10 em and 100 em dishes from 
Nalge Nunc International (Naperville, IL), and e-well chambered glass slides from Nalge 
Nunc International. 
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2.1.3 DRUGS 
1) Lavendustin A (LA) and lavendustin B (LB) were both obtained from Biomol 
Research Laboratories (Plymouth Meeting, PA). Drugs were dissolved in DMSO in a 
concentration of 10 mg/ml and the stock solutions were stored in -20°C. Precautions 
were taken in handling the drugs because they are light-sensitive. Further dilutions were 
made in L-15 media (supplemented with or without FBS for tissue culture assays) or in 
sterile water. 
2) Genistein and methyl2,5-dihydroxycinnamate were purchased from GIBCO BRL 
Baicalein was a kind gift from Aldrich Chemical Company, Inc. (Milwaukee, WI, USA). 
All three drugs were dissolved in DMSO and stored at -20°C; during the time of 
experiment appropriate dilutions were made in L-15 media (supplemented with or 
without FBS for tissue culture assays) or in sterile water. Genistein, and its analogue 
baicalein, were sonicated to dissolution in aqueous tissue culture media. 
3) Cisplatin (1 mglml) was obtained from Faulding (Canada) Inc. (Vaudreuil, Quebec). 
2.1.4 ANTIBODIES 
2.1.4.1 Primary antibodies 
1) AntiEGFR, a mouse monoclonal antibody was obtained from Amersham LHe 
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Science, Buckinghamshire, UK. This antibody was used for immunoprecipitation of 
EGFR from cells. 
2) Antiphosphotyrosine (PY20), a mouse monoclonal (lgG2bJ antibody was obtained 
from Upstate Biotechnology, Lake Placid, NY. 
4) Antip53 antibodies were obtained from Oncogene Science, Manhasset, NY 
(distributed by Cedarlane, Mississauga, Ontario). These were as follows: 
a) PAb 1801 (Ab 2), a human-specific antibody (lgG1), reactive with both wild-type and 
mutant p53 was obtained from Cedarlane (Oncogene Science, Manhasset, NY), 
b) PAb 240 (Ab 3), a mutant-specific and conformation-dependent antibody {lgG1) was 
obtained from Cedarlane (Oncogene Science, Manhasset, NY), 
c) PAb 1620 (Ab 5), a human wild-type specific antibody (lgG~). was from Cedar 
Lane (Oncogene Science, Manhasset, NY). 
5) Antip21 WAFtiCIPt, a mouse monoclonal antibody (lgG2b) was from Pierce and Biolynx 
(distributor). 
6) Anticdk2, a rabbit polyclonal antibody {lgG), was obtained from Upstate 
Biotechnology, Lake Placid, NY. 
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2.1.4.2 Secondary antibodies 
1) Sheep anti-mouse lgG horse radish peroxidase (HRP)-Iinked whole antibody was 
obtained from Amersham Life Science. 
2) Antirabbit lgG-HRP conjugated secondary antibody was obtained from Santa Cruz 
Biotechnology. 
3) Antimouse/antirabbit lgG-FITC {fluorescein isothiocyanate) conjugated secondary 
antibodies were obtained from Santa Cruz Biotechnology. 
2.1.5 RADIOISOTOPES 
(3H)-myo-inositol {specific activity 20 CVmmol) was obtained from Mandel 
Scientific, Guelph, ON. [3H)-myo-inositol phosphate mix consisting of inositol1-
phosphate, inositol1 ,4-bisphosphate, and inositol1 ,4,5-trisphosphate (each 4.5 
Ci/mmol) was obtained from DuPont NEN, Boston, MA. [3H]-thymidine (specific activity 
85.4 mCilmmol) was obtained from Mandel Scientific Company. 
2.1.6 HPLC MATERIALS 
The Partisil SAX 10 column (25 X 0.46 em) was a kind gift from Phenomenex 
(CA, USA); this column was fitted with a Partisil SAX 1 o (Mandel Scientific Company, 
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Guelph, ON) direct contact guard cartridge. Standard DL-myo-inositol1,2-cyctic inositol 
monophosphate and ammonium phosphate (dibasic) were obtained from Sigma· 
Aldrich Canada Ltd. (OakvillE'. ON). Reactyflow Ill scintillation cocktail was obtained from 
Beckman Instruments (Mississauga, ON). 
2.2 METHODS 
2.2.1 TISSUE CULTURE 
MDA 468 cells were maintained in L·15 modified media supplemented with 1 OOJo 
FBS, 50 IU/ml penicillin, and 50 ~g/ml streptomycin at 37°C in a C02-free incubator.ln 
the case of serum-starvation, cells were transferred to serum-free L-15 media 
supplemented with antibiotics only. 
2.2.1.1 Routine tissue cuHure 
MDA 468 cells were routinely maintained in L-15 with penicillin/streptomycin in 
75 cm2 flasks seeded at a cell density of 1.0 x 1 06 cells. Cells were harvested by 
trypsinization at a 70% confluence weekly, and counted by hemocytometer. 
MDA 468 cell stocks were maintained by freezing and then thawing as required. The 
cells were harvested by trypsinization, counted and a 1 ml (1·2 x 106 cells/ml) 
suspension was made. This suspension was transferred to a sterile cryotube and FBS 
(1 0% v/v) and DMSO (1 0% v/v) were added to the cryotube. The tube was closed tightly 
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and transferred to a Nalgene TM Cryo 1 oc freezing container (with isopropanol) to 
achieve a -1 oc/min rate of cooling and kept at -70°C overnight. The isopropanol was 
changed after every five uses and the container was kept at room temperature when not 
in use. 
For thawing cells, cryotubes were taken from liquid nitrogen and transferred to 
a 37°C water bath for a few min. Then the contents of the tube were transferred to a 
sterile centrifuge tube and centrifuged. The pellet was washed with 1 x PBS to remove 
residual DMSO. Cells were then routinely cultured in 75 cm2 flask for use in 
experiments. 
2.2.21MMUNOPRECIPITATION and WESTERN BLOniNG 
2.2.2.1 Drug Treatment 
For phosphorylation experiments, 5 x 1 OS cells were plated in six-well plates. The 
next day, cells were transferred to serum-free L 15 and serum-starved for 48 h, at the 
end of which cells were treated with the drugs under investigation. After drug treatment, 
cells were stimulated with 1 o.a M EGF for 1 o min at 37°C and harvested for protein 
extraction. In separate experiments, 5 x 105 cells were seeded in 60 mm dishes, and 
the next day cells were exposed to LA for a period of 6 h and harvested for protein 
extraction. 
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2.2.2.2 Protein extraction 
After the various drug treatments, cell mono layers were washed twice with ice-
cold 1 x PBS in the presence or absence of phosphatase inhibitors (1 mM sodium 
orthovanadate, 10 mM pyrophosphate and 100 mM sodium fluoride) and then treated 
with ice-cold Pawson's lysis buffer [50 mM Hepes, pH 7.5, 150 mM NaCI, 10% glycerol, 
1% Triton X-1 00, 1.5 mM MgCI2, 1 mM EGTA, 10 ~g/ml aprotinin, 10 ~g/mlleupeptin, 
1 mM phenylmethylsulfonylfluoride (PMSF), 200 IJM sodium orthovanadate, 10 mM 
pyrophosphate, and 100 mM sodium fluoride] (Church et at., 1992). Orthovanadate is 
a known inhibitor of tyrosine phosphatases (Daniel eta/., 1996). Cells were harvested 
by scraping in lysis buffer using Costar sterile disposable cell scrapers. Celllysates 
were collected in 1.5 ml microfuge tubes and kept in ice for 20 min with occasional 
mixing. Cell lysates were cleared by centrifugation at 13,000 x g for 15 min at 4 oc. 
Supernatants were collected in separate microfuge tubes and protein analysis was 
done using the BioRad protein detection dye reagent concentrate {Bradford, 1976) in 
the microassay range ( s25 J.lg/ml) with bovine serum albumin (BSA) as the standard. 
2.2.2.3 lmmunoprecipitatlon 
In the case of immunoprecipitation studies, the supematants were mixed with the 
appropriate antibody (in a concentration as specified by the manufacturer) and 
incubated ovemight with continual rotation at 4 oc. The next day, 40 1J I of 50o/o protein 
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A-Sepharose was added to the samples with antibodies and incubation was continued 
for another hour with constant rotation at 4 oc. Immune complexes were washed 3 xwith 
cold wash buffer (20 mM Hepes pH 7.5, 10°A, glycerol, 0.1o/o Triton X-100, 150 mM 
NaCI, and 1 mM sodium orthovanadate). Sepharose beads were collected each time 
(after washing) by a microcentrifuge pulse ( -20 sees) and the supernatants discarded. 
The samples were boiled with 40 tJI of 1 0°/o SDS sample buffer and separated by 
polyacrylamide gel electrophoresis (PAGE), followed by Western blotting and detection 
by Amersham's enhanced chemiluminescence (ECL) detection kit. 
2.2.2.4 Western blotting 
Protein extracts were subjected to PAGE for separation of proteins. Volumes 
of supernatants (of cell extracts) were adjusted to 20-25 tJg per sample which was then 
loaded onto a gel; this volume was mixed with 2 x 10°/o SDS sample buffer (0.5 M Tris-
HCI, pH 6.8, glycerol, 1 0°A, SDS, (3-mercaptoethanol, 0.05o/o bromophenol blue) heated 
for a few min at 1 oooc and loaded on to a 7 .5o/o polyacrylamide gel and 
electrophoresed in a Mini-PROTEANR II Dual Slab Cell (BioRad) minigel apparatus. 
The gel was run at 20 mA (milliamps) for 30 min followed by 30 rnA constant current for 
2 h to get sufficient protein separation. The stock (5X) electrode buffer used comprised 
of Tris (25 mM). glycine (250 mM). SDS (1 %). This was diluted to 1 x and used as 
running buffer. At completion, the gel was washed in cold transfer buffer a few times to 
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remove the SDS in the running buffer. The gel was then ready for transfer. 
For transfer, all components of the Western sandwich assembly 'Nere collected 
together. Fibre pads, filter paper, membrane were all soaked in cold transfer buffer 
(192 mM glycine, 25 mM Tris and 20°/o v/v methanol) for 15 min. The sandwich was 
assembled as per the manufacturer's directions and transfer was done at 60 V 
(constant voltage) for 1~ h in a BioRad miniblot transfer apparatus at 4°C. The 
separated proteins were transferred to Hybond™·ECL Nitrocellulose-hybridization 
transfer membranes (Amersham). After transfer, the sandwich was disassembled and 
the membrane was blocked for non-specific binding sites by incubating in 5°/o non-fat 
milk in TBS-T (Tris-buffered saline and Tween-20) for 1 h or 1 o/o milk/1 °/o BSA (in TBS-
T) in some cases as per manufacturer's directions. The membrane was incubated 
overnight with the primary antibody (antiphosphotyrosine/antiEGFR) diluted in 5% non-
fat milk (in TBS-n according to the manufacturer's directions with constant rocking at 
4 oc. The blot was washed with TBS-T for 1 h at room temperature with at least four 
changes. The membrane was incubated at room temperature for 1 h with constant 
rocking with the secondary antibody (sheep anti-mouse whole lgG HRP-Iinked antibody) 
diluted in TBS-T. Following this the membrane was washed extensively with TBS-T. 
After washing, the peroxidase activity was detected with Amersham's ECL kit (reagent 
1 and reagent 2 were mixed in equal volumes and spread over the whole surface area 
of the blot for 1 min) using Hyperfilm ™-ECL high performance luminescence detection 
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films from Amersham. Exposed films of individual blots were scanned in a 
Chemiimager™ 4000 model of Low Ught Imaging system (Digitallmaging and Analysis 
Systems, Alpha lnnotech Corporation) attached to a Multiimage™ light cabinet for the 
determination of band intensities. 
2.2.3 MEMBRANE EXTRACTION FROM MDA 468 CELLS 
MDA 468 cells were grown in 100 em dishes at 4x1 06 density. Confluent 
monolayers were then washed twice with ice-cold 1 x PBS after which membrane 
extraction buffer was added to the dishes. Cells were then scraped with a disposable 
cell scraper and collected in a homogenization tube. Cells were then homogenized in 
a variable speed laboratory rotor, TRI-R STIR-R (Model #S63C, Tri-A Instruments, Inc.) 
for 1 0-15 strokes. The suspension was then kept in ice for 1 min. This process was 
repeated five times to ensure complete disruption of cells. The homogenized cell 
suspension was transferred to 30 ml Co rex glass tubes and were then centrifuged at 
1.400 x g for 10 min. The supernatant was transferred to 70 Ti rotor ultracentrifuge 
tubes; the tubes were balanced and the samples were ultracentrifuged at 50,000 x g for 
55 min in a Beckman Model L8-70M Ultracentrifuge. The supernatants were discarded 
and the pellets were resuspended in ice-cold membrane extraction buffer (without 
PMSF) and the protein content determined. The membrane preparations were aliqoted 
in cryovials and stored in liquid nitrogen for future use. 
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2.2.4 ELECTRON MICROSCOPY 
2 x 105 cells were grown in 60 mm dishes and cells were treated with 
appropriate drugs in order to examine morphological changes of cell death. Cells were 
washed with 1 x PBS and harvested by trypsinization. The total population of cells were 
collected. The attached cell monolayer was washed and trypsinized and fixed. 
The EM specimens were processed by a modification of the method of Hyam 
( 1981 ). Any residual amounts of media were washed off and after one additional wash 
the cells were fixed by resuspending the cell pellet in 4°k paraformaldehyde, 5°/o 
glutaraldehyde in 0. 1 M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature. 
The steps that followed sequentially are as follows: 
1) brief wash 2~ (5 min each) with 0.1 M sodium cacodylate buffer (pH 7.4), 
2) 1 wash ( 1 0 min) with 1 °/o osmium tetroxide (in 0. 1 M sodium cacodylate) to fix any 
lipids in the specimen, 
3) 1 wash in 0.1 M sodium cacodylate buffer (5 min each), 
4) 2 washes in 70% ethanol (5 min each), 
5) 2 washes in 95°/o ethanol (5 min each), 
6) 2 washes in absolute ethanol (10 min each), 
7) 2 washes in absolute acetone (10 min each), 
8) infiltration with 50:50 mixture of Epon (resin):acetone (10 min each), 
9) infiltration with 100% Epoxy (Epon) resin-2 x (10 min each), 
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1 0) polymerization in 1 OOo/o epoxy resin at 70°C overnight. 
After polymerization, ultrathin sections (900A) of the specimens were cut using 
a Reichert OMU 2 Model ultramicrotome, collected on 300 mesh copper grids and 
doubly stained in 2.5% uranyl acetate in ethanol and 0.3o/o aqueous lead acetate. The 
sections of doubly stained specimens were observed using a JOEL 1200 EX electron 
microscope and photographed using Kodak Electron Image Film #4489. Prints were 
made using Kodak Ektomatic black and white paper. 
2.2.5 DNA FRAGMENTATION 
3.0 x 1 06 cells were seeded in 1 00 mm dishes. The next day, cells were treated 
with LA for 14 h. Adherent cells were washed with 1 x PBS and harvested by 
trypsinization. Floating cells from the media were pelleted and mixed with trypsinized 
cells and then the whole population of cells centrifuged. The method used was a 
modification of Oridate eta/. (1996). The pellet was washed a few times with 1 x PBS, 
resuspended in 0.85°k NaCI solution and centrifuged for 5 min. The pellet was then 
resuspended in nuclear lysis buffer (10o/o SDS, 20 mg/ml proteinase K and 50 
mMTris/EDTA, pH 8.0) overnight at 37°C. The next day 150 mM NaCI was added and 
centrifuged, and DNA was precipitated by mixing ethanol (2 volumes) with the 
supernatant at -2o·c. The pellet was washed twice with 70°k ethanol, air dried and 
resuspended with 1 0 mM Tris/EDTA (8.0) with RNAse (20 IJg/ml). Samples were 
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incubated at 37°C for 2 h for RNA digestion (with RNAse). DNA concentration was 
determined at 260 nm and 10 IJg of DNA was loaded in each well and electrophoresed 
in a 1.5°/o agarose gel against 1 kB standard (Gibco BRL). The gel was stained with 
ethidium bromide, visualized by UV fluorescence, and photographed. 
2.2.6 FLOW CVTOMETRIC ANALYSIS (FACS) 
To analyze the DNA content of cells and to investigate the percentages of cells 
in the various phases of the cell cycle, cells were subjected to flow cytometric analysis. 
2 x 105 cells were seeded in 60 mm dishes. The next day, cells were treated with 0.2 
IJM LA, 1 o-a M EGF, and 0.21JM LA+ 1 o·8 M EGF respectively. Cells were treated with 
the drugs for 72 h; in the case of growth reversibility experiments, the cells were treated 
for 72 hand at the end of the 72 h period, the drug-containing media was removed and 
replaced with fresh media for a further 24 h period. In other experiments, cells were 
treated with 0.125-1 IJM LA and incubated for 14 h after which cells were harvested. At 
the end of the incubation periods, the cells were harvested by trypsinization and the cell 
pellets were washed 2 x with 1 x PBS and fixed in 50°/o ethanol (in PBS) for 1 h at -
20°C. The cells were centrifuged and the pellet was washed 3 x with 1 x PBS to remove 
residual ethanol. The cells were then treated with Vindelov's propidium iodide stain 
(0.01 M Tris pH 8.0, 10 mM NaCI. 700 U RNAse, 0.05 mg/ml propidium iodide, Nonidet 
P·40) (Krishnan, 1975), which wasfilteredthrough0.451JMmembranefilterandstored 
59 
at 4 ac. As prepared, the stain is stable for a month after preparation. Cells were treated 
with propidium iodide for 2 hat 4°C. Prior to analysis, the propidium iodide treated cell 
suspension was passed through 50 micron Filcon syringe type filters (Dako) to remove 
clumps and the clump-free suspension was transferred to Falcon 6 ml sterile tubes 
(Becton Dickinson) prior to analysis. Analysis was done in a FACStar'us (Becton 
Dickinson) fluorescence-activated cell sorter (FACS) fitted with a 50 Watt argon laser 
source, set at an excitation wavelength of 488 nm. Approximately 10,000 cells were 
analyzed per sample. The fraction of cells in different phases of the cell cycle, namely 
Go/G1, S and G2M, was determined using CELL Quest Software (Version 3.1) in a 
Power Mackintosh 7300/200 computer. 
2.2.7 MTT ASSAY 
The cytotoxic effect of LA in MDA 468 cells was determined by the 3-
( 4,5dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide {MTT) assay by a modification 
of the method of Ford eta/. ( 1989). 1 x 104 cells were seeded in each well in a 96-well 
plate. The next day cells were treated with drugs in doubling dilutions, five wells for each 
concentration as well as controls (which included untreated control, 0.5% DMSO and 
a media blank). The cells were exposed to the drug for 24 h. The next day, the drug-
containing media was removed and the cells were washed 3x with 1 x PBS and 
replaced by fresh media for another 24 h. The following day, 0.5 mg/ml MTT dissolved 
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in L 15 media was added to each well and a 4 h incubation period followed. At the end 
of 4 h, L 15 containing MTT was removed and replaced by DMSO and the resulting 
absorbance was read in a BIORAD Model 3550 Microplate Reader. 
2.2.8 HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) 
2.2.8.1 Extraction of inositol phosphates from MDA 468 cells 
Inositol phosphates were determined by labelling the cells with [3H]-myo-inositol 
followed by the separation of the metabolites by high pressure liquid chromatography 
(HPLC). All samples were extracted under neutral conditions. The method of extraction 
was as described by Wong eta/. {1988). Briefly, 1 x 106 cells were seeded in S-well 
plates. The next day cells were washed twice with 1 x PBS and switched to inositol-free 
DMEM under serum-free conditions and 2 J,JCi [3H]-myo-inositol was added for 48 h 
(5%» C02 at 37°C). After 48 h 10 mM LiCI was added and incubated for 30 min (5% 
C02, 37°C) followed by the addition of 1 o-a M EGF for yet another 20 min under the 
same conditions. 
After the incubation period, the cells were washed 2 x with ice-cold 1 x PBS (1 ml 
each) and the washes were discarded into radioactive waste. Then 1 ml of quenching 
buffer (phenol/chloroform/EDT A) was added and left on ice for 20 min. Cells were 
scraped with Costar sterile disposable cell scrapers and the contents transferred to 
autoclaved Corex glass tubes. Two more 0.5 ml washes were carried out and 
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combined in the same Corex tubes. In a second Corex tube, 2 ml mixture of 
phenol/chloroform/butanol (38:24: 1 vlv) was made and the cell washes combined with 
it. The mixture was vigorously vortexed for 30 sees for proper mixing and then 
centrifuged at 1370 x g for 10 min. The upper phase was withdrawn for analysis by 
HPLC. 
2.2.8.2 Separation of inositol phosphates by HPLC 
Inositol and its charged metabolites were separated by HPLC by the 
modification of the method of Dean and Moyer ( 1987). Separation was achieved 
through a Partisil SAX 10 column (25 x0.46 em) with a Partisil SAX 10C direct contact 
guard cartridge. All standards and samples were filtered through Millipore syringe type 
451JM filters (Nihon Millipore, Kogyo, Japan) before application to the column. Water 
(A) and ammonium phosphate (B, pH 3.8) were used to separate the inositol 
phosphates. A flow rate of 1 mllmin was maintained throughout the gradient. 1 ml 
fractions were collected in tubes in a Pharmacia FRAC-1 00 fraction collector. Each 
fraction was mixed with 8 ml of Readyflow Ill scintillation cocktail and analyzed for 
radioactivity by scintillation counting. The resulting data were analyzed by calculating the 
area under the curves for the individual inositol phosphate peaks using a computer 
based •1NPLOr' software package (Graph pad, San Diego, CA), which uses a cubic 
spline curve fitting programme. All graphs were done in Graph Pad Prism ™ (Version 
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2.0). 
2.2.9 ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY (ESI 
MSIMS) 
HPLC fractions were collected and freeze-dried in a LABCONCO Freeze Dry-5 
freeze drying machine. Standard solutions for ESI MS/MS and CAD MS/MS were 
prepared in a mixture of HPLC solvent grade methanol-water (CH30H-H20; 6Q-40%) 
and analyzed on a Micromass VG Quattro quadrupole-hexapole-quadrupole mass 
spectrometer equipped with a megaflow electrospray ionization source capable of 
analyzing ions up to 4000 rnlz (mass over charge ratio) operating on a negative-ion 
mode. A 20 IJI aliquot of each sample was introduced into the electrospray ion source 
with a continuous flow of CH30H-H20, (60-40o/o) with a flow rate of 10 IJVmin using a 
Shimadzu LC-1 OAD pump connected to the Rheodyne injector with a 20 1JIIoop. The 
temperature of the ES ionization source was maintained at 75°C. The operating voltage 
of the ES capillary was 3.00 kV and the high voltage lens was set at 0.40 kV throughout 
the whole operation. ES mass spectra were recorded with a cone voltage of 25 V. 
Mass spectra were obtained by scanning in the multi-channel analysis (MCA) mode with 
a scan time of 1 sec per 250 a.m.u. MicroMass MASSL YNX 3.2.0 Mass Spectrometry 
Data System software running on a Compaq Desk Pro (Pentium processor 266 MHz) 
with Windows NT 4 was used for data acquisition and analysis. CAD MSJMS analysis 
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experiments were conducted using the same instrument. Fragment ion spectra of mass-
selected compounds were induced by collision with argon in the RF-only hexapole. The 
resulting fragments were analyzed by the second quadrupole. A cone voltage varying 
from 3.5 x 10 ... to6.5 X 10 ... mbar (1 bar=1 05 Pa) were used in all MSIMS experiments. 
2.2.1 0 GROWTH ASSAYS 
Cells were se!3ded at a density of 2 x 105 in 60 mm dishes. The next day drug 
::t: EGF were added to the media for the appropriate time (24 or 72 h). In all cases there 
was a no-treatment control, an EGF-treated control and a O.So/o DMSO control (the 
concentration of DMSO did not exceed 0.5°/o). 
2.2.1 0.1 Cell count and ['H)-thymidine assays 
At specified time intervals, cells were harvested by trypsinization and counted 
by hemocytometer. Each treatment group was done in duplicate in four separate 
experiments. 
For DNA synthesis assays, cells were labelled with 3. 0 tJCi per ml (3H)-thymidine 
for 24 h. At the end of the incubation period, cells were washed with cold 1x PBS, 
harvested by trypsinization and precipitated by ice-cold 1 Oo/o trichloroacetic acid (TCA). 
The TeA-precipitate was filtered through filters (glass microfibre filters GF/A 21 mm 
Whatman); the filters were washed twice with cold 1 Oo/o TCA and counted in 5 ml of 
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biodegradable counting scintillant (BCS scintillation fluid, Amersham) and in a 
Beckman counter (Model LS 3801). 
2.2.11 IMMUNOFLUORESCENCE EXPERIMENTS 
Cells were grown in glass-chambered slides and subjected to appropriate 
treatments (with 1 a-sM EGF, 0.2 ~M LA and EGF+LA) at 37°C. The method used was 
a modification of the method of Banasiak and Haddad { 1998). Following incubation, 
cells were washed with 1 x PBS in Couplin jars and fixed in methanol (5 min) and 
acetone ( 15 min) at -20°C and then air-dried. The cells were washed 2 xwith PBS and 
permeabilized with 0.2% Triton X-1 00/PBS for 5 min at room temperature in a 
humidified chamber. The cells were then washed with PBS. The cells were blocked with 
3% bovine serum albumin/PBS (BSA/PBS) for 1 hat room temperature in a humidified 
chamber. The cells were then incubated with primary antibody diluted in 1.5°/0 BSA/PBS 
ovemight in a humidified chamber at 4°C. The next day cells were washed with 1 x PBS 
(3x) and incubated with 1 :50 dilution of fluorescein-conjugated antimouselantirabbit (as 
appropriate) secondary antibody for 30 min in the dark in a humidified chamber and 
washed with PBS (3x) and mounted with 10°/0 glycerol/PBS and viewed under an 
Olympus BHT System fluorescence microscope fitted to a Cool SNAP digital camera 
system controlled by the Cool SNAP software (Version 1.1) with a Seanix Computer 
with Windows 98. All pictures were taken at the original magnification of 200X 
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( eyepiece-1 OX X objective lens-20X). Portions of the microscope images were 
selected in Adobe Photoshop, (Version 5.4), and page-fitted in a page using Corel 
Draw (Version 7.0). The computer generated images as displayed herein were 
enlarged by a factor of 3; this produced a final magnification of SOOX. 
CHAPTER Ill 
INHIBITION OF EGF RECEPTOR KINASE ACTIVITY 
BY LAVENDUSTIN A: EFFECTS ON EGF 
RECEPTOR PHOSPHORYLATION AND VIABILITY 
IN MDA 468 CELLS 
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3.1 INTRODUCTION 
Growth factors produce cellular signals that are critically important for influencing 
diverse cellular responses including proliferation, differentiation and cell survival. 
Activation of growth factor receptors at the plasma membrane is the initial step in signal 
transmission to the cell interior {Resh, 1993). The effects of many growth factors are 
known to be mediated by receptor tyrosine kinases. 
Binding of ligand to the extracellular domain activates the tyrosine kinase in the 
cytoplasmic domain, thus triggering a sequence of events between receptors and 
cellular components, which, in turn, are responsible for the generation of second 
messengers {Fantl et al., 1993). Growth factors such as the epidermal growth factor 
(EGF), platelet derived growth factor (PDGF), and insulin enhance the phosphorylation 
of specific cell surface receptors leading to the downstream activation of common 
signaling molecules. Frequently activated proteins include phospholipase c-v (PLC·y), 
phosphatidylinositol3'·kinase (PI3'K), GTPase-activating protein (GAP), and MAP 
kinases {Fantl et al., 1993). The ultimate result of activation of these molecules leads 
to changes in gene expression and phenotypic state of the cell. 
The 53 amino acid polypeptide growth factor, EGF causes the proliferation of 
a variety of cells (Carpenter, 1984). This proliferative response of EGF is mediated by 
the 170 kD EGF receptor {EGFR). Increased expression and activity of the EGF 
receptor has been reported in several types of tumors including squamous cell 
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carcinomas of the lung, skin, oral cavity, and esophagus, brain tui raors (glioblastomas 
and meningiomas), breast carcinomas (Grosset a/., 1991 ), colon adenocarcinomas 
(Normanna et aL, 1998) and pancreatic adenocarcinomas (Friess eta/., 1996). EGFR 
overproduction has been associated with amplification of the EGF receptor gene in 
tumors of the head and neck (Grandis et al, 1998). In squamous cell carcinomas of the 
head or neck, disease-free survival and cause-specific survival was reduced in patients 
with higher levels of EGFR and TGF-a (Grandis eta/., 1998). In the DiFi cell line 
derived from a hereditary colorectal carcinoma there is overexpression of the EGF-
receptor-specific mRNA and overproduction of its membrane-associated EGFR (Gross 
eta/., 1991 ). Increased level of EGFR expression in tumors, its clear involvement in the 
malignant process and its accessibility on tumor cell surfaces (Modjtahedi et at., 1998) 
makes interception of the overexpressed EGFR activity an attractive target for the 
delivery of therapeutic agents aimed at restricting tumor progression and metastases. 
Study of the receptor protein, relationship to growth control and carcinogenesis 
have often relied on human tumor cell lines overexpressing the receptor. MDA 468 is 
an estrogen receptor negative human breast cancer cell line which overexpresses the 
EGFR to approximately 1.5 x 1 06 EGFRs/cell due to a 2Q-fold gene amplification 
located to an abnormal banding region on one copy of chromosome 7 (Filmus eta/., 
1985). The properties of the overexpressed receptor appear normal with respect to the 
binding affinity, synthesis, turnover, and autophosphorylation (Filmus eta/., 1987; 
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Kudlow eta/., 1986). 
3.1.1 Importance of EGFR in clinical studies 
Human breast cancer cell lines, malignant mammary epithelial cells and their 
surrounding stromal cells are responsible for the synthesis of a large number of growth 
factors (Ma eta/., 1998). The EGF ligand family includes EGF, transforming growth 
factor alpha {TGF-a), amphiregulin, heparin binding EGF (HBEGF) (Chandler et al., 
1998), hepatocyte growth factor (HGF) (Ma and Niederkom, 1998), and related 
polypeptides that stimulate the EGFR (Chandler et al., 1998). It has been postulated 
that the requirement of serum in cell culture is primarily due to the need for specific 
polypeptide growth factors and growth promoters. Inhibition of cell growth has been 
suggested to result from the blocking of EGF receptor activation by growth factor 
present either in the culture medium or produced by the cells in an autocrine fashion 
rNu et aL, 1995). EGFR overexpression is often accompanied by the production of one 
or more of its ligands by the same tumors suggestive of an autocrine loop which may 
be responsible for proliferation (Modjtahedi eta/., 1998). It has been seen that in about 
20-60% of EGFR overexpressing tumors in vivo, TGF-a is also overexpressed 
suggesting the presence of an autocrine loop which may provide a growth advantage 
to such tumors (Ma et al., 1998). Another ligand, amphiregulin, is also coexpressed 
(with EGF) in breast cancer cell lines and tumors (Plowman et al., 1990). 
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The EGFR plays an extremely important role in tumor progression and 
maintenance, and also EGFR and its ligands have been shown to be potentially 
involved in the growth of breast cancers in vivo. On an average, 45°/o of the breast 
cancers investigated by 40 different study groups were shown to be EGFR positive 
(Kiijn eta/., 1992). EGFR overelCPression has been shown to have a positive correlation 
with poor prognosis and a high risk of relapse (Ma eta/., 1998). 
EGFR expression is an important target of inhibition in many cancers because 
it is presumed to be one means by which cells acquire a selective growth advantage 
(Chandler eta/., 1998}. EGFR expression has been correlated with metastatic potential 
and capacity of human blood-borne uveal melanoma cells to localize in the liver. EGFR 
renders these cells resistant to the cytolytic activity of TNF-a. This is also true of colon 
carcinomas; colon carcinomas form progressive liver metastases in nude mice 
because TGF-a and HGF produced in the liver stimulate the proliferation of tumor cells 
by interacting with EGFR expressed in a wide variety of normal and malignant cells. 
EGFR expression is also correlated with the growth and metastases of hepatic. renal, 
laryngeal, esophageal and lung cancers (Ma and Niederkom, 1998). 
Blocking EGFR with a neutralizing antibody increased the susceptibility of uveal 
melanoma cells to transforming growth factor-a (TNFa) mediated cytolytic effects (Ma 
and Niederkom, 1998). Also, it has been shown that growth factor deprivation by the 
use of anti-EGFR monoclonal antibody (MAb) 225 in DiFi colorectal carcinoma cells, 
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induces apoptosis (Mandai et al., 1998). In a pilot study, where breast fine needle 
aspirations were performed on 224 high-risk and 30 low-risk women, it was found that 
overexpression of EGFR occurred in 37o/o of high risk and 3% of low risk subjects; the 
percentage of subjects with EGFR overexpression was higher than any other parameter 
measured including p53, ER (estrogen receptor) and HER-2/neuoverexpression in 
both high and low risk patients (Fabian eta/., 1997). 
3.1.2 Approaches to inhibition of the EGFR 
PTK inhibitors are useful tools to study the mechanism of action of various 
oncogenes exhibiting tyrosine kinase activity and perhaps also in the suppression of 
neoplastic diseases (Onoda eta/., 1989). Tyrosine kinase inhibitors have been used 
to dissect various intracellular effects of receptor and non-receptor kinases in a variety 
of in vivo and in vitro systems. It has been reported that inhibition of the EGFR kinase 
blocks EGF-dependent cell proliferation (Gazit et al., 1989). A class of PTK inhibitors, 
the tyrphostins are antiproliferative because they block the EGF-induced EGFR 
phosphorylation and subsequent PLC phosphorylation and Ca2+ release in living cells. 
Both of these EGF induced signaling steps lead to a cascade of molecular events 
ultimately leading to DNA synthesis and growth {Margolis eta/., 1989). 
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3.1.3 EGFR phosphorylation and cell viability 
Growth factor-stimulated EGFR kinase activity has been studied extensively. 
A correlation between cell survival and EGFR tyrosine kinase activity in growth factor 
dependent signaling pathways has been reported (Ertel eta/., 1998). Overexpression 
of the EGFR and elevated tyrosine kinase activity is associated with tumors of 
various types (Ward et al., 1994). Downregulation of the receptor kinase activity by 
antiEGFR MAb 225 induces apoptosis in human colorectal carcinoma DiFi and FER 
cells (Mandai et al., 1998). DiFi cells, which also overexpress the EGFR, were found 
to be sensitive to inhibition of EGFR kinase activity which eventually resulted in a 
loss of cell viability. EGFR blockade in EGFR overexpressing tumors induces cell 
death by apoptosis {Modjtahedi eta/., 1998). It is also well established that ligand 
deprivation leading to inhibition of the EGFR tyrosine kinase activity causes cell 
death by apoptosis (Moyer et al., 1997). 
In hematopoietic cells apoptosis is prevented by the inhibition of protein 
tyrosine kinase phosphorylation in response to a variety of stimuli (Hagar eta/., 
1997). In contrast, in thymocytes (Otani et al., 1993) and Molt-4 cells (Falcieri eta/., 
1993) inhibition of PTK activity enhances apoptotic mode of cell injury in thymocytes. 
In ovarian tumour cells, taxol (an antineoplastic agent)-induced apoptosis can be 
prevented by inhibition of PTK activity (Liu eta/., 1994 ). From these studies it can be 
seen clearly that tyrosine phosphorylation is linked to apoptotic cell death. 
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3.1.4 Objectives 
The basis of experiments described in this chapter deal with the modulation of 
EGF-stimulated EGFR tyrosine kinase activity in MDA 468 cells. To this end, "We used 
different PTK inhibitors to achieve inhibition of autophosphorytation of the EGFR. Initially 
these inhibitors were screened for their ability to inhibit EGFR autophosphorylation in 
isolated membrane preparations from serum-starved MDA 468 cells. Among the 
inhibitors screened, the PTK inhibitor lavendustin A (LA) effectively inhibited the EGF-
stimulated EGFR autophosphorylation in a time and concentration dependent manner. 
Since we intended to use this inhibitor for physiological studies, we also tested this 
inhibitor for any effects on cell viability in a time and concentration dependent manner. 
The results of this chapter lay the foundation for further experiments where the effects 
of blocking EGFR phosphorylation were investigated in MDA 468 cells. 
3.2 RESULTS 
3.2.1 Identification of the 170 kD EGFR 
EGF receptor phosphorylation is the initial event in dovvnstream signaling events 
following EGF binding.ln the initial experiments we confirmed the identity of the 170 kD 
EGFR protein by immunoprecipitating the EGFR with a mouse monoclonal antibody 
specific to the protein. Figure 3.1 (lane 1) represents the immunoprecipitated 170 kD 
EGFR band in response to EGF treatment. EGF greatly increased the phosphotyrosine 
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Figure 3.1 ldentHication of the 170 kD EGFR band In MDA 468 calls. 
Cells were serum-starved for 48 h following which they were treated with 1 o.a M EGF 
for 10 min. lmmunoprecipitated EGFR from EGF-treated cells and celllysates of control 
(untreated) and EGF-treated cells were run on a 7 .5°/o polyacrylamide gel. Separated 
proteins were transferred to a nitrocellulose membrane, probed with 
antiphosphotyrosine-specific PY20, and detected by enhanced chemiluminesence 
(Section 2.2.2, Chapter 2). This Western blot depicts the phosphotyrosine content of the 
immunoprecipitated EGFR and of EGFRfrom celllysates of unstimulated control and 
EGF-treated cells. The blot was probed with PY20 as described in the Materials and 
Methods (Section 2.2.2, Chapter 2). 
Lane 1-immunoprecipitated EGFR from cells stimulated with EGF. 
Lane 2-phosphotyrosine content of EGFR of cell lysate from unstimulated control cells. 
Lane 3-phosphotyrosine content of EGFR of cell lysate from cells stimulated with EGF. 
200 ,..,. 
116 ,... 
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content of the EGF-stimulated receptor (lane 3) with respect to the non-stimulated 
control (lane 2). 
3.2.2 Effect of PTK Inhibitors on the autophosphorylatlon of the EGF-stlmulated 
receptor 
In order to test the most effective PTK inhibitor capable of inhibiting the EGF· 
stimulated EGFR autophosphorylation, we used the inhibitors genistein, baicalein (an 
analogue of genistein), methyl2,5-dihydroxycinnamate (MHC), Iaven dustin B (LB), and 
lavendustin A (LA) in crude membrane preparations of serum-starved as well as whole 
MDA 468 cells. Examination of the chemical strudures showed that (Figure 3.2) LA and 
LB possess three benzene rings, A, B, C with a 2.5-dihydroxybenzene moiety in ring A. 
LB (LB is an analogue of LA) has a similar structure with the exception of a hydroxyl (-
OH) group at position 5 in ring A. MHC has a 2.5-dihydroxybenzene moiety and in 
genistein the hydroxyl groups are in the 3 and 5 positions of the benzene ring. In the 
following experiments we wanted to test whether the structural similarities and the 
dissimilarities among these PTKs would have an effect on the EGF-stimulated EGFR 
autophosphorylation. 
Cognizant of potential difficulties in obtaining sufficient drug concentration 
intracellularly, we tested them initially in crude membrane preparations of serum-starved 
MDA 468 cells. Genistein inhibited receptor autophosphorylation (Figure 3.3,1ane 4) 
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Figure 3.2 Chemical structures of PTK Inhibitors. 
Benzene ring A is present in all the 4 inhibitors. LA. LB. genistein and MHC possess 
a hydroxybenzene moiety (denoted by a square). 
LAVENDUmNB 
METHYL 2,5-DIIIYDROXYCINNAMA TE 
3 
4 
LA VENDUSTIN A 
GENISTEIN 
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Figure 3.3 Effect of PTK inhibitors on the autophosphorylation of EGFR in 
crude membrane preparations of serum-starved MDA 468 cells. 
Cells were serum-starved for 48 h following which crude membrane preparations 
were prepared as described in Materials and Methods (Section 2.2.2, Chapter 2). 
Serum-starved cells were exposed to PTK inhibitors listed below and then treated 
with 1 o-a M EGF for 1 0 min to test for their ability to inhibit the EGF-stimulated EGFR 
autophosphorylation. Cell lysates of control (untreated), EGF-treated, and 
inhibitor+EGF-treated cells were run on a 7.5% polyacrylamide gel. Separated 
proteins were transferred to a nitrocellulose membrane, probed with 
antiphosphotyrosine-specific PY20, and detected by enhanced chemiluminesence 
(described in Section 2.2.2, Chapter 2). This Western blot depicts changes (inhibition 
or no response) in EGFR autophosphorylation in response to genistein, MHC, LA, 
and LB. 
Lane 1-control, 
lane 2-10-a M EGF, 
lane 3-1% DMS0+10-a M EGF, 
lane 4-250 IJM genistein+10-a M EGF, 
lane 5-250 IJM baicalein+1 o.a M EGF, 
lane 6-530 IJM MHC+1 o-a M EGF, 
lane 7-1 IJM LA+10-a M EGF, 
lane 8-1 IJM LB+10-a M EGF. 
200 ~ 
EGFR~ 
116 ~ 
97.4~ 
123 4 56 7 8 
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at a concentration of 250 ~M. MHC showed no activity (lane 6). Both LA and LB 
effectively inhibited the receptor phosphorylation (lanes 7, 8). This differential sensitivity 
to these PTK inhibitors was also evident in serum-starved whole MDA 468 cells. 
Genistein was ineffective even at a concentration of 350 ~M (1 0 h) (Figure 3.4, lane 3). 
Cells exposed to as much as 530 ~M (2 h) MHC (lane 5) did not show any reduction in 
receptor autophosphorylation. LB inhibited the receptor autophosphorylation in isolated 
membrane preparations, but failed to inhibit receptor autophosphorylation at 1 J,JM after 
6 h of exposure (lane 6). 
3.2.3 Time-dependent inhibition of EGF-stimulated EGFR autophosphorylatlon 
by LA 
In the following experiments, we tested the ability of LA to inhibit the EGF-
stimulated receptor autophosphorylation in serum-starved MDA 468 cells. Although LB 
was effective in membrane preparations (Figure 3.3) but did not show any effect even 
after6 h of exposure in whole cells (Figure 3.4), even after 10 h exposure (not shown), 
LB has been reported to have an ICso value of 1.31JM (Onoda eta/., 1989) of inhibition 
of receptor phosphorylation. As seen from Figure 3.5, LA induced inhibition of the EGF-
stimulated receptor autophosphorylation in a time-dependent manner; this inhibition 
was not pronounced before 2 h of exposure (lanes 6-7).1nhibition appeared complete 
at6h (Figure3.5, lane4). Therefore, in laterexperimentsaperiodof6h incubation was 
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Figure 3.4 Lack of effect of some PTK inhibitors on EGF-stlmulated EGFA 
autophosphorylation in serum-starved MDA 468 cells. 
Serum-starved cells were exposed to PTK inhibitors listed below and then treated with 
10-a M EGF for 10 min to test for their ability to inhibit the EGF-stimulated EGFR 
autophosphorylation. Cell lysates of control (untreated), EGF-treated, and 
inhibitor+EGF-treated cells were run on a 7.5o/o polyacrylamide gel. Separated proteins 
were transferred to a nitrocellulose membrane, probed with antiphosphotyrosine-
specific PY20, and detected by enhanced chemiluminesence (described in Section 
2.2.2, Chapter 2). This Western blot depicts changes in EGF-stimulated EGFR 
autophosphorylation in response to the PTK inhibitors tested. Arrows to the left of figure 
indicate molecular weights of protein standards. 
Lane 1-control, 
lane 2-10-a M EGF, 
lane 3-350 IJM genistein (10 h)+10.a M EGF, 
lane 4-350 tJM baicalein (10 h)+10.a M EGF, 
lane 5-530 tJM MHC(2 h)+10-a M EGF, 
lane 6-1 IJM LB (6 h}+10-a M EGF. 
200~ 
EGFR~ 
116~ 
97.4~ 
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Figure 3.5 LA inhibits the EGF-stlmulatecl autophosphorylatlon of EGFR in a 
time-dependent manner in MDA 468 cells. 
Serum-starved cells were exposed to 1 J,JM LA from 15 min to 1 0 hand then treated with 
10-s M EGF for 10 min to test for its ability to inhibit the EGF-stimulated EGFR 
autophosphorylation. Cell lysates of control (untreated), EGF-treated, and 
inhibitor+EGF-treated cells were run on a 7.5°/o polyacrylamide gel. Separated proteins 
were transferred to a nitrocellulose membrane, probed with antiphosphotyrosine-
specific PY20, and detected by enhanced chemiluminesence (described in Section 
2.2.2, Chapter 2). Arrows in the figure indicate molecular weights of protein standards. 
Lane 1-control, 
lane 2-10-a M EGF, 
lane 3-1 IJM LA (10 h)+10-a M EGF, 
lane 4-1 IJM LA (6 h)+10-a M EGF, 
lane 5-1 IJM LA (4 h)+10-s M EGF, 
lane 6-1 J,JM LA (2 h)+10-a M EGF, 
lane 7-1 IJM LA (15 min)+10-s M EGF. 
1 2 3 4 5 7 
200~ EGFR 
116~ 
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chosen as a time period during which LA effectively inhibited the EGF-stimulated EGFR 
autophosphorylation. 
Interestingly, LA-induced inhibition of receptor autophosphorylation could be 
completely reversed 4 h after removal ofthedrugfromthemedium (Figure3.6, lane 5). 
Taken together, these results showed that LA effectively inhibited EGF-stimulated 
EGFR autophosphorylation in a reversible and a time-dependent manner in MDA 468 
cells. 
3.2.4 Dos•dependent inhibition of receptor autophosphorylation by LA 
LA was found to effectively inhibit receptor autophosphorylation in a dose -
dependent manner (Figure 3.7A). LA inhibited the EGF-stimulated EGFR 
autophosphorylation in MDA 468 cells with an IC50 value of 0.8 JJM (800 nM) as 
predicted from a sigmoidal dose response curve (Figure 3. 78). The IC50 of inhibition 
of autophosphorylation of EGFR was much higher in MDA 468 cells in contrast to the 
reported IC50 value of 20 nM for the inhibition of EGFR phosphorylation in A431 cells 
(Onoda eta/., 1989). 
3.2.5 Time and doa.dependent effect of LA on cellular morphology and DNA 
fragmentation 
MDA 468 cells treated with 1 J,JM LA were examined by light microscopy and 
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Figure 3.6 LA Induces reversal of inhibition of EGF-stimulated 
autophosphorylation of the EGFR. 
Cells were treated with 1 IJM LA for a period of 6 h, and then the drug containing 
medium was removed at specified intervals. At the end of these intervals, cells were 
stimulated with 1 o-a M EGF for 1 0 min and protein extraction was done. Celllysates of 
control (untreated), EGF-stimulated, and LA+EGF-treated cells were loaded on a 7 .5°k 
gel (Section 2.2.2, Chapter 2). 
Lane 1-control, 
lane 2-1 o..a M EGF, 
lane 3-1 IJM LA+ 1 o..a M EGF, 
lane 4-1 IJM LA 2 h after removal of LA, 
lane 5-1 IJM LA 4 h after removal of LA. 
1 2 3 4 5 
200,... 
EGFR,.._ 
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Figure 3.7 LA inhibits the EGF·stimulated EGFA autophosphorylatlon in a dose-
dependent manner in MDA 468 calls. 
Cells were serum-starved for 48 h were exposed to various concentrations of LA for 6 
h and stimulated with 1 a-a M EGF for 1 0 min. 
3. 7 A A Western blot showing the concentration-dependent effects of LA on the EGF-
stimulated phosphotyrosine content of the EGFR. 
Lane 1-control, 
lane 2-1 a.a M EGF, 
lane 3-0.5 °k DMS0+10-a M EGF, 
lane 4-1.0 JJM LA+10-a M EGF, 
lane 5-0.5 IJM LA+10..a M EGF, 
lane 6-0.251JM LA+10..a M EGF, 
lane 7-0.1251JM LA+10-a M EGF, 
lane 8-0.01 J,JM LA+10.a M EGF. 
3. 78 A dose-response curve was constructed from densitometric analysis of blots from 
5 separate experiments. Results were normalized for each experiment using 
unstimulated controls as zero and EGF-treated group as 1 OOo/o. A sigmoidal dose-
response curve was fitted to the data from which an IC50 value of 0.8 IJM was 
determined for the inhibition of EGFR phosphorylation. 
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quantitation showed that beyond 1 0 h, a large population of cells were surrounded by 
apoptotic bodies (not shown). This was confirmed by electron microscopy (EM). 
Cellular morphology was examined at various times (up to 24 h) after LA treatment 
(Figure 3.8). Cells exhibited membrane blabbing and nuclear condensation (14 h). At 
14 h 0.5 and 1 J,JM LA·treated cells exhibited classical ultrastructural features of 
apoptosis (Konstantinov eta/., 1998) such as chromatin condensation, cell shrinkage, 
vacuolization, and membrane blabbing (Figure 3.9). Since morphological evidence 
indicated that LA might be causing cell death by apoptosis, we examined the DNA 
fragmentation pattern by DNA gel electrophoresis. Figure 3.10 shows that at higher 
concentrations, LA produced DNA smearing (Lanes 3 and 4) similar to the positive 
control, cisplatin (20 IJg/ml) -treated cells (Lane 7). Cisplatin is a known cytotoxic agent 
with DNA binding capability (Coste eta/., 1999). We did not see a DNA laddering 
pattem which is produced as a result of smaller DNA fragments {180 bp), as is 
commonly seen in apoptotic cell death (Moyer eta/., 1997). 
3.2.6 Effect of LA on cell cycle 
Morphological evidence (Figures 3.8 and 3.9) is consistent with LA-induced 
apoptotic cell death in MDA 468 cells exposed beyond 10 h, as compared to cisplatin-
treated cells. We next examined if treatment of cells with LA produced any perturbations 
in the distribution of cells in various phases of the cell cycle (Figure 3.11 and Table 3. 1 ). 
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Figure 3.8 LA (1 JJM) induces changes in cellular morphology of MDA 468 cells 
beyond 1 o h exposure time. 
Cells were seeded in 60 mm dishes. The next day, cells were treated with 1 IJM LA for 
different periods of time in order to identify a time period when cells lost viability. Cells 
were trypsinized, fixed, and the cell pellets were resuspended in 0.1 M sodium 
cacodylate buffer, pH 7.4. EM specimens were processed as described in Materials 
and Methods (Section 2.2.4, Chapter 2) and viewed under a JOEL 1200 EX electron 
microscope at 3000X and photographed. 
1-control 
2-1 IJM LA-treated cells (8 h) 
3-1 IJM LA-treated cells (10 h) 
4-1 IJM LA-treated cells (14 h) 
5-1 IJM LA-treated cells (24 h) 
6-20 IJg/ml cisplatin (a positive control)-treated cells (8 h) 
B denotes blabbing (of membrane) 
1 
4 5 
6 
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Figure 3.9 LA induces changes in cellular morphology of MDA 468 cells in a 
dose-dependent manner at 14 h. 
Cells were seeded in 60 mm dishes. The next day, cells were treated with different 
doses of LA for a period of 14 h. Cells were trypsinized, fixed, and the cell pellets 
were resuspended in 0.1 M sodium cacodylate buffer, pH 7 .4. EM specimens were 
processed as described in Materials and Methods (Section 2.2.4, Chapter 2) and 
viewed under a JOEL 1200 EX electron microscope at 3000X and photographed. 
A-control untreated cells 
B-1 IJM LA-treated .cells 
C-0.5 IJM LA-treated cells 
D-0.25 IJM LA-treated cells 
E-0.125 IJM LA-treated cells 
In the figures, B denotes membrane blebbing; V-vacuoles; RER-rough endoplasmic 
reticulum; M-mitochondria. 
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Figure 3.10 Dose-dependent effect of LA on DNA fragmentation at 14 h. 
Cells were seeded in 1 0 em dishes. The next day LA was applied in various 
concentrations and cells were exposed to the drug for a period of 14 h. At the end of this 
period, cells vvere harvested by trypsinization and DNA was extracted as described in 
Materials and Methods (Section 2.2.5, Chapter 2). 
Lane 1-1 kb DNA marker 
iane 2-untreated control 
lane 3-1 ~M LA-treated cells 
lane 4·0.5 IJM LA-treated cells 
lane 5-0.25 ~M LA-treated cells 
lane s-o. 125 IJM LA-treated cells 
lane 7 -cisplatin (20 IJg/ml)-treated cells 
bp 
12,000 
4,000 
3,054 
2,036 
1,636 
1,018 
500 
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Figure 3.11 LA produces concentration-dependent effects In cell cycle 
distribution at 14 h in MDA 468 cells. 
Representative FACS generated DNA histograms of MDA 468 cells treated with LA 
for 14 h. The histograms are a representation of propidium iodide (PI) fluorescence 
(FL2-A) versus cell number. The PI fluorescence is directly proportional to the amount 
of DNA in the cell and the relative cell number is given by counts. DNA was analyzed 
using PI fluorescence. Approximately 10,000 cells were analyzed per sample as 
described in the Materials and Methods (Section 2.2.6, Chapter 2). AO denotes a 
subdiploid peak. 
1-untreated control 
2-1 IJM LA-treated cells 
3-0.5 J,JM LA-treated cells 
4-0.25 IJM LA-treated cells 
5-0.125 IJM LA-treated cells 
0.5 IJM (3) and 1 IJM (2) LA caused a decrease in the surviving cell population 
(represented in the Gh Sand G2M peaks respectively), compared to 4 (0.25 IJM) and 
5 (0.125 IJM) respectively .In 2 and 3 respectively, a prominent subdiploid peak (AO) is 
present. 
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Table 3.1 Percentage distribution of cells in various phases of the cell cycle in 
response to different concentrations of LA after 14 h incubation. 
G, s 
Control 52.3 :t 0.95 33.9 ::t 0.52 14.9 :1: 1.60 
1 t.JM LA 41.1 :t 0.74 21.0 :t 0.54 37.9 :t 1.21 * 
0.51JM LA 36.3 :t 0.50 18.5 ::t 2.60 47.8 :t 2.60* 
0.25 t.JM LA 42.8 :t 1.41 17.8 :t 1.30 39.4 :t 2.1 0* 
0.125 t.JM LA 61.8 :1: 1.62 24.6 :t 1.80 13.6 :t 1.83 
Data are represented as mean :t S. E. M. of four experiments. *Values are significantly 
higher than control (p<0.005). 
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Flowcytometry showed the appearance of a subdiploid peak (Ao). at concentrations of 
0.5 and 1 IJM after cells were exposed for 14 h. LA treatment caused a distinct G2M 
arrest at concentrations between 0.25-1 IJM with a concomitant decrease of cells in the 
G1 and S phases respectively (Figure 3.11 and Table 3.1). 
3.2. 7 Toxicity of LA in MDA 468 cells 
EM. DNA fragmentation, and cell cycle analysis data are consistent with the idea 
that LA might induce cell death by apoptosis. From Figure 3. 7 we found that when cells 
were exposed to 1 IJM LA, there was an inhibition in the EGF-stimulated 
phosphorylation. However, it was evident that beyond 1 0 h exposure, cells lost their 
viability. Thus, 1 IJM LA was lethal to the cells at longer exposures. We therefore tested 
the cytotoxic activity of LA using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay in MDA 468 cells (Cole, 1986; Alley eta/., 1988) with 1 IJM as the 
highest concentration. To predict an TC50 value for the cytotoxicity of LA, we exposed 
the cells for a period of 24 h to various concentrations of LA. A 24 h exposure time is 
a more sensitive assessment of the cytotoxicity (or cell killing) activity of a cell cy~le 
specific drug (Matsushima et al., 1985). Cells were found to be growth arrested at 14 
h, and therefore, the MTT was used to assess cell viability following a 24 h period of 
exposure to LA. Cells were exposed to doubling dilutions upto 1 IJM, the highest 
concentration used earlier. Figure 3.12 shows that LA was also highly cytotoxic at 
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Figure 3.12 Toxicity of LA in MDA 468 cells at 24 h. 
Cells were grown in 96-well plates. The next day LA (at a starting concentration of 1 IJM) 
was applied in doubling dilutions in five wells for each concentration and the cells were 
exposed to drug for a period of 24 h. After 24 h cells were washed with 1 x PBS and 
fresh media was applied and the cells were incubated for a further 24 h period. The next 
day 0.5 mglml MTT (in L 15) was added to the cells for 4 h. At the end of 4 h, MTT was 
removed and replaced by DMSO and the resulting absorbance was read at 540 nm 
(Section 2.2.7, Chapter2). Each concentration is represented as a mean :t:S. E. M. of 
five data points. 
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concentrations vvhich caused maximal inhibition of EGFR autophosphorylation. In MDA 
468 cells the TCso of LA was determined to be 0.4 IJM from the fitted sigmoidal dose 
response curve (Figure 3. 12). At a lesser exposure time (6 h) of cells to LA in the same 
concentrations, we found that LA caused inhibition of the EGFR autophosphorylation, 
but inhibited the biochemical effect with a much higher 50°/o value (IC50 was 0.81JM; 
Figure 3.7b). 
MTT is reduced by mitochondrial dehydrogenases (succinate-tetrazolium 
reductase system of the mitochondrial respiratory chain) to form an insoluble formazan 
salt (Bradshaw eta/., 1998), which absorbs maximally at 540 nm. The MTT is cleaved 
by metabolically active cells with an active respiratory chain, and therefore, this assay 
detects only viable cells (Cole, 1986; Alley eta/., 1988), which would reduce the MTT 
to form insoluble formazan crystals. Following exposure of drug to the cells, cells were 
allowed a further 24 h recovery period. From this dose-response curve we were able 
to predict the effective non-toxic concentration range (and exposure time) of LA to use 
for further studies. 
3.3 DISCUSSION 
Receptor autophosphorylation is a central event in growth factor signaling. The 
tyrosine kinase domain of the EGFR, intracellular to the ligand binding region, is not only 
responsible for the receptor-triggered stimuli, but also non-specific stimuli like cell-cell 
•. 
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contact or chemical insult. Thus this domain is regarded as an attractive target for 
various PTK inhibitors developed in an attempt to inhibit uncontrolled proliferation in the 
study of malignant diseases. Our aim was to find a drug that would effectively block 
EGF-stimulated EGFR tyrosine kinase activity in whole MDA 468 cells. 
Our experiments with a selection of drugs showed that EGF-stimulated EGFR 
autophosphorylation in MDA 468 cells could only be inhibited by the PTK inhibitor LA. 
LA was reported to be a potent inhibitor of EGFR autophosphorylation in A431 cells 
(Onoda et al., 1989). LA, first isolated from the butyl acetate extract of Streptomyces 
griseo/avendusculturefiltrate, is a competitive inhibitor of intracellular ATP (Onoda et 
a/., 1989). However, there have been reports that LA is a "mixed-type" inhibitor i.e. it is 
competitive with respect to ATP binding as well as the ligand EGF with the receptor 
(Hsu et al., 1991). As a potent PTK inhibitor, LA blocked the autophosphorylation of the 
EGFR in MDA 468 cells. LA matched the criteria for successful inhibitors like stability 
in biological media, selectivity, cell permeability, and formulability respectively (Levitzki 
and Gazit, 1995; Traxler, 1997). 
MDA 468 cells exhibited a differential sensitivity towards the PTK inhibitors 
tested (Mandai eta/., 1998). From results in this chapter, we can hypothesize a 
systematic structural relationship between the PTK inhibitors used and correlate it with 
the response of the MDA 468 cells to the inhibitors. Of the inhibitors with a 2,5· 
dihydroxybenzene moiety, namely LA, and MHC (Figure 3.2}, only LA effectively 
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inhibited EGFR autophosphorylation in crude membrane preparations and in whole 
cells. LA has an additionai-OH group as compared to LB and genistein has two -OH 
groups in positions 3 and 5 of the benzene ring. LB was effective only in crude 
membrane preparations. Therefore it can assumed that having the 2,5-dihydroxyl 
benzene moiety with the other structures in LA must provide the essential criteria 
necessary for cell permeability and effectiveness in inhibiting autophosphorylation in 
MDA 468 cells. Interestingly, this moiety present in LA is also present in another PTK 
inhibitor, erbstatin (we did not test this compound), which is a competitive inhibitor of 
substrate binding to the receptor (Burke, 1992). It has been shown from structure-activity 
studies that this simplified structure of LA may contain the key elements necessary for 
PTK inhibition (Onoda eta/., 1989). Changing the positions of -OH groups (3 and 5 of 
A in genistein), the absence of the additional hydroxyl group (at position 5 of A in LB), 
or the presence of the 2,5-hydroxylbenzene moiety alone (as in MHC) were probably 
inadequate to meet the structural requirements for effective inhibition of EGFR 
autophosphorylation in MDA 468 cells. 
The ineffectiveness of the other PTK inhibitors with the exception of LA may also 
be due to factors other than their structural characteristics. Pharmacological properties 
such as stability in biological media, cell permeability. or metabolism of the inhibitor are 
some of the factors which also determine the potency of a particular drug (Levitzski and 
Gazit, 1995; Traxler, 1997). Several erbstatin derivatives were synthesized with 
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improved stability, but the result was poor cell permeability (Traxler, 1997). MHC was 
synthesized as an erbstatin derivative with improved stability and cell permeability, and 
it, like genistein, was found to be very effective in inhibiting EGFR autophosphorylation 
in A431 cells (Umezawa et al., 1990). Since MHC was not effective either in MDA 468 
membrane preparations (Figure 3.2) or in whole cells (Figure 3.3), it may be indicative 
of the instability of the compound under the conditions used (in membrane preps.), as 
well as perhaps poor penetration (in whole cells), or both (this is particularly true in case 
of whole cells). The required effective concentration of some PTK inhibitors may be 
higher than that of monoclonal antibodies (MAb) because larger number of inhibitor 
molecules are also required to prevent phosphorylation of the five tyrosines on the 
EGFR molecule compared to one MAb which can block activation of two receptors 
(Mod~ahedi et al., 1998). In some cases, PTK inhibitors (those that are competitive with 
ATP binding to the intracellular membranes) that are potent in vitro are ineffective in 
whole cells unless the intracellular concentration of ATP is reduced artificially (Levitzski 
and Gazit, 1995). We have no data of the energy content of the MDA 468 cells after 
serum starvation. Genistein, a natural isoflavone, isolated from the fermentation broth 
of Pseudomonas sp., is a highly specific inhibitor of tyrosine kinases. It was found to 
effectively inhibit the EGF-stimulated tyrosine phosphorylation of the EGFR 
overexpressing cell line, A431 (Akiyama eta/., 1987), but was ineffective in MDA 468 
cells, which also overexpress the EGFR (Figure 3.3). It is difficult to say, but inhibitors 
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used, other than LA, were perhaps ineffective in inhibiting the receptor kinase activity 
due to a high intracellular A TP content which actually blunted the effect of the inhibitors. 
In this study, LA can produce an inhibition of receptor tyrosine kinase activity in 
a time and concentration dependent manner at short incubation times {6 h) without 
cytotoxicity. Ultrastructural changes in morphology of MDA 468 cells treated with 1 IJM 
LA at various times show that this concentration is lethal to the cells when exposed for 
a period beyond 10 h (Figure 3.8). Cells start to show changes in morphology such as 
membrane blabbing, nuclear condensation, and vacuolization at 14 h (Figures 3.8 and 
3.9).1n addition, the appearance of a pronounced subdiploid peak in cells treated with 
0.5-1 IJM LA ( 14 h) from flow cytometric analysis is also consistent with apoptotic cell 
death (Figure 3.11 ). From these data we concluded that at longer incubation times, LA 
at higher concentrations produces a loss of cell viability at concentrations which 
inhibited EGFR kinase activity maximally. However, we observed DNA smearing 
{Figure 3.11) rather than a fragmentation pattem commonly observed in apoptosis 
(Moyer eta/., 1997) in response to LA or cisplatin treatment. lntemucleosomal DNA 
degradation results in DNA ladder formation, although the absence of DNA laddering 
is not unprecedented in apoptotic cell death. Apoptosis without DNA ladder formation 
has been reported (Tomei eta/., 1993; Gulli eta/., 1996; Oridate eta/., 1996). It has 
also been shown that DNA can be cut into larger (30 kbp) rather than smaller ( 180 bp) 
fragments, resulting in a DNA smear instead of a DNA ladder on gel electrophoresis 
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(Ormerod et al., 1994 ). It is also possible that intemucleosomal DNA fragmentation as 
a result of LA treatment may be occurring at a later time point beyond 14 h. Probably 
this is the reason we saw an absence of DNA laddering; we observed smearing in 
response to higher doses of LA and cisplatin-treated cells. 
Apoptosis or programmed cell death (PCD) occurs in response to both 
physiological and pathological stimuli in a variety of tissues. This mode of cell death 
may be triggered by specific inducers. such as cytotoxic agents, irradiation, growth 
factor deprivation. hormones, or by blockers of G1, S, or M phases of the cell cycle 
(Alison and Saraf, 1992; Columbel eta/., 1992; Ryan eta/., 1993; Amstrong et al., 
1994; Yamamoto et a/., 1999). Such is the case in squamous cell carcinomas 
overexpressing the EGFR where inhibition of the receptor by anti-EGFR MAbs or PTK 
inhibitor causes the cells to undergo apoptosis (Modjtahedi eta/., 1998).1n MDA 468 
cells too we speculate that LA may be producing cell death by blocking EGFR tyrosine 
kinase activity which may be thus playing a functional role in cell death progression. 
EGFR overexpression is an important factor in the progression and maintenance 
of a wide variety of cancers. Besides extensive laboratory research of the EGFR 
signaling pathway in different cell lines and xenographic studies, the approach of 
interception of the EGFR kinase activity has advanced to phase II clinical trials. Thus, 
the concept of inhibition of growth factor receptor-mediated signal transduction via 
inhibition of its PTK is a novel concept which is and will be in future greatly utilized in 
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clinical studies in attempts to stop unwanted proliferation of malignant cells. Using this 
estrogen receptor-negative human breast cancer cell line model, we have been able to 
interfere with EGF-stimulated EGFR kinase pathway to further investigate the 
proliferative outcome of MDA 468 cells. 
CHAPTER IV 
INHIBITION OF EGF RECEPTOR TYROSINE 
KINASE ACTIVITY BY LAVENDUSTIN A: EFFECTS 
ON PI TURNOVER IN MDA 468 CELLS 
4.1 INTRODUCTION 
4.1.1 Background 
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Stimulation of MDA 468 cells by the epidermal growth factor (EGF) leads to the 
autophosphorylation of EGF receptor (EGFR). From the results of chapter 3, it became 
clear that this growth factor stimulated effect was inhibited by the protein tyrosine kinase 
(PTK) inhibitor lavendustin A (LA) after a 6 h exposure. Longer incubation with LA 
however, became toxic to the cells. In this chapter we discuss the effect of inhibition of 
EGF-mediated EGFR autophosphorylation on an early signaling event following 
receptor autophosphorylation, namely phosphatidylinositol {PI) turnover. 
Activated EGFR associates with a number of signaling molecules. It is known 
that EGF stimulation leads to an increase in PI turnover because of EGFR interaction 
with phospholipase C-y (PLC-y). This comes about due to a high-affinity interaction 
between autophosphorylated tyrosine 992 in the EGFR molecule and PLC-V (Rotin et 
a/., 1993) through its SH2 domain (Koch eta/., 1991). Earlier work from this laboratory 
(Church eta/., 1992) demonstrated an increase in PI turnover in response to EGF. On 
closer examination it was found that MDA 468 cells exhibit an atypical PI turnover 
profile, unlike that generated by PLC-y (Church et al., unpublished observations). Here 
we show that changes in EGFR phosphorylation, either by EGF stimulation or by 
inhibition with the PTK inhibitor LA, correspond with changes in an acid labile PI 
metabolite, which we identify as my~inositol1,2-{cyclic) monophosphate (ciP) using 
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electrospray ionization mass spectrometry (ESI MSJMS). The implications of the 
formation of ciP in these cells as a result of changes in the status of EGFR 
autophosphorylation are discussed. 
4.1.2 PI turnover and ciP 
Binding of EGF in a wide variety of cells (Fantl et al., 1993) expressing the 170 
kO epidermal growth factor receptor (EGFR) leads to receptor dimerization and rapid 
phosphorylation (Margolis eta/., 1989) leading to the downstream phosphorylation and 
activation of substrates including PLC-y. The tyrosyl phosphorylation of PLC stimulates 
the increased hydrolysis of the membrane phosphatidylinositols (Pis), namely 
phosphatidylinositol {PI), phosphatidylinositol 4-phosphate (PIP) and 
phosphatidylinositol 4,5-bisphosphate (PIP:z), leading to the generation of inositol 
phosphates and diacylglycerol (DAG) {Rhee eta/., 1989; Ross eta/., 1991). 
When PLC cleaves PI (direct cleavage) or when PIP2 is cleaved (indirect 
cleavage) both cyclic and non-cyclic inositol phosphates are generated (Ryu eta/., 
1 987). The enzymatic removal of phosphates at positions 4 and 5 of the inositol ring 
results in the production of myo-inositol1 .2-( cyclic) monophosphate (ciP) (Connolly et 
a/., 1986; Kim eta/., 1989). In most mammalian systems the proportion of cyclic and 
non-cyclic inositol phosphates generated depends upon which of the various isoforms 
of PLC interact with the activated receptor. All three isoforms of PLC (namely p, 6, y) 
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catalyze the hydrolysis of the PI (Ryu eta/., 1987). The ratio of production of cyclic to 
non-cyclic phosphates decreases in the order of PLC-13>PLC-0>PLC-y (Connolly et 
a/., 1986). Only 5-1 OOk of the PLC-y hydrolysis products are cyclic in contrast to 90-95o/o 
of non-cyclic PI products comprising of OAG, IP (inositol monophosphate), IP2 (inositol 
bisphosphate) and IP3 (inositol trisphosphate) (Berridge and Irvine, 1989; Rhee and 
Choi, 1992). Accumulation of cyclic PI metabolites in response to agonist stimulation 
has been observed in mouse pancreas (Dixon and Hokin, 1985; Sekar et al., 1987; 
Dixon and Hokin, 1987), in kidneys of mouse, rat, guinea pig and ox (Dawson and 
Clarke, 1973), human platelets (Tarver et a/., 1987), Limulus photoreceptor cells 
(Wilson eta/., 1985) and SV40 transformed STU-51 A/2328 mouse cells (Koch and 
Diringer, 1974). In some species, such as the intracellular bacterial pathogen L. 
monocytogenes, a specific PLC produces only ciP and DAG from PI breakdown 
(Camilli eta/., 1991 ). In Morris hepatomas and in cell lines derived from these tumors, 
high levels of ciP (1 00 IJM) have been observed (Graham eta/., 1987) compared to 
non-detectable levels in normal liver tissues (Ross eta/., 1991 ). 
Evidence suggests that ciP and its polyphosphates have physiological functions 
in cells. They have been shown to act as second messengers (Putney and Bird, 1993) 
correlated with cell growth (Ross et a/., 1991 ). Thus, if ciPs are physiologically 
important, a mechanism for their breakdown must be present (Sekar et a/., 1997). 
Dawson and Clarke (1972) showed the existence of an enzyme known as cyclic inositol 
115 
phosphohydrolase (ciPH) which had a high degree of specificity because it cleaved the 
cyclic bond of ciP between the phosphates at positions 1 and 2 only, but not the higher 
cyclic inositol polyphosphates (Boss and Majerus, 1986). This 1 :2 cyclic bond in ciP is 
also sensitive to acid hydrolysis (Dean and Moyer, 1987). The activity of this enzyme 
has been found to change in disease. ciPH released per day was found to be several 
hundred-fold higher in urine of patients with various pathological conditions, such as 
diabetes, hypertension, multiple myeloma, renal transplants and stroke compared to the 
relatively low activity in normal, healthy volunteers (Sekar eta/., 1997). Thus, cyclic 
inositol phosphates are potentially important components of the PI metabolic pathway 
and changes in their metabolism may be indicative of disease. 
4.1.3 Analysis and identification of PI metabolites in MDA 468 cells 
Prelabeling cells with radiolabeled inositol enables the investigation of 
components of PI tumover after their extraction and separation from the cells (Dean and 
Moyer, 1987). To avoid dilution of the radiolabelleading to inadequate labeling of the 
inositol pools, we used an inositol-free media and labeled the inositol pools for a period 
of 48 h. Uthium chloride (1 0 mM) was added to the media before adding EGF, because 
u+ inhibits several of the inositol phosphomonoesterases and causes increased 
accumulation of inositol phosphates (Dixon eta/., 1992; Lee eta/., 1992; Dixon and 
Hokin, 1994); without u• the increase in levels of the IPs is substantially reduced 
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because of the rapid turnover of these compounds in tissues. The use of u• is 
dependent on the objective of the experiment. For example, if an increase in IP3 is to 
be related to an increase in [Ca2•), then u• should be avoided. But if a measurement 
of the extent of receptor activation is done, the paccumulation of inositol phosphates in 
the presence of u• is a more accurate measure of the state of activation of the cell 
(Dean and Beaven, 1989). We extracted the inositol phosphates under neutral 
conditions to avoid breakdown of any acid-labile PI metabolites (Dean and Beaven, 
1989). 
High pressure liquid chromatography (HPLC) has been the method of choice for 
separating the PI metabolites, both cyclic and non-cyclic. Most HPLC procedures 
employ anion-exchange column (example, Partisil SAX 1 0) and an aqueous mobile 
phase of ammonium formate, acetate, or phosphate to elute the water-soluble inositol 
phosphates. Stepped gradients are employed now, although original procedures used 
linear gradients. In our experiments, we have used ammonium phosphate gradient and 
a Partisil SAX 10 anion-exchange column with stepwise increments in concentrations 
of ammonium phosphate to allow adequate time for the separation of PI metabolites 
(Dean and Beaven, 1989). This aqueous mobile phase gradient gave us a good 
separation. The elution profile of non-cyclic IPs were compared with the available 
tritiated IP standards (described in Chapter 2, Section 2.2.8.2). 
To confirm the identity of the acid labile PI metabolite, we used the technique of 
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low energy collision tandem mass spectrometry (ESI CAD MS/MS) using electrospray 
ionization mass spectrometry. Mass Spectrometry using etectrospray ionization (ESI 
MS) was selected as a method of choice for the purpose of identification of the PI 
metabolite since this ionization method did not require derivatization of the analytes. 
ESI MS allows rapid, accurate and sensitive analysis of a wide range of anatytes of a 
broad spectrum of natural products from the low molecular weight polar compounds 
( 100 Daltons) to biopoymers larger than 200 kDa. The ESI MS technique usually yields 
the intact protonated or deprotonated molecular ion. By using ESI MSIMS identification 
of unknown substances can be achieved by their characteristic ion fragmentation 
pattem (Gysler eta/., 1999). Dissociation may be induced or activated by collision.ln 
this process part of the kinetic energy of the ions is converted to internal energy by 
colliding with a neutral gas phase species, usually in the pressurized collision cell of the 
tandem mass spectrometer (MS/MS) instrument. Ions that have undergone this 
collisional excitation process may subsequently fragment. Thus, collision activated 
dissociation (CAD) MS/MS and in particular low energy CAD MSIMS is a valuable 
method for generating structural information (Busch eta/., 1988). 
4.1.4 Objectives 
From the results of Chapter 3, it is clear that stimulation of MDA 468 cells with 
growth inhibitory concentrations of EGF (10-a M), caused autophosphorylation of the 
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EGFR. This effect could be inhibited by the PTK inhibitor, LA. It was demonstrated by 
Church eta/. ( 1992) that 1 o-e M EGF caused an overall increase in the total PI turnover 
in the MDA 468 cells. In the course of further experiments, it became clear that a 
considerable portion of the PI turnover constituents consisted of a metabolite which was 
acid-labile. Our aim was to identify this metabolite and to study the effect of both the 
stimulation and inhibition of EGFR phosphorylation on the PI tumover profile in this cell 
line. We further demonstrated that EGFR autophosphorylation-mediated increase in PI 
turnover was largely due to increase in ciP production, and that this increase was 
inhibited by the PTK inhibitor, LA in MDA 468 cells. 
4.2 RESULTS 
4.2.1 Separation of IPs and their HPLC profiles in EGF and LA treated cells 
Since increased PI turnover has been linked to EGFR autophosphorylation. we 
examined the PI turnover profiles in both EGF and LA+EGF treated cells (6 h). Figure 
4.1 A shows the HPLC profile of individual [3H]-inositol phosphate standards. Figures 
4. 1 B. 4. 1 C, and 4. 1 D show the representative profiles of [3H]-inositol phosphates of 
control. EGF and LA treated, serum-starved MDA468 cells, respectively. Compared 
to the standard profile, we found that cell extracts from all three groups (B. c. and 0 
respectively) showed a peak eluting between fractions 9-14 (peak 3). As can be seen 
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Figura 4.1 Effect of EGF and LA on the profiles of inositol phosphates in MDA 
468 cells. 
Cells were labelled with [3H)-mycrinositol for 48 h under serum-free, inositol-free 
conditions at 5°A. C02 at 37°C followed by the addition of 1 0 mM UCI for 30 min. Cells 
were treated with 1 J,JM LA for 6 h and stimulated with 1 o-a M EGF for 20 min and 
inositol phosphates were extracted under neutral conditions as described under 
Materials and Methods (Section 2.2.8.1, Chapter 2). Samples were analyzed by HPLC 
and inositol and its charged metabolites were separated by HPLC using a Partisil SAX 
10 column (Section 2.2.8.2, Chapter 2). Representative HPLC profiles generated by 
EGF and LA treatment are shown: standard inositol phosphates (A), untreated control 
(B), EGF-treated (C) and LA-treated (D) MDA 468 cells. 
Peak "3" is the component which corresponded to the changes as a result of various 
changes in 8, C, and D as mentioned above. 
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from Figure 4.1 B, the untreated control cells showed that peak 3 was a major (60°/o) 
constituent of the PI metabolites in the HPLC profile. Interestingly, peak 3 showed a 
large increase upon 1 o.a M EGF treatment (Figure 4.1 C) while 1 IJM LA prevented the 
EGF-mediated increase (Figures 4.1 D). 
4.2.2 Effect of acid treatment on peak 3 
Peak 3 elutes immediately after the [3H]-myo-inositol peak comparing that with 
similar data from published literature (Dean and Moyer, 1987). We therefore suspected 
that this peak could be ciP. If this was the case, peak 3 eluting between fractions 9-14, 
might be acid labile. Therefore, we separated the IPs from a control, untreated cell 
lysate and collected fractions from it (Figure 4.2A). We then subjected the fractions 
harboring this peak (peak 3) to acid hydrolysis for 3 min with 0.1 M HCI at 80°C. As can 
be seen from Figure 4.28, as a result the peak was abolished and 90% of the 
radioactivity was recovered as the inositol1-phosphate (1-1 P) and inositol2-phosphate 
(I-2P) peak. From this experiment we obtained biochemical evidence that peak 3 was 
acid-labile and that subjecting it to acid hydrolysis caused its breakdown to IP. 
4.2.3 Identification of peak 3 by ESI MS/MS analysis 
To confirm the identity of this acid labile metabolite, we subjected peak 3 (Figure 
4.1 B) to mass spectrometric analysis. We analyzed a sample of available ciP standard 
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Figure 4.2 Effect of acid-treatment on peak 3 
Cells were seeded and then after 48 h inositol phosphates were extracted under neutral 
conditions. The PI turnover metabolites as a result of different treatments are shown in 
Figure 4.1. A control, untreated sample before acid treatment (A); the same sample 
was treated with 0.1M HCI at aoac for-3 min and then run on the column with the 
gradient. Acid hydrolysis of the sample was done to test if peak 3 was acid-labile or not. 
Counts in peak 3 disappeared on acid treatment and the counts were recovered as the 
1-1 P peak (B). 
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by negative ion electrospray mass spectrometry (Figure 4.3A) at m/z241. The ESI MS 
showed the presence of the deprotonated molecule [M-H)" at mlz 241 and the 
deprotonated dimer [2M-HT at mlz 483 and no fragmentations were observed. Low 
energy collision activated dissociation (CAD MS/MS) analysis was conducted to 
enhance the fragmentations observed in [M-Hr at mlz 241 in the conventional 
electrospray mass spectrum of ciP. The product ion spectrum (CAD MS/MS) arising 
from the fragmentation of precursor ion at m/z241 in the RF-only hexapole collision cell 
is presented in Figure 4.38. The connectivity between fragment ions was established 
using MS/MS analysis of precursor and fragment ions. The CAD tandem mass 
spectrum of deprotonated ciP molecule shown in Figure 4.38 suggested that the series 
of product ions originated from ciP precursor deprotonated molecule. Figure 4.3C 
shows the CAD tandem mass spectrum of the precursor ciP deprotonated molecule 
{obtained from peak 3, Figure 4.1 B). 
4.2.4 Effect of EGF and LA on the overall PI turnover and the proportion of 
cyclic and non-cyclic IPs 
Cells were labelled with [3H]-myo-inositol for 48 h and then treated with 1 o·8 M 
EGF and 1 IJM LA (6 h) and the cellular content of total inositol phosphates were 
determined as described in Materials and Methods (Chapter 2; Section 2.2.8). Figure 
4.4 shows the changes in the overall PI turnover and the change in the proportion of 
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Figure 4.3 ESI MS and CAD MSIMS of standard ciP and peak 3. 
Neutrally extracted samples from HPLC fractions (9·14) were collected, freeze-dried 
and analyzed using ESI MS/MS and CAD MS/MS on a Micromass VG Quattro 
quadrupole-hexapole-quadrupole mass spectrometer. Fractions harboring peak 3 
(Figure 4.1 B, C and D respectively) were compared to the standard ciP for the specific 
fragmentation pattern. A) is the electrospray mass spectrum of deprotonated standard 
ciP molecule [M-Hr at m/z241. B) is the product ion spectrum (CAD MSIMS) of product 
ion arising from the fragmentation of m/z241, and C) is the CAD MS/MS spectrum of 
the precursor deprotonated molecule derived from the HPLC fraction (peak 3, 4. 1 B) 
(described in Section 2.2.9, Chapter 2). 
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Figure 4.4 Effect of EGF and LA on the total PI turnover and the relative 
proportions of cyclic and non-cyclic PI metabolites in MDA 468 cells. 
Neutral extracts from serum-starved cells treated with EGF ( 1 o-s M) and 1 IJM LA+ 1 a-s 
M EGF respectively were analyzed by HPLC and the overall PI turnover and the change 
in the proportion of cyclic and non-cyclic phosphates were quantitated from the area 
under the curves. Results are expressed as mean :t S. E. M. of four experiments each 
performed in duplicate. '*Total PI turnover significantly higher control (p<O.OS); ••total PI 
turnover significantly lower compared to control (p<0.005). 
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cyclic and non·cyclic phosphates in response to EGF (10-a M) and LA (11JM)+10-a M 
EGF respectively. As seen from Figure 4.4, EGF causes a significant increase (p<O.OS) 
in the overall PI turnover, and LA causes a significant decrease (p<0.005) when 
compared to the control. Untreated control MDA 468 celts showed a very high 
proportion of ciP 'Nhich was about 60% of the total inositol phosphates. EGF stimulation 
more than doubledtheciPfraction, accountingfor80°/o ofthetotaiiP.In comparison, 
LA treatment resulted in more than a 90°/o decrease in ciP production. Clearly, the 
fraction responsible for the overall change in PI tumover in these cells was cl P, and thus 
changes in receptor phosphorylation status are reflected through the changes in the 
proportion of ciP alone in MDA 468 cells. 
4.3 DISCUSSION 
Cyclic inositol phosphates have been reported to have cellular functions. It is 
known that cyclic inositol phosphates produced as a result of PI turnover accumulate 
and persist longer as a result of agonist stimulation (Putney and Bird, 1993). (3H]·myo-
inositol prelabelled pancreatic mini lobules incubated with carbamylcholine for 30 min, 
showed increases in ciP, ciP2, and ciP3 which preceded increases in inositol mono, bis 
and trisphosphates, respectively (Sekar et al., 1987), suggesting a second messenger 
role for the cyclic metabolites. Furthermore, the metabolite ciP3 was found to be five 
times more potent than IP3 in increasing Ca2+ conductance in Limu/us photoreceptor 
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cells (Wilson eta/., 1985). The accumulation of ciP3 (Dixon and Hokin, 1987) and the 
formation of cl P upon agonist stimulation in mouse pancreatic mini lobules (Dixon and 
Hokin, 1985) all suggest a second messenger function for ciP. 
PLC-V is a substrate of the EGF and platelet derived growth factor (PDGF) 
receptor kinases. This phosphorylation is thought to be responsible for the increase in 
PLC-V activity in cell types where these growth factors stimulate PI tumover 
(Meisenhelder eta/., 1989). Certainly, both EGF and PDGF stimulate PI tumover in 3T3, 
A431 (Meisenhelder eta/., 1989; Wahl eta/., 1987), MDA 468 cells and R1 hER cells 
(Church eta/., 1992). While it is not clear as to what determines the ratio of cyclic and 
non-cyclic Pis produced (Majerus, 1992), in the PLCy-dependent PI metabolic pathway, 
less than 1 0°/o of the total inositol phosphates produced are cyclic phosphates of 
inositol (Berridge and Irvine, 1989; Koch and Diringer, 1974; Sekar eta/., 1993). In 
MDA 468 cells the early signal transduction events beginning with the 
autophosphorylation of the EGFR lead to the association of PLC-y with the receptor 
and activation of it by tyrosine phosphorylation leading to an increase in the total PI 
turnover (Church eta/., 1992). Such increases in PI tum over have been demonstrated 
in cell lines such as A431, NA, HSC-1, HSC-2 and CA-922, all of which overexpress 
the EGFR. However, the increases were largely due to changes in the levels of non-
cyclic phosphates, even in MDA 468 cells (Wahl et al., 1987). In our experiments in 
MDA 468 cells, the percentage ciP of total phosphatidylinositol generated increased 
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to 80% as a result of EGF stimulation and decreased to 90% following LA treatment 
(Figure 4.4). While such differences in response to PI turnover in EGF treated MDA 468 
may be due to differences in cell culture conditions or other factors (Bjorge and Kudlow, 
1987), suffice it to say that receptor overexpression may not always accurately reflect 
the nature of PI metabolites generated. However, receptor phosphorylation seems to 
be a requirement for increases in PI turnover, whatever metabolites result. Our findings 
suggest that production of the cyclic PI metabolite is associated with EGF~stimulated 
receptor autophosphorylation, since changes in phosphorylation is related to the 
changes in the production of this metabolite. Conversely, when LA inhibits the effects 
of EGF on EGFR phosphorylation status, ciP levels go below those in control, untreated 
MDA 468 cells. Thus the only component of PI tumover in MDA 468 cells whose 
proportion changes concomitant to changes in receptor phosphorylation is ciP. 
In general, while the signal transductional control seems similar, the mechanism 
by which PI turnover occurs is unlike that generated by EGFR phosphorylated PLC~y. 
It is possible that the activated EGFR may associate with an unidentified PLC isoform 
and cause the agonist mediated changes in the levels of ciP in these cells. An activated 
EGFR~complex has been shown to be coupled to a G protein and this step has been 
shown to be mandatory in producing EGF~mediated responses (Church and Buick, 
1988). It is also known that the P isoform of PLC, acting through a G protein, causes PI 
hydrolysis upon agonist stimulation (Cockcroft and Thomas, 1992). In fact, PI~PLCs 
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producing ciP and DAG have been demonstrated in many bacterial species. PI-PLC 
from B. thuringiensis was found to catalyze the formation of DAG and ciP (Lewis eta/., 
1993). In S. antibioticustwo distinct types of PI-PLCs were present. Of the two, PLC1, 
a Ca2• -dependent enzyme, had a short stretch of sequence similarity with the eukaryotic 
PLC enzyme and was found to generate both non-cyclic and the cyclic inositol 
phosphates simultaneously from PI (Iwasaki et a/., 1998). The 8. cereus PI-PLC 
enzyme was found to possess both phosphotransferase and cyclic phosphodiesterase 
activities (Volwerk et al., 1990). A eDNA encoding the B. cereus PI-PLC transfected 
in NIH 3T3, Swiss mouse 3T3, CV-1, and Cos-7 cells resulted in increased levels of ciP 
(Ross et al., 1992). Thus it may be possible that a non-PLC-V may be interacting with 
the EGFR to produce changes in the proportion of ciP in response to stimulation or 
inhibition of receptor phosphorylation. On the other hand, synthesis of ciP from glucose 
6-phosphate is unlikely because this pathway constitutes the agonist-insensitive inositol 
phosphate metabolism (Berridge and Irvine, 1989). 
The aberrant production and accumulation of cyclic inositol phosphates may be 
due to defects either in thei.· production and/or their degradation. The very fact that ciP 
levels only change may actually be the result of alterations in the degradation pathway 
of cyclic metabolites. Our observation that even untreated MDA 468 cells contain about 
60°k of its IPs as ciP may be suggestive of a slow turnover of this metabolite. And, 
indeed, high levels of cyclic PI metabolites may contribute to the maintenance of a 
133 
transformed phenotype. In a Morris hepatoma cell line which also has a very high level 
of ciP, it has been suggested that there is a metabolic defect in the phosphatidylinositol 
pathway in the fast growing tumor, facilitating inositol accumulation {Graham et at., 
1987). Such slow metabolism of ciPs may be a factor for sustaining uncontrolled cellular 
growth; ciP involvement was demonstrated in 3T3 cells, where decreased ciP levels 
correlated with a lower cell density at confluence (Ross eta/., 1991 ). 
Accumulation of ciP in an EGFR overexpressing human breast cancer cell line 
such as MDA 468 cells raises some interesting questions as to its relationship to cell 
proliferation and transformation. It is possible that a class of breast cancers may 
produce high amounts of ciP and that this may help in the maintenance of a transformed 
phenotype. Thus a thorough knowledge is required about the possible synthesis and 
degradation components in the signaling pathways generating this metabolite. Our work 
demonstrates that using a PTK inhibitor, any sustained effects on cellular proliferation 
by ciP in these cells can be modulated starting from the initial signaling event of ligand 
mediated receptor phosphorylation. This study adds to a growing body of evidence 
about the possible role of this constituent or its higher phosphorylated forms, in EGF 
receptor mediated signal transduction pathways in human breast cancer cells. 
CHAPTERV 
INHIBITION OF EGF RECEPTOR TYROSINE 
KINASE ACTIVITY BY LAVENDUSTIN A: A 
PHOSPHORYLATION-DEPENDENT EFFECT ON 
CELL PROLIFERATION AND ITS RELATION TO 
CELL CYCLE AND REGULATORS IN MDA 468 
CELLS 
5.1 INTRODUCTION 
5.1.1 Background 
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From the results of Chapter 3 and 4, it is clear that the protein tyrosine kinase 
(PTK) inhibitor lavendustin A (LA) can inhibit the epidermal growth factor receptor 
(EGFR) autophosphorylation and PI tumover in MDA 468 cells during agonist (EGF)-
stimulation. We postulated in Chapter 4 that any effects on cell proliferation by cyclic 
inositol phosphate (ciP) in the longer term can be modulated through receptor 
phosphorylation, the initial signaling event in EGF-mediated signaling. In this study, we 
intended to investigate any sustained effects of modulation of receptor phosphorylation 
(in the presence of EGF and LA) on cell proliferation. 
5.1.2 EGFR and cell proliferation 
MDA 468 cells undergo growth arrest in response to pharmacological 
concentrations of EGF (Filmus eta/., 1987; Amstrong et al., 1994). MDA 468 cells 
overexpress the EGFR. An EGF concentration of 1 o.a M, though stimulatory to cell 
proliferation in many cell types (Carpenter and Cohen, 1979), including mammary 
epithelium (Taketani, and Oka, 1983), is responsible for causing growth inhibition in 
MDA468 cells (Filmus eta/., 1985).1t has also been reported (Yaish eta/., 1988) that 
PTK inhibitors can cause growth inhibition leading to growth arrest in cell lines 
overe:xpressing the EGFR. In fact the PTK inhibitor LA has been reported to inhibit 
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growth of A431 cells, NIH 3T3 cells, RSV-NIH 3T3 cells, P388 leukemia cells and 
L 12121eukemia cells (Onoda et al., 1989) and MDA 468 cells (this thesis). 
Extensive research is under way using various approaches, such as monoclonal 
antibodies (Modjtahedi eta/., 1998) or PTK inhibitors (Chang eta/., 1992; DeWitte et 
a/., 1993; Posner eta/., 1993; Fry eta/., 1994; Traxler eta/., 1997), to interfere with or 
block EGFR-mediated growth stimulation as a means to control proliferation. In fact, the 
approach of blocking the EGFR by using monoclonal antibodies is now being used in 
xenograft studies (van Gog eta/., 1998; Perrotta eta/., 1999) and in clinical trials to 
control proliferation of various tumors which overexpress the EGFR (Bier eta/., 1995; 
Grandis eta/., 1998). 
Previous studies in this lab have demonstrated a link between EGF-mediated 
G1 cell cycle arrest and alteration in the cellular localization of the growth regulatory 
protein, p53 in MDA 468 cells (Prasad and Church, 1997). Perturbations in p531evels 
induce changes in normal cell proliferation. Wild-type p53 functions in growth arrest, 
while mutant p53 'Nhich accumulates in transformed cells, has been shown to enhance 
malignant transformation (Shaulsky eta/., 1991 ). It has also been observed that p53 
undergoes alteration of subcellular localization with the cell cycle. This protein 
accumulates in the cytoplasm during the G, phase, enters the nucleus at the early S 
phase and remains there for a short period. Modulations in the subcellular distribution 
suggest that p53 is regulated during the normal cell cycle (Shaulsky et al., 1990). MDA 
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468 cells possess psazn.tts mutant of p53; this mutant has a wild-type epitope map 
which reacts with the wild-type specific antibody PAb 1620 and is PAb 240 negative 
(this antibody recognizes wild-type p53) (Slingerland eta/., 1993). p53211His has 
reduced non-specific DNA binding and it also fails to bind some sequences that are 
recognized by wild-type p53, but it retains the ability to transactivate through a 
consensus sequence identified by Funk eta/. (1993) (Bargonetti eta/., 1991; Kern et 
a/., 1991 ). Though wild-type p53 is a negative regulator of cell proliferation, p53 mutants 
such as p53273·Hs are active in inducing proliferation. Therefore, there exists a definite 
possibility that if the PTK inhibitor LA has any negative effect on cell proliferation, then 
in MOA 468 cells, p5~73·His would actively function in this growth inhibition and that it 
may also trigger other checkpoint regulators that participate in regulating the cell cycle. 
5.1.3 Estimation of DNA synthesis 
The rate of cell proliferation can be assessed by measuring DNA synthesis. 
Incorporation of [3H]-thymidine is a common parameter used to measure accumulated 
DNA synthesis in high density cultures (Freshney, 1994a). 
5.1.4 Analysis of a cell population by flow cytomatry 
Row cytometry allows the detailed analysis of cell population and discriminates 
between viable and non-viable cell (apoptotic and necrotic) populations (Barbiero eta/., 
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1995}. This method allows the estimation of cell populations in each phase of the cell 
cycle from the overall DNA content (as determined from the DNA per cell) in a 
quantitative and reproducible way; one stain extensively used for this purpose is 
propidium iodide to quantitate DNA fluorescence. Since fluorescence is directly 
proportional to the amount of DNA in the cell, the trace gives a distribution analysis of 
the cell population by the DNA content, thus depicting the cell population in the various 
phases of the cell cycle, namely the G0-G, Sand G2M phases respectively (Freshney, 
1994b). 
5.1.5 Objectives 
From the results of Chapter 3 we see that LA caused an inhibition of EGF-
stimulated EGFR autophosphorylation (Figure 3.7). On one hand, we can enhance 
receptor phosphorylation (by EGF), and on the other, we can an inhibit it (by LA). We 
know from the results of Chapter 4 that differences in the phosphotyrosine content of the 
receptor correlate with differences in PI turnover, an EGF-dependent early signaling 
event. 
MDA 468 cells exhibit a biphasic growth response when treated with EGF, and 
EGF receptor phosphorylation increases with increasing concentrations of EGF (Gulli 
et a/., 1996). EGF receptor phosphorylation and growth show a positive linear 
relationship at picomolar concentrations of EGF. However, at nanomolar 
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concentrations, although the receptor kinase activity and phosphotyrosine content 
increase, there is growth inhibition (Filmus et al., 1987}.1n general however, inhibition 
of cell growth also results from the blocking of EGFR kinase activity (Yaish eta/., 1988). 
In this study, our objective was to examine the effects of modulating receptor tyrosine 
kinase activity and observe the effect on cell proliferation in MDA 468 cells. We 
attempted to investigate the changes in the status of EGFR phosphorylation and its 
relationship with growth, in the presence of exogenous ligand, and secondly, by 
inhibiting the intrinsic receptor tyrosine kinase activity of EGFR. We therefore used 
EGF and LA alone and in combination for this purpose. Since growth responses in the 
cell are related to the progression of cells through the cell cycle, our objective was also 
to relate growth responses to the role of cell cycle checkpoint regulators. 
5.2 RESULTS 
5.2.1 Effect of EGF, LA, and EGF+LA on call number and [3H)-thymldlne uptake 
In initial experiments, we found that at 0.2 iJM, LA effectively inhibited the 
proliferation of MDA 468 cells, and this inhibition was enhanced in the presence of EGF 
at 72 h (Figure 5.1 ). At this concentration there was growth inhibition and cells were 
viable during this period. In the experiments that followed, we examined the effect of 
EGF and LA alone and in combination on cell proliferation and DNA synthesis after 24 
and 72 h respectively. Figures 5.2A and B display the effects of 0.2 J,&M LA, 1 o.a M EGF 
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Figure 5.1 Effect of LA in presence and absence of EGF on the proiHeratlon of 
MDA 468 calls. 
24 h after seeding, cells were exposed to different concentrations of LA in presence 
and absence of 1 o.a M EGF for a period of 72 h. At the end of the exposure period, 
cells were harvested by trypsinization and cell numbers were counted using a 
haemocytometer. Data are shown as a percentage of control. Values are mean:t:S.E.M. 
from four experiments, each performed in duplicate. 
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Figure 5.2 Effect of EGF, LA, and EGF+LA on cell proliferation and DNA 
synthesis of MDA 468 cells. 
After seeding, the next day cells were exposed to 1 o-a M EGF or 0.2 J,JM LA, or 1 o-a M 
EGF+0.2 IJM LA for a period of 24, 72, and 96 h (24 h after EGF or LA removal) 
respectively. At the end of the indicated intervals, the cell number or eH]-thymidine 
uptake were determined (Section 2.2.1 0 in Chapter 2). 
Figure 5.2A represents the effect of LA, EGF, and LA+EGF on cell proliferation at the 
indicated intervals. Data are shown as a percentage of control. Values are 
mean:tS.E.M. from four individual experiments, each performed in duplicate. 
Figure 5.2B represents the effect of LA, EGF, and LA+EGF on DNA synthesis at the 
indicated intervals. Cells were labelled with [3H]-thymidine (3.0 IJCi/ml) and incubated 
for 24 h prior to harvesting. At the end of labelling, cells were harvested by trypsinization 
and the TeA-precipitable counts were determined. The data are shown as a 
percentage of control. Values are mean ± S.E.M. from four individual experiments, each 
performed in triplicate. 
Arrows in Figures 5.2 A and B indicate time of drug removal from media. 
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and LA+EGF on cell number and DNA synthesis (as measured by (3H]-thymidine 
uptake) respectively. Both LA and EGF caused a significant reduction in cell 
proliferation (35-40°/o) and [3H]-thymidine uptake at 72 h {25-35°.4), and in the case of 
both LA+EGF, the effect was augmented as early as after 24 h incubation. The effect 
of LA alone was reversed 24 h after its removal from the media, compared to that of 
untreated control cells. In contrast, the EGF-treated cells, however, continued to show 
a steady decline in both cell nuf'T1ber and [3H]-thymidine uptake, 24 h after its removal; 
the growth of cells treated with EGF+LA was partially reversed 24 h after their removal. 
It is clear that the growth inhibitory effect of EGF is not as easily reversed as that of LA. 
Though a combination of EGF and LA produced a more pronounced growth inhibition 
(as measured by cell number and [3H]-thymidine incorporation), this growth inhibition 
was more readily reversed than the inhibitory effect of EGF alone. 
5.2.2 Flow cytometric analysis of cell cycle distribution 
To investigate the effect of EGF, LA and EGF+LA on cell cycle progression and 
the distribution of cells in various phases of the cell cycle, the DNA content was 
measured by flow cytometry using propidium iodide-dependent DNA fluorescence 
(described in Chapter 2, Section 2.6). Flow cytometry revealed perturbations in the 
distribution of cell populations in the various phases of the cell cycle in response to LA, 
EGF and LA+EGF. Figure 5.3 shows the representative DNA histograms with cell 
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Figure 5.3 Effect of EGF, LA, and EGF+LA on the cell cycle at 72 h. 
Representative FACS generated DNA histograms of MDA 468 cells of control, 
untreated cells (1 ), cells treated with 10-a M EGF (2), cells treated with 0.21JM LA (3), 
and cells treated with 10-a M EGF+0.2 IJM LA (4) for 72 h. The histograms are a 
representation of propidium iodide (PI) fluoresence (FL2-A) versus counts. The PI 
fluorescence is directly proportional to the amount of DNA in the cell and the relative cell 
number is given by counts. DNA was analyzed using PI fluorescence. Approximately 
10,000 cells were analyzed per sample as described in the Materials and Methods 
(Section 2.6, Chapter 2). 
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distribution in cells treated with LA or EGF alone, or both for 72 h. EGF (Figure 5.3·2), 
LA (Figure 5.3-3), and EGF+LA (Figure 5.3-4) caused a significant (p<0.005) 
accumulation of cells in G, phase of the cell cycle (Table 5.1) compared to control after 
72 h, concomitant with a decrease in the number of cells in S phase. Table 5.1 also 
shows a numerical summary of the percentage distribution of cells in various phases 
at 72 hand 24 h after removal EGF or LA. G, arrest produced by EGF was more 
persistent. Though LA alone and in combination with EGF produced a pronounced G 1 
arrest, this arrest was more readily reversed. 
5.2.3 IMMUNOFLUORESCENCE EXPERIMENTS 
5.2.3.1 Effect of EGF, LA, and EGF+LA on the subcellular localization of p53 
The p53 protein acts in the nucteus of the cell. MDA 468 cells contain a particular 
mutant, p53273·His, which has been shown to have a differential reactivity with 
conformation-specific antibodies, corresponding to alterations in the cell cycle 
(Shaulsky et al, 1990; Prasad and Church, 1997). Since we have demonstrated in this 
study that both EGF and LA produce a pronounced G, arrest in MDA 468 cells, we 
examined how p53273·H15 might be involved in producing changes in its conformation in 
response to G1 arrest. We now examined if there are any changes in p531ocalization 
at the subcellular level in response to EGF and LA, alone and in combination. To this 
end, we made use of three conformation-specific monoclonal antibodies to p53. PAb 
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Table 5.1 Effect of EGF, LA and EGF+LA on the percentage distribution of cells 
in the different phases of the cell cycle at 72 h and 24 h after removal 
respectively. 
72 h(A) 
Control 
10-a M EGF 
0.21JM LA 
0.2 IJM LA + 1 o.a M EGF 
24 h after removai(B) 
Control 
104 M EGF 
0.21JM LA 
0.2 IJM LA +10-a M EGF 
G, s 
47.6 ::t 1.80 37.7 ::t0.71 14.7 ± 2.12 
59.9 ::t 1.15* 24.2 ± 0.80** 16.4 ± 0. 71 
57.9 ::t 2.13* 25.1 :t 1.01 ** 16.3 :t 1.00 
62.0 :t 1.60* 21.9 ± 0.80** 16.1 ± 1.10 
G, s 
48.9 ::t 1.90 38.4 :t 1.90 
60.4 ± 0.50* 22. 1 :t 2.40 
52.0 ::t 0.61 34.0 ::1: 0.30 
53.0 ::t 1.41 32.4 ± 1.80 
14.6 ::t 1.1 0 
17.5 ::t 1.91 
14.0::1:0.34 
14.6 ::1: 2.40 
Data are represented as mean :t S. E. M. of four experiments. *Values significantly 
higher than control (p<0.005); -values significantly higher than control (p<0.0001 ). 
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PAb 240 specifically reacts with mutant p53 (Milner et al., 1987;Halazonetis eta/., 
1993). A human-specific PAb 1801 (pan-specific p53) which reactive with both wild-
type and mutant p53 (Banks eta/., 1986) was used. These antibodies react with p53 
in MDA 468 cells, both in immunoprecipitation and in immunofluorescence reactions 
(Milner eta/., 1987; Bartek eta/., 1990; Prasad and Church, 1997). PAb 240 reliably 
detects a wide variety of p53 mutations (Bartek eta/., 1990). We used PAb 1620, 
known to recognize wild-type p53 (Milner et a/., 1987) to detect wild-type p53. 
The results of immunofluorescence experiments from time points as early as 24 
h after treatment indicated changes in the subcellular localization of the wild-type and 
mutant forms of p53. Control untreated cells displayed a very strong nuclear and 
cytoplasmic staining at 24 h with mutant-specific PAb 240 (Figure 5.4, panel A) and 
pan-specific PAb 1801 (Figure 5.4, panel C). This pattern of staining was altered when 
cells were treated with EGF, LA alone or EGF+LA. In more than 95°~ of cells treated 
with LA and EGF, an absence of nuclear staining with mutant p53-specific PAb 240 
was observed (Figure 5.4, panel A). In contrast EGF and EGF+LA treated cells (95°/o) 
had a very strong nuclear with both pan p53-specific PAb 1801 (Figure 5.4, panel C, 
2 and 4) and wild-type p53-specific PAb 1620 (Figure 5.4, panel B, 1). 
Nuclear staining with PAb 240 at 72 h of EGF, LA, and EGF+LA treatment 
(Figure 5.5, panel A, 2, 3, and 4) was absent. When EGF, LA, or EGF+LA were 
removed at 72 h, EGF-treated cells continued to show a lack of nuclear staining with 
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Figure 5.4 Effect of EGF, LA, and EGF+LA on the subcellular localization of p53 
at 24 h. 
Cells were grown in a-chambered glass slides. The next day, cells were treated with 
EGF, LA, and EGF+LA for a period of 24 h. At the end of this period, cells were fixed 
in methanol and acetone, blocked with 3o/o BSA, and incubated with different antip53 
antibodies. Cells were then stained with FITC-conjugated antimouse lgG ( 1 :50). The 
p53 localization was detected by fluorescence microscope and presented at a final 
magnification of 600X (Section 2.2. 11, Chapter 2). 
Primary anti-p53 used in Panel A-PAb 240 (mutant-specific), 
primary anti-p53 used in Panel B-PAb 1620 (wild-type-specific), 
primary anti-p53 used in Panel C-PAb 1801 (pan-specific). 
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Figure 5.5 Effect of EGF, LA, and EGF+LA on the subcellular localization of 
mutant p53 at 72 h and 24 h after drug removal respectively. 
Cells were grown in a-chambered glass slides. The next day, cells were treated with 
EGF, LA, and EGF+LA for a period of 72 h. In another set of experiments cells were 
treated with the respective drugs for a period of 72 h, at the end of which the drugs were 
removed and the cells were washed with 1 x PBS and fresh media (with no drugs) was 
added to the cells for a further period of 24 h. At the end of the incubation periods (72 
h or 24 h after removal), cells were washed with 1 x PBS, fixed in methanol and 
acetone, blocked with 3o/o BSA, and incubated with PAb 240 (mutant-specific) antip53 
antibody. Cells were then stained with FITC-conjugated antimouse lgG (1 :50). The 
mutant p53 localization was detected by fluorescence microscope and images are 
presented at a final magnification of 600X. 
Panel A-duration of treatment of LA and EGF was 72 h, 
Panel B-24 h after removal of drugs. 
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PAb 240 (Figure 5.5. panel B, 2), in contrast to cells treated with both EGF and LA 
respectively. in which case about 75% of cells showed a reappearance of nuclear signal 
with mutant p53-specific PAb 240.24 h after removal of EGF, LA, or EGF+LA, only 
cells treated with EGF showed a lack of p53 reactivity with mutant p53-specific PAb 
240 (Figure 5.5, panel B. 3). Thus, 24 h after EGF or LA {or both) removal. only cells 
treated with EGF alone continued to show a loss of reactivity with mutant p53-specific 
PAb 240, evident from the absence of mutant p53 staining in the nucleus. 
Taken together. our results show that EGF or LA alone or in combination 
produce an alteration in the subcellular localization of mutant and wild-type p53. 
However, only EGF alone, in contrast to LA or EGF+LAcontinues to show an absence 
of mutant p53 in the nucleus 24 h after removal of EGF from the media. These data are 
consistent with DNA synthesis (Figure 5.28) and flow cytometry (Table 5.1, Figure 5.3) 
results which show that the effects of EGF on growth are persistent in comparison to LA 
or EGF+LA respectively. Our immunofluorescence results also indicate that the loss of 
reactivity of p53 to mutant p53-specific PAb 240 and p53 reactivity to wild-type p53-
specific P Ab 1620 as early as 24 h is consistent with a possible involvement of wild-
type p53 in G1 growth arrest in MDA 468 cells. 
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5.2.3.2 Effect of EGF, LA, and EGF+LA on the subcellular localization of 
p21 WAF1ICIP1 and Cdk2 
The CDKs play important roles in the regulation of the cell cycle, since their 
activation and subsequent deactivation have been shown to regulate the progression 
of cells from one stage to the other (Sherr, 1993). In many mammalian cell lines, 
transcription of the p21wAFtiCIPt gene is directly promoted by wild-type p53. The cdk 
inhibitory protein p21 WAFl/CIP1 exerts its growth inhibitory effect during the G1 phase, by 
binding to multiple CDKs (Ding et al., 1999). This protein has a wide range of actions 
in cell cycle control, including induction of G1 arrest (Petrocelli eta/., 1996; Sherr, 1996; 
Waldman et at., 1996; Bunz eta/., 1998; Kramer eta/., 1999; Saito eta/., 1999). After 
24 h incubation, EGF (Figure 5.6, panel A, 1) and EGF+LA- (Figure 5.6, panel A. 4) 
treated cells showed nuclear staining for p21 WAFl/CIP,. Nuclear staining of p21 WAFlJCIP1 
was not evident with cells treated wfth LA at 24 h (Figure 5.6, panel A, 3). LA. after 72 
h, induced nuclear staining (Figure 5.6, panel B, 3), while EGF (Figure 5.6, panel B, 2) 
and EGF+LA (Figure 5.6, panel B, 4) continued to show strong nuclear staining at 72 
h. As early as 24 h, l:GF, LA and EGF+LA treated cells displayed an absence of 
nuclear localization of cyclin dependent kinase 2 ( cdk2), known to regulate the G, to S 
transition (Harper eta/., 1993; Xiong eta/., 1993) in the cell cycle (Figure 5.7). 
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Figure 5.6 Effect of EGF, LA, and EGF+LA on the subcellular localization of 
p21 wAF11C1'1 at 24 h and 72 h respectively. 
Cells were grown in a-chambered glass slides. The next day. cells were treated with 
EGF, LA, and EGF+LA for 24 h or 72 h periods respectively. At the end of the 
incubation periods, cells were fixed in methanol and acetone, blocked with 3°/o BSA, 
and incubated with antip21wAF1ICIP1• Cells were then stained with FITC-conjugated 
antimouse lgG (1 :50). Subcellular localization of p21wAF11c1P1 was detected by 
fluorescence microscope; the images are presented at a final magnification of 600X. 
Panel A-24 h after treatment with LA or EGF 
Panel B-72 h after treatment with LA or EGF. 
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Figure 5. 7 Effect of EGF, LA, and EGF+LA on the subcellular localization of cdk2 
at 24 h. 
Cells were grown in a-chambered glass slides. The next day, cells were treated with 
EGF, LA, and EGF+LA for a period of 24 h. At the end of this period, cells were fixed 
in methanol and acetone. blocked with 3% BSA. and incubated with rabbit polyclonal 
anticdk2. Cells were then stained with FITC-conjugated anti rabbit lgG (1 :1 00). The cdk2 
localization was detected by fluorescence microscope; the images are presented at a 
final magnification of 600X. 
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5.3 DISCUSSION 
It is known that receptor phosphorylation and growth have a positive correlation 
at picomolar concentration of EGF. This correlation does not hold at nanomolar EGF 
concentrations in cell lines overexpressing the EGFR. In A431 cells there is a 15-fold 
increase in EGFR autophosphorylation at EGF concentrations of 1 nM, leading to 
inhibition of cell proliferation (Gulli eta/., 1996). DiFi cells, derived from human 
colorectal carcinoma, overexpressing EGFR, are also growth inhibited by EGF 
concentrations above 1 nM (Grosset a/., 1991 ). Thus, mitogenic responses mediated 
by growth factors in EGFR overexpressing cell lines do not correlate with increased 
EGF binding capacity (Gulli eta/., 1996). In fact EGF-stimulated receptor tyrosine 
kinase activation and growth of cells overexpressing the EGFR at nanomolar 
concentrations are inversely related (Gulli et a/., 1996). EGF causes a biphasic 
response to growth in A431 cells; cells are growth-inhibited at high (nanomolar) EGF 
concentration and growth-stimulated at low (picomolar) EGF concentration. 
It was shown in Chapter 3 that at 1 o-s M {1 0 nM), EGF caused an increase in the 
phosphotyrosine content of the EGFR, while LA effectively inhibited this EGF-stimulated 
increase. From Figure 3. 7 (Chapter 3) it is evident that at 0.25 iJM LA significantly 
inhibits EGFR phosphorylation. From initial trial experiments, we observed that at 0.2 
IJM, LA effectively caused growth inhibition without compromising viability of cells 
exposed for a period of 72 h {Figure 5.1 ). At 72 h, EGF, in nanomolar concentration 
161 
caused growth inhibition; this is in agreement with published literature (Kawamoto et 
a/., 1983; Gulli eta/., 1996; Prasad and Church, 1997). EGF or LA alone, caused a 
significant reduction in cell number and DNA synthesis which, though not evident at 24 
h, was clearly seen by 72 h. EGF and 0.2 IJM LA in combination produced a greater 
reduction in cell number and DNA synthesis (Figure 5.2 A and B). 
From our results too we found growth inhibition in the presence of nanomolar 
EGF concentrations in MDA 468 cells. Nevertheless, this increased EGF concentration 
led to increased receptor phosphorylation (Figure 3. 7, lane 2). EGFR overexpressing 
cell lines such as A431 exhibit increased receptor phosphorylation (as a result of EGF 
treatment) and growth inhibition. Our results are in agreement with this observation. 
Studies with antibodies antagonistic to EGF binding and tyrosine kinase activity of the 
receptor have demonstrated the relationship between proliferative responses of EGF 
and the receptor kinase activity of the (at picomolar and nanomolar concentrations) 
receptor. These antibodies block EGF binding to EGFRs. Reduction in available 
EGFRs permits growth stimulation. In A431 cells low EGF concentration {20 pM) 
stimulated proliferation whereas high concentrations (2-200 nM) inhibited proliferation 
{Kawamoto eta/., 1984). In the presence of I nM lgG there was maximal growth 
stimulation, while there was optimal stimulation at 2 nM EGF even when the 
concentration of lgG was increased from 1 0-100 nM. But at a very high EGF 
concentration (200 nM), there was strong growth inhibition even in the presence of very 
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high lgG concentration of 1 IJM. Thus, EGF concentration seems to be the determinant 
factor for effects on growth. With increasing concentrations of EGF {2-200 nM), the 
concentration of antibody has to be increased in order to attain a reversal of the growth 
inhibitory effect of EGF to growth stimulation (Kawamoto eta/. 1984). Since MDA 468 
cells are also growth inhibited at nanomolar concentrations, we started these growth 
experiments by hypothesizing that LA, by causing a decrease in receptor 
phosphorylation (Figure 3. 7, Chapter 3) would reverse the growth inhibitory effect of 
EGF; this in tum would lead to the reversal of growth inhibition and uncover the growth-
stimulatory effect of EGF (Figure 5.8). We thus set out to test this hypothesis to examine 
cell proliferation in presence of both EGF and LA. 
Reversion to EGF-mediated growth inhibition in A431 clones 29, 4, and 18 was 
associated with increased receptor concentration in each case. In certain clones, a 
reduction in EGF receptor number was associated with a loss of growth inhibition and 
acquisition of EGF-stimulated growth (Kawamoto eta/., 1984). This evidence indicates 
that increased kinase activity and growth inhibition are associated with each other in 
an inverse manner. The fact that reduction in receptor phosphorylation was associated 
with growth inhibition by LA (in the presence of EGF) proves that there may not be a 
direct correlation existing between receptor kinase activity and growth. However, LA 
caused both, a reduction in receptor phosphorylation and cell proliferation. This is due 
to the fact that LA is a protein tyrosine kinase inhibitor and that the inhibition of the 
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Figure 5.8 Biphasic response of EGF on cell proliferation 
This hypothetical bell-shaped curve depicts the biphasic response to EGF with 
increasing concentrations. There is growth stimulation at low concentrations of EGF and 
growth inhibition at high concentrations. However, we hypothesized a rightward shift of 
this curve in presence of LA (dotted line curve). The bar in the X-axis represents the 
concentration range of EGF which is inhibitory (in control), but as we hypothesized, EGF 
becomes growth stimulatory in the presence of LA. 
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EGFR tyrosine kinase activity is the cause for growth inhibition in MDA 468 cells. In fact 
there is ample evidence that tyrosine kinase inhibitors (Seynaeve eta/., 1993; Moyer 
eta/., 1997), monoclonal antibodies (Wu eta/., 1995; Mendelsohn, 1997; Ma et al .• 
1998), or EGFR antisense RNA (Hong eta/., 1998) all, by inhibiting the EGFR tyrosine 
kinase activity cause growth inhibition in many cells, including those that overexpress 
the EGFR. 
We find that the EGF-induced growth inhibition was persistent compared to that 
of LA-induced growth inhibition; also the EGF-induced growth inhibition was not 
reversed 24 h after its removal, as compared to LA. It seems likely that a constant 
presence of intracellular LA is required to produce a sustained inhibitory response. 
Removal of drug from the media probably releases cells of inhibition of receptor kinase 
and thus we see a reversal of the drug effect. On the other hand, a prolonged EGF-
mediated EGFR phosphorylation may be a reason for a sustained effect on growth. It 
has been shown in A431 cells that the prolonged effect of growth arrest by EGF may be 
due to a more sustained phosphorylation of EGFR which may cause a higher 
expression of growth regulators, such as p21wAF1'c1P1 (Skarpen eta/., 1998). 
EGF and LA in combination produced a greater reduction in cell number and 
DNA synthesis in comparison to EGF or LA-treated cells alone (Figure 5.2A and B). 
This indicated that LA enhanced the growth inhibitory effects of EGF (making us unable 
to correlate growth inhibition with changes in receptor phosphorylation), although this 
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is contrary to the assumption that inhibition of EGFR kinase activity by LA would relieve 
the cells of the growth inhibitory effects of EGF (even when EGF is present in nanomolar 
concentrations). Kawamoto et a/. (1983) showed that A431 cells were growth 
stimulated at picomolar concentration of EGF, but not at nanomolar concentration of 
EGF, in the presence of monoclonal antibody, which blocks EGF binding to EGFR. 
They attributed this growth stimulation (at picomolar EGF concentration) to a population 
of high affinity receptors which could bind EGF with a much higher affinity compared to 
the low affinity receptors. However, at nanomolar concentration of EGF, they suggested 
that EGF became growth inhibitory in the presence of antagonizing antibody, because 
EGF could ·now compete effectively for access to the low affinity receptors. Like 
Kawamoto et a/. (1983), MDA 468 cells also underwent EGF-mediated growth 
inhibition at nanomolar EGF concentrations in presence of LA although the cause may 
be different. We know that LA is a competitive inhibitor of ATP binding to the receptor 
kinase, but is non-competitive with respect to substrate (EGF) binding at the cell surface 
(Hsu eta/., 1991 ). Therefore we assume that EGF at nanomofar concentrations has a 
chance to bind to all available receptors and we thus see the inhibitory effect of EGF. 
In the similar situation LA also inhibits the kinase activity of the receptors. Thus we have 
a situation where there is excess EGF binding as well as inhibition of EGFR kinase 
activity. The result is growth inhibition. We might speculate that binding of LA to the 
receptor may cause a conformational change in the receptor, thereby facilitating the 
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EGF (in nanomolar concentrations) binding to EGF receptors causing growth inhibition. 
It is also possible that LA may be interfering with some post-receptor mechanisms 
which lead to growth inhibition in presence of EGF. In fact 24 h after removal of LA, 
there is only a partial reversal of growth. Whatever the mechanism, MDA 468 cells fail 
to demonstrate a stimulation of growth as a result of EGF treatment in the presence of 
LA. 
Growth inhibition leading to G1 growth arrest as a result of EGF and LA treatment 
led us to investigate some of the regulators of cell cycle, participating in this phase of 
the cell cycle. Previously published results by Prasad and Church (1997) showed that 
EGF-induced G1 arrest was accompanied by an absence of nuclear localization of PAb 
240 positive mutant p53. EGF as well as LA both produced a G, arrest in MDA 468 
cells (Figure 5.3). Therefore we speculate that LA-treated cells may undergo alterations 
in the subcellular localization of p53 in cells as a result of G1 arrest. If this is the case, 
then LA may also produce alteration in the subcellular localization of p53. To test this 
we examined alterations in the subcellular localization of p53 as well as p21 wAF1JC1P1 and 
cdk2, associated with the G1 phase of the cell cycle. 
The interplay between checkpoint regulators of the cell cycle determines the final 
balance between mitogenesis or inhibition of mitogenesis. G, to S transition is a major 
checkpoint in cell cycle progression, and deregulation of the G1/S checkpoint is 
considered to be an important step towards carcinogenesis (Ding eta/., 1999). p53, 
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a tumor suppressor gene, activates the transcription of the cyclin·dependent kinase 
inhibitor p21 WAFlJCIP1, which, in tum, prevents cdk2 activation and cell cycle progression, 
thus delaying tumorigenesis and progression of the cell cycle (L6pez-Sciez eta/., 1998), 
ultimately leading to G1 arrest. In this part of the study we demonstrate that MDA 468 
cells were growth arrested in the G, phase of the cell cycle in response to the growth 
factor EGF or by the PTK inhibitor LA, alone, or in combination. Our studies thus 
focused on the localization of the cell cycle regulatory proteins controlling G,/S phase 
of cell cycle. Previous studies were consistent with the hypothesis that in its "pseudo 
wild-type" conformation, p53 plays an active role in EGF-mediated G1 arrest (Prasad 
and Church, 1997) in MDA 468 cells. Consistent with these previous findings, we also 
found that EGF induced changes in the subcellular localization of p53, p21 WAFlJCIPl and 
cdk2, the G1 checkpoint regulators. In addition, we found that the PTK inhibitor LA also 
altered the subcellular localization of G1 checkpoint regulators. These results are 
consistent with the fact that EGF/LA-mediated G1 arrest causes an induction of 
p21wAF1ICIP, in a p53-dependent manner. 
Mutations of p53 have been implicated in the etiology of breast cancer because 
it is required continuously to maintain the transformed phenotype (Avila eta/., 1994). 
The wild·type p53 protein can negatively regulate cell proliferation (Martinez et a/., 
1991) and act as a suppressor of transformation (Finlay et al., 1989) and tumorigenesis 
(Chen eta/., 1990). EGF (Prasad and Church, 1997), PTK inhibitors (Moyer eta/., 
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1997), or monoclonal antibodies (Mendelsohn, 1997) activate wild-type p53. In some 
breast cancers sequestration of wild-type p53 protein in the cytoplasm, away from its 
site of action in the cell nucleus, may also inactivate p53 function without mutation (Moll 
eta/., 1992). Besides mutations of p53 found in many types of breast tumors, some 
cancer cells can also inactivate the tumor-suppressor activity of the wild-type protein by 
means other than mutations (Mollet a/., 1992). These evidence are in favor of the role 
of wild-type p53 as a tumor suppressor. 
MDA 468 cells possess a single allele for p53 with a point mutation at codon 
273 (p53273·His) resulting in the substitution of arginine by histidine (Nigro eta/., 1989; 
Bartek eta/., 1990); this mutant is frequently present in human tumors (Hollstein eta/., 
1991 ). p53213·H15 has a wild-type epitope map, which is PAb 240 negative and PAb 
1620 positive (Slingerland eta/., 1993). Consistent with this notion is the fact that 
p53m.His exhibits a tumor suppressor or a wild-type function, which, in tum, is consistent 
with its translocation to its active site, the nucleus. Our immunofluorescence data agrees 
with this. We have observed that cells showing positive nuclearp53 staining with PAb 
1620 (P Ab 1620 stains untreated control cells very weakly) may have p53273·His in the 
wild-type conformation (PAb 1620 positive) (Figure 5.4; panel B) during G1 arrest as 
a result of EGF, LA or EGF+LA treatment (Bartek et al., 1990). Conversely, the 
absence of nuclear staining with mutant p53-specific PAb 240 (this means that nuclear 
p53 is non-reactive with PAb 240) (Figure 5.4; panel A) shows that cells arrested in G1 
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due to both EGF and LA, by some mechanism exhibit a translocation of mutant p53 
population from nucleus to the cytoplasm within 24 h of treatment. Cytoplasmic staining 
with pan-specific p53 was more pronounced in LA-treated cells in contrast to the EGF 
and EGF+LA-treated cells (which showed less intense staining). This may be indicative 
of lesser quantities of PAb 1620 positive p53 in the nucleus (Figure 5.4, panel C). In 
MDA 468 cells undergoing arrest at G1 phase, PAb 1620 positive p53 appears to play 
an active role as a tumor suppressor protein; this is evident from a shift in its localization 
to its active site, the nucleus. 
Our data indicates that the subcellular localization of p53273·Hts has relevance to 
the growth suppressor function of p53 that is a characteristic of wild-type p53. We see 
a change in the PAb 240 positive p53 translocation from nucleus to the cytoplasm in 
response to EGF and LA. It appears that in MDA 468 cells G, arrest alters the PAb 240 
positive p53 population subcellularly. Changes in p53 immunoreactivity are evident from 
changes in subcellular localization as a result of cell cycle arrest. The wild-type function 
of p53273·His is evident from literature (Chen eta/., 1990; Slingerland eta/., 1993; 
Prasad and Church, 1997). 
The p53273·Hisallele in cooperation with H-rashad a weak transforming potential 
in rat embryo fibroblasts even when it was highly expressed from the strong human P-
act in promoter (Slingerland et at., 1993}. This mutant allele lacked ability to interfere 
with wild-type p53 protein in a dominant negative manner. When single copies of wild-
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type human p53 and p53273.Hs alleles were coexpressed in SAOS-2, an osteosarcoma 
cell line lacking endogenous p53 protein expression, the wild-type p53 phenotype 
function slowed growth, decreased saturation density, and reduced tumorigenicity 
(Chen eta/., 1990). In the absence of wild-type p53, the mutant promoted cell growth 
to a higher saturation density than that of parental cells (Chen eta/., 1990) .In rat embryo 
fibroblast transformation assays, the weakly transforming p53273·His became strongly 
transforming when the intad nuclear localization signal site was replaced by the mutated 
nuclear localization signal site {Slingerland eta/., 1993). Bartek eta/. ( 1990) called the 
p53 molecules with mutations in the primary sequence as "pseudo-wild type." On careful 
examination of cell lines with mutant p53, Bartek eta/. (1990) also found a second 
population of molecules which they called "overtly mutant." These molecules are present 
in human cell lines because both PAb 240 positive (overtly mutant) and PAb 1620 
positive (pseudo-wild type) are derived from the same mANA (Bartek et al., 1990). 
Halazonetis et a/. ( 1993) have shown that wild-type p53 can adopt a "mutant" 
conformation and these changes are associated with sequence-specific DNA binding. 
They showed that under certain conditions (such as during cell division) wild-type p53 
can transiently adopt the "mutant" conformation (Halazonetis et al., 1993). Thus p53 
(mutant or wild-type) is associated with changes in its conformation under certain 
conditions and also in a majority of tumors which is manifest in its altered conformation. 
Our results taken together conform to the notion of change of p53 conformation as a 
172 
result of changes in the cellular environment (EGF or LA); the overall effect is in favor 
of growth arrest. 
Change in the subcellular localization of mutant and wild-type 53 in MDA 468 
cells led us to examine another cell cycle regulatory protein, p21 WAF,JctP1• p53 
transcriptionally activates the production of p21 WAFtJctP1, a potent inhibitor of cyclin-
dependent kinases (Harper eta/., 1993). Also, induction of p21wAF1/ctP, has been 
reported to occur in cells undergoing p53-mediated growth arrest (EI-Oeiry et al., 
1994). We wanted to see if localization of wild-type 53 in the nucleus as a result of EGF 
or LA treatment had any influence on the localization of p21 WAF,JCIP1• This protein exerts 
its growth inhibitory effect (EI-Deiry eta/., 1993; Kagawa eta/., 1997) primarily during 
G, to S phase transition in the cell cycle (Ji eta/., 1997; Ding eta/., 1999). Data from 
our immunofluorescence experiments indicate that the G1 phase arrest is accompanied 
by a shift in the subcellular localization of p53 and is concomitant with the nuclear 
localization of p21wAF,JCtP1• EGF, LA alone and in combination produces a nuclear 
staining of p21 WAFt/CtP, but in varying intensities. At 24 h, LA-treated cells showed a 
moderate increase in the intensity of nuclear staining. In a mixed population, not all cells 
exhibited staining with p21 WAFttctP,, in contrast to the very strong staining induced by 
EGF or EGF+LA treated cells at 24 h (Figure 5.4; panel A 2, 3, 4). At 72 h, LA induced 
a relatively stronger nuclear staining of p21 WAF,JctPt_ We may speculate that induction 
of p21 wAF1tc1P1 by LA treatment may be a more delayed and a weaker response than 
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that of EGF and EGF+LA. Correlation between increased expression of p21 WAFt/ciPt 
and growth suppression at high concentrations of EGF has been demonstrated in A431 
cells (Fan eta/., 1995; Chin et al., 1996), while increased p21 WAFt/CIPt levels was not 
observed at growth stimulatory concentrations of EGF (Jakus et al., 1996). Our results 
also show that both EGF or LA, alone or in combination, produced an absence of 
nuclear localization of cdk2 which is possibly an outcome of p53273·Hs-induced (in the 
wild-type conformation) up regulation of p21 wAFtiCIPt in these cells 24 h after treatment 
(Figure 5.6; panel A). This is consistent with the fact that p21 wAFtiCIPt is a potent inhibitor 
of cdk2 controlling the G1 to S phase transition (Harper eta/., 1993; Xiong eta/., 1993). 
We initiated this part of the study wfth the aim of understanding the relationship 
between EGF-mediated cell proliferation and changes in cellular levels of myo-inositol 
1 ,2-( cyclic) monophosphate (ciP) (in response to EGFILA). Our studies have shown that 
EGF and LA both influence the production of ciP in the short term; but irrespective of 
changes in ciP production in the short term (Chapter 4). growth inhibition occurs in 
response to EGF and LA (this Chapter). Therefore alterations in ciP production and cell 
proliferation do not seem to correlate with each other in MDA 468 cells. 
Taken together, these data suggest that MDA 468 cells undergoing arrest in G1 
phase exhibit alterations in subcellular localization of various proteins which regulate the 
G1 phase of the cell cycle; it is also suggestive that alterations in the subcellular 
localization of G, regulators which accompany this arrest is consistent with their 
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involvement in G, arrest in MDA 468 cells. In other words, MDA 468 cells exhibit a 
correlation between the subcellular localization of G1 regulators and arrest in G1 phase 
of the cell cycle. 
CHAPTER VI 
DISCUSSION AND FUTURE DIRECTIONS 
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6.1 SUMMARY OF RESULTS 
Cell signaling events mediated by the epidermal growth factor receptor (EGFR) 
regulate survival, proliferation, and differentiation of many cell types (Haugh eta/., 
1999). Our study was initiated with the aim of understanding the influence of the EGFR 
in EGF-mediated growth inhibition in the human breast cancer cell line, MDA 468. Our 
specific aim was to examine the influence of changes in EGFR autophosphorylation on 
PI turnover and cell proliferation. To address this issue, we used the strategy of 
inhibiting phosphorylation of the receptor in response to growth factor stimulation. By 
inhibiting the receptor kinase activity in a time and concentration dependent manner, 
we were able to delineate the nature of PI tumover, as well as the various cell cycle 
regulators associated with cell proliferation in MDA 468 cells. Our results with the PTK 
inhibitor, ravendustin A (LA) show that the drug inhibits EGFR autophosphorylation and 
causes perturbations in the cell cycle in a time and concentration dependent manner. 
In the initial part of the study, our aim was to interfere with the EGF-mediated 
EGF receptor (EGFR) phosphorylation. To this end we tested some of the well-
recognized PTK inhibitors. In the course of our studies, we found that these inhibitors 
were ineffective in inhibiting receptor phosphorylation in MDA 468 cells. Of the inhibitors 
used in this study, only LA effectively inhibited the EGF-stimulated EGFR 
phosphorylation in these cells. In addition, we observed that cells exposed to 1 IJM LA 
beyond 1 o h, lost viability. Since LA is a potent PTK inhibitor which exerts its inhibitory 
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action on the EGF receptor tyrosine kinase, we speculated that a inhibition of receptor 
kinase activity may have effects on cell viability as well as cell proliferation. Evidence 
from EM and FACS analyses are consistent with the fact that LA appears to cause cell 
death by apoptosis in the absence of intemucleosomal DNA fragmentation. At higher 
concentrations LA caused a G2M arrest leading to cell death after 14 h of exposure. 
Thus, biochemical and pharmacological effects of LA are manifest by dependence on 
concentration and duration of incubation in these cells, and that, inhibition of receptor 
kinase activity is the mechanism for the action of the drug. In the later experiments, we 
used this inhibitor to study the effects of inhibition of receptor phosphorylation on PI 
turnover and cell proliferation. 
This part of our study was initiated after it was observed by Church eta/. ( 1992) 
that EGF stimulated an increase in PI turnover. We examined the nature of PI turnover 
and found that a major portion of the metabolites comprised a constituent distinct from 
the major PLC-y metabolites; this metabolite was later found to be acid-labile. Using 
the technique of electrospray ionization mass spectrometry, we identified this 
metabolite to be cyclic 1,2-inositol monophosphate (ciP). Changes in EGFR 
phosphorylation resulted almost entirely in changes in the proportion of this metabolite 
alone. This kind of a PI profile is unlike that of a PLC-y generated PI profile. We 
speculate that this kind of aberrant production of the cyclic metabolite could either 
involve an unknown PLC producing it or that this cell line may have a defect in 
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breakdown in ciP. 
LA inhibited EGFR phosphorylation and PI turnover in the short term. This 
inhibitor was cytocidal at higher concentrations on longer exposure; however, at lower 
concentrations it was cytostatic. Both EGF and LA inhibited cell proliferation as a result 
of G1 arrest, alone and in combination. Irrespective of changes in receptor 
phosphorylation, by LA {decrease) or EGF {increase), growth arrest in the G1 phase 
occurred. LA failed to inhibit the EGF-mediated growth inhibition and uncover the 
growth-stimulatory effect of EGF. The resultant effect was growth inhibition. 
6.2 DISCUSSION 
In this study, we have used an inhibitor which fulfills the relevant criterion of a 
"true" signal transduction inhibitor. Such an inhibitor would, at the cellular level, cause 
a selective inhibition of early signal transduction events such as (auto)phosphorylation, 
and inhibition of proliferation in cellular systems of study {Traxler, 1997). LA effectively 
inhibited the EGF-stimulated EGFR {auto)phosphorylation and PI turnover and caused 
an inhibition of proliferation in the system that we used, namely MDA 468 cells. With the 
help of this inhibitor we were able to further study the influence of the disruption on 
EGFR signaling and cellular checkpoint regulators in cell growth and inhibition of cell 
growth. 
LA is a competitive inhibitor of ATP binding to the EGF receptor kinase (Onoda 
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et al., 1989). Interference with EGFR kinase activity influences the EGF-mediated 
signaling events. In some cases though, a correlation between the EGF-mediated short-
term and long-term effects is not evident. LA inhibited the EGF-stimulated PI tum over 
resulting in a decrease in ciP levels (Chapter 4). Thus, increases (by EGF) or 
decreases (by LA) in receptor phosphorylation reflect changes in ciP production in the 
short term. However, changes in clP levels do not correlate with growth inhibition, 
because inhibition occurs in the longer term regardless of changes in ciP. It is not 
unprecedented that enhanced PI tumoverthat results from EGFR phosphorylation is not 
an indicator of proliferative outcome. In NIH 3T3 cells treated with POGF, DNA 
synthesis was not enhanced; this was also true in cells in which PLC-y was 
overexpressed and these cells demonstrated PDGF-induced IP3 production (Margolis 
et al., 1990). Swiss 3T3 cells in which PLC-(3 is activated immediately after IGF-1 
(insulin-like growth factor) stimulation (and enhanced PI turnover) and whose activity 
retums to normal after 30 mins., it seems unlikely that the enzyme plays important roles 
during the S phase (Hughes eta/., 1988). Another evidence comes from the subcellular 
localization of PLCs. PLC-V and l5 are mostly located in the cytosol and whose 
expression do not change during the cell cycle make them unlikely candidates for 
participating in the S phase (Hughes eta/., 1988). In MDA 468 cells PLC-y has been 
shown to be associated with activated EGFR resulting in enhanced PI tumover 
irrespective of EGF concentration (physiological or pharmacological) (Church et al., 
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1992). It has been unequivocally demonstrated that the cellular decision concerning the 
proliferative response of EGF rests at some considerable distance from EGF·mediated 
early signaling events which are identical irrespective of the proliferative outcome In 
MDA 468 cells (Church eta/., 1992). Our results of EGF-dependent PI turnover and 
growth conform to this notion in MDA 468 cells. 
p53 mutations provide cells with a selective growth advantage; with such 
mutations cells suffer a significant checkpoint deficit, as a result they cannot respond 
normally to DNA-damaging agents, and therefore they enter mitosis and subsequently 
replicate their genomes in spite of DNA damage. These checkpoint defects may be 
exploited by specific targeting to treat many cancers with abnormalities of p53 function 
(Bunz et al., 1998). MDA 468 cells possess a single allele for p53 with a point mutation 
at codon 273. Thus p5~.Hs has substitution of arginine by histidine (Nigro et al., 1989; 
Bartek eta/., 1990). We provide evidence 'Nhich suggests that p53273·His is undergoing 
a change in its conformation from mutant to the wild-type. Exposure of MDA 468 cells 
to the PTK inhibitor LA in a time and concentration-dependent manner influences cells 
to be growth arrested or to die. We see a change in the conformation of p53273·Hsfrom 
mutant to wild-type at 24 h after 0.2 tJM LA treatment, prior to the manifestation of 
growth arrest at 72 h (in response to EGF or LA). We do not have evidence of a 
correlation between change in EGFR kinase phosphorylation and the altered 
conformation of p53. We know from Chapter 3 that in the shorter term (6 h), LA 
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decreases the receptor phosphorylation at 0.25 ~M (Figure 3. 7, lane 6), and we also 
see that there is an increase in the phosphorylation of EGFR in response to EGF 
(Figure 3.7, lane 3). Therefore, 'Ne conclude two things: G, arrest is independent of 
changes in the phosphorylation of EGFR kinase, and secondly, irrespective of the 
phosphorylation status of EGFR kinase, MDA 468 cells exhibit changes in p53 
conformation, an effect which accompanies G, arrest. 
In these studies the antiproliferative effect of both EGF and LA in MDA 468 cells 
is evident. They exert their anti proliferative effect by causing an accumulation of cells 
in the G1 phase. Fluorescence microscopy data are consistent with the fact that this cell 
cycle arrest may be responsible for the nuclear localization of psam·Hs in the wild·type 
conformation, which, in tum, induces the nuclear localization of p21 WAFt/CIPt, a cdk 
inhibitor. At 24 h, EGF-treated cells showed a pronounced nuclear localization of 
p21wAFt/CIPt (compared to LA) along with an absence of nuclear localization of cdk2. 
We suggest a possible involvement of p53 in EGF/LA-mediated G1 block. A functional 
role for p53273·His was deduced by Prasad and Church (1997) in EGF-mediated G1 
growth arrest. Our studies confirm the role of pS~73.H1s in G1 growth arrest by both the 
PTK inhibitor LA as well as EGF. Irrespective of the status of EGFR phosphorylation, 
alterations in the subcellular localization of psam·His and other cell cycle regulatory 
proteins accompany G, arrest. 
The PTK inhibitor LA has a dual mode of action, because it exerts both cytocidal 
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and cytostatic effects in a time and concentration-dependent manner. Therefore, its 
anti proliferative effects are manifest through growth arrest or cell killing. Its effect on the 
cell cycle is differential. It causes inhibition of cellular proliferation leading to G1 arrest 
(cytostatic effect) and G2M arrest leading to apoptosis. 
6.3 FUTURE DIRECTIONS 
EGF-stimulated receptor phosphorylation is a crucial step in the EGF-mediated 
signaling pathway which ultimately influences a cells' mitogenic behavior. Our results 
have provided evidence of some atypical signaling events in a breast cancer cell line 
with EGFR overexpression. We discuss in the ensuing paragraphs some possible 
future directions in understanding the influence of EGFR in regulating signaling 
responses. 
According to Levitzski and Gazit (1995) many PTK inhibitors which are effective 
in inhibiting receptor phosphorylation in membrane preparations may not be effective 
in whole cells. We tested PTK inhibitors in this study as a strategy aimed at inhibiting 
the EGFR phosphorylation. Our work shows that only LA (but not lavendustin 8, 
genistein, or 2,5-dihydroxymethylcinnamate) effectively inhibited the EGFR 
phosphorylation in whole cells, although others were effective in membrane 
preparations. We do not have any evidence of the intracellular ATP content of MDA 468 
cells. It is important to measure the [ATP]1 (intracellular ATP) content in these cells and 
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titrate it with each of these inhibitors. In this way the effective concentration of the 
inhibitor required to produce a biochemical effect such as inhibition of receptor 
phosphorylation could be predicted. The effectiveness of these inhibitors could also be 
different due to differences in the binding of inhibitors to EGFR and/or A TP. The binding 
of inhibitors with EGFR and/or ATP could be studied using techniques like X-Ray 
crystallography or by mass spectroscopy. No crystal structure of EGFR has yet 
appeared (Traxler eta/., 1999). Thus future studies will lead to elucidation of crystal 
structures of EGFRIATP/inhibitor complexes and this, in tum, would enable one to study 
the differences in the effectiveness of the inhibitors. 
The aberrant production of ciP in a breast cancer cell line, such as MDA 468 
cells is an interesting observation and warrants further work because the profile of 
inositol phosphates was unlike that generated by PLC-y. Untreated control cells have 
a high percentage of ciP production and this malignant phenotype shows a PAb 240 
(reactive with mutant p53) positive p53 staining. It is possible that these cells may 
require this metabolite for maintenance of the transformed phenotype as well as 
viability. It is intriguing to see that cells are still susceptible to growth inhibition in 
presence of ciP increases to a certain range (1 o.a M EGF produces a 20°/o increase 
in ciP production). Therefore, there appears to be no relationship between the long term 
EGF-mediated growth inhibition and ciP production in the short term. Decreases in ciP 
(we see -30% decrease in ciP production on treatment with LA) levels probably play 
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some as yet unidentified role in cooperating with LA in the loss of cell viability in the 
longer term (exposure of cells to LA for 14 h causes loss of viability). If the level of 
intracellular ciP could be altered by underor overexpressing cyclic hydrolase, we could 
study the effective levels of ciP required for cells to prevent growth arrest (or vice versa) 
or lose cell viability. 
An in depth investigation is required to find out what might be a possible reason 
for the high intracellular levels of ciP. We have extensively discussed the different 
possibilities in Chapter 4. We speculate that aberrant production of ciP could very well 
be the effect of PLC-~, a PLC isoform known to generate the most cyclic PI 
metabolites, interacting with EGFR via an intermediate G protein. Changes in the PLC-
p protein as a result of EGF stimulation using PLC-13-specific antibody can be studied 
in order to assess if the activity of this PLC isoform changes with EGFR 
autophosphorylation (both EGFR autophosphorylation and PI tumover results from EGF-
stimulated EGFR phosphorylation).lt is also possible that an unidentified PLC may be 
responsible for the generation of ciP. Studies of growth factor signal transduction have 
often taken advantage of the fact that intracellu far substrates form a tight association 
with activated receptors through the interaction of phosphotyrosine and SH2 domains 
(Koch st al., 1991; Cohen st a/., 1995; Pawson st al., 1995). Using available 
monoclonal antibodies directed at EGFR, the activated receptor immunoprecipitate 
complex can be incubated with PI (PI, PIP or PIP~ in vitro and the products can be 
185 
measured by HPLC following extraction under neutral conditions to obtain profiles of PI 
metabolites. From such experiments we could show, firstly. which of the above Pis give 
a profile that is similar to that as we obtain from our experimental results. Secondly, we 
eventually would be able to show an SH2 domain-tyrosylphosphorylation-dependent 
interaction of the receptor with a distinct PLC isoform. If this isoform is isolated, we 
could eventually characterize this protein. 
Since aberrant production of ciP may possibly be due to the low expression of 
the enzyme responsible for its breakdown (cyclic hydrolase), investigation to delineate 
the possible involvement of this enzyme is necessary in MDA 468 cells. Changes in the 
production of ciP in proliferating cells treated with sense or antisense constructs to this 
enzyme would allow one to elucidate the role of this metabolite in proliferation, cell 
viability or even in the maintenance of the transformed phenotype of these cells. Low 
expression may allow the cells to have a growth advantage, and on the other hand, 
overexpression may favor a decrease in proliferation by triggering the activation of 
cellular regulators which favor decreased proliferative response. In other words, this 
would lead us to elucidate if cyclic hydrolase could act as a possible antioncogene and 
even reverse the transformed phenotype. 
Results in Chapter 5 show that EGF and LA in combination produced a growth 
inhibitory response greater than the inhibition produced by EGF and LA alone. Our 
initial hypothesis was that LA would block the EGF-mediated growth inhibition because 
186 
it inhibited EGFR phosphorylation {Figure 3.7; Chapter 3). A431 cells are growth 
stimulated at picomolar EGF concentration and growth inhibited at nanomolar 
concentration of EGF, and this is also true for MDA 468 cells (Filmus eta/., 1985; 
Prasad and Church, 1991; Gulli eta/., 1996). Kawamoto eta/. (1983) showed that even 
in the presence of an antagonizing antibody (which blocks EGF binding to EGFR), EGF 
was growth stimulatory at picomolar concentrations and growth inhibitory at nanomolar 
concentrations. They suggested that this difference in growth response was due to the 
presence of a population of high affinity receptors which could bind EGF with a much 
higher affinity compared to the low affinity receptors. From 1251 .. EGF binding, they 
predicted that 0.1-0.2% of the total receptors were high affinity receptors with an 
apparent K0 of 7 x 10-11 M (7.0 pM), which bound EGF with very high affinity. At high 
EGF concentration cells were growth inhibited even in presence of saturating 
concentrations of the antagonizing antibody because EGF could now compete 
effectively for access to the low affinity receptors. We assume that EGF becomes 
growth stimulatory at picomolar concentrations (ascending portion of the bell-shaped 
curve; Figure 5.8) due to binding of EGF by a population of high affinity receptors. With 
increasing concentrations of EGF, all populations of receptors are saturated and growth 
inhibition occurs (descending portion of the curve; Figure 5.8). In MDA 468 cells too, we 
found that EGF (1 o.a M) caused growth inhibition in presence of LA. In this study we do 
not have evidence of the existence of low or high affinity receptors in MDA 468 cells. 
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We also faced problems with cell viability at high concentrations of the drug (Chapter 
3). Therefore, we could not increase the concentration of the drug and expose cells for 
a longer length oftime. Besides this, we also know that LA is a competitive inhibitor of 
ATP binding to the intracellular kinase domain of the EGFR. Therefore, we assumed 
that LA would not compete with EGF binding at the cell surface. We would like to further 
investigate how an antagonizing antibody competes with EGF binding at the cell surface 
in a concentration-dependent manner and what impact this might have on EGF-
mediated growth responses. Through 1251-EGF/IgG binding assays, EGF/IgG binding 
of EGF or the antagonizing antobody to the EGF receptor can be estimated. With 
increasing concentrations of EGF in presence of more than saturating concentrations 
of antibody, we could predict from 1251-binding the existence of high and low affinity 
receptors as well as predict their dissociation c;:onstant (K0 ) in MDA 468 cells. 
In the present study we provide evidence whereby receptor tyrosine kinase 
activity can be modulated by a PTK inhibitor in a cell line which overexpresses the 
receptor. The PTK inhibitor LA exerts a dual action in a time and concentration-
dependent manner. Acting as a cytostatic agent LA caused inhibition of proliferation via 
a G, arrest at low concentrations, while it induced a G2M arrest leading to apoptosis at 
higher concentrations. Thus, using LA, we have studied the effect of EGF-stimulated 
receptor phosphorylation in EGF-mediated signaling events. 
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